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ABSTRACT 
IEC-specific overexpression of CD98 mediates intestinal inflammation and intestinal 
epithelial barrier dysfunction in experimental colitis and increase the susceptibility to colitis-
asociated cancer. Here we demonstrated homeostatic gene profile dysregulation in the villus-crypt 
axis via CD98 overexpression. Using miRNA-target gene prediction module, we observed 
differentially expressed miRNAs to target proteins of villus and crypt profoundly affected by 
CD98 overexpression. We have utilized online bioinformatics as methods to further scrutinize the 
biological meanings of miRNA-target data.  We identified significant interactions among the 
differentially regulated proteins targeted by altered miRNAs in Tg mice. The biological processes 
affected by the predicted targets of miRNAs deviate from the homeostatic functions of the 
miRNA-gene-protein axis of the wildtype mice. Our results emphasize a dynamic perturbation of 
miRNA and protein expression in villus-crypt axis contributing to potential biological 
consequences of altering CD98 expression. Such mechanism of endogenous miRNA gene-protein 
network dysregulation via host gene modification as modeled in our animal study has great 
implication in the translational understanding of the etiology of inflammatory bowel disease (IBD) 
in human population. It is hypothesized that diet-derived miRNAs, or exogenous miRNAs, can 
also potentially modify host gene expression profile. Various miRNAs have been detected in both 
plant and animial-derived foods. Furthermore, diet has been implicated as a  potential facilitator 
of microbiota activities in gut health. We found evidence of consumption of foods typically known 
as junk food in US adult population with IBD. The idea that miRNAs from the exogenous source 
such as food can be another co-factor as a potential underlying mechanism behind the differential 
effect of food and diet on IBD risk and pathogenesis is quite feasible.   The concept adds another 
layer of complexity in the interplay between the host, genetics, immune system, microbiota, and 
food and environment in the pathogenesis of IBD.  
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1 SPECIFIC AIMS AND HYPOTHESIS  
In US alone, there are currently 1-1.3 million people diagnosed with inflammatory bowel 
disease (IBD), most commonly in a form of either ulcerative colitis (UC) or Crohn’s disease (CD) 
that render patients with debilitating symptoms 1–3. Having an IBD diagnosis also increases the 
risk of colitis-associated carcinoma. Indeed, compounded by the chronic inflammation presented 
by the disease, a patient with clinically diagnosed IBD is at an increased risk for developing colon 
cancer4–6. The critical barrier to progress to prevent the development of intestinal inflammation 
and its associated diseases, and ultimately cancer, is the lack of understanding the mechanism in 
which intestinal epithelial cells (IECs) are induced to become pathological.  
Clinically, association between increased expression of CD98 and IBD have been    
shown7–9. One potential way a dysregulated CD98 expression can modulate the pathogenesis of 
IBD and tumorigenesis is through microRNAs (miRNAs)10,11. Our goals for this study are to 
examine miRNAs as one of the players of CD98-mediated gene and protein regulator and to use 
bioinformatics as research tool to navigate the data obtained from high-dimensional approaches.   
Our central hypothesis, therefore, is that increased IE-specific CD98 expression alters the 
miRNA and protein expression associated with pathologies of IBD. The following aims are 
proposed to address the hypothesis:  
Specific Aim 1. Identify changes of the miRNA expression pattern due to overexpression of CD98 
in intestinal epithelia. We will isolate crypt and villus from the small intestines (SI) of wildtype 
(WT) mice and transgenic mice that overexpresses IE-specific human CD98 (Tg). miRNAs levels 
in the crypt and villus will be compared between the groups.      
Experiment 1: Determine changes in the miRNA expression from the crypt and villus of 
Tg and WT mice. 
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Experiment 2: Identify genes targeted by miRNAs and determine its association with IBD 
pathology.   
Specific Aim 2. Determine alterations to the protein expression due to the overexpression of CD98 
in intestinal epithelia and identify downstream targets of dysregulated miRNA expression 
Experiment 3: Determine changes in the protein expression from the crypt and villus of Tg 
and WT mice. 
Experiment 4: Determine whether protein expression in Tg mice are the downstream 
targets of the predicted target genes of miRNA determined to be differentially expressed. 
Specific Aim 3.   Determine the potential interactions and their contributions to biological 
processes among the proteins identified to be the targets of dysregulated miRNA expression profile 
in villus-crypt axis due to CD98 overexpression. 
Experiment 5: Determine potential interaction of proteins targeted by differentially 
expressed miRNAs. 
Experiment 6: Determine biological processes affected by protein-protein interaction due 
to CD98 overexpression.  
 
2 GENERAL BACKGROUND 
2.1 Epidemiology of IBD 
In US alone, there are approximately 3.1 million adults living with a chronic condition of 
the gastrointestinal tract or inflammatory bowel disease (IBD)12,13. This is a profound increase 
from ‘1.8 million’ reported in 201414. Ulcerative colitis and Crohn’s disease are the two most 
common conditions of IBD.  Disease onset can occur during childhood, but diagnosis is more 
prevalent in early adulthood15–17.  Among the two most prevalent forms of IBD, ulcerative colitis 
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(UC) occurs at a higher rate than Crohn’s disease18–20.  The prevalence of both UC and CD are 
high across industrialized nations of Northern Europe and North America, but UC is more 
commonly diagnosed.  Globally,  disease occurrence variations exist where developed countries 
report higher prevalence21,22 while countries with less industrialization report generally lower 
incidences16,23–27. However, IBD in countries with previously known lower incidence rates such 
as in countries of Asia are steadily reporting greater number of cases which parallels the country’s 
economic growth28–30.  In South Korea, UC incidences rose from less than 1 per 100,000 persons 
(1986-1990) to 3.1 per 100,000 persons (2001-2005)27, while UC incidence in northern India is 6 
per 100,000 persons31.  Based on the study among US insured adults, trending prevalence of from 
234.9 (95% CI: 234.2-235.6) to 248 (95% CI: 247.4-248.9) cases per 100,000 persons for UC and 
from 43.0 (95% CI: 42.6 – 43.5) to 48.0 (95% CI: 47.5-48.5) cases per 100,000 persons for CD 
were estimated for US population during the years of 2004 to 200919.   
According to CDC, IBD is most prevalent among US adults who are aged 45 or older, 
white in racial background, education level of less than 12 years, unemployed, US native, at or 
below poverty level, and/or reside in suburban area32. Risks have been associated with lifestyles 
and diets that are of Western in characteristics, such as industrialization, sedentary lifestyles, 
smoking, high fat and high sugar diets, high stress, and high socioeconomic status33,34. Of note, a 
review of literatures studying the role of smoking in IBD has found smoking to be protective on 
UC, but positively associated with CD35–37.  
IBD etiology is multifaced. As such, interactions of diet, lifestyle, and social factors, 
genetic predisposition, gut microbiota composition, and altered innate and adaptive immune 
responses26,38 has been suggested as a plausible source. Active disease state can persist throughout 
one’s life with interim remission. Symptoms of diarrhea, abdominal pain, intestinal bleeding, and 
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malnutrition and weight loss due to nutrient malabsorption1,2 can relapse and can introduce 
debilitation to livelihood, potentially reducing the quality of life and the ability to thrive physically1 
and socially39. Oftentimes, surgery is an option for those with severe symptoms and complications, 
long disease duration, or therapy unresponsiveness18,19 
While disease etiology may vary for each individual case and since there is no cure, primary 
goal of a health professional is to help IBD patient remain symptom free. A conventional approach 
to treat IBD chiefly targets inflammation driven by T-cell mediated cytokine production and other 
pro-inflammatory effectors40,41. Such management of relapse and inflammation is critical because 
the diagnosis carries an added risk of colitis-associated cancer (i.e. colon cancer), which is already 
one of the most fatal cancers for both men and women in US4–6,42. Indeed, an assessment of cohort 
study among Manitoba residents with a comprehensive medical history registry and database 
indicated an increased colon cancer incidence rate of 2.64 for CD and 2.75 for UC patients 
compared to those without IBD diagnosis43. While a systemic review of population-relative 
assessment of colon carcinoma prevalence among IBD patients in different regions and countries 
showed an overall trend for an increased risk, the outcome varied amongst countries, the type of 
therapy received, and severity of relapse44.   
2.2 Intestinal epithelium 
Small intestine is burdened with nutrient absorption and metabolism and the maintenance 
of its single-layer epithelium to prevent foreign pathogens from penetrating the protective mucosal 
layer into the host immune system. Small intestinal epithelium is distinguished by distinctive 
functional compartments: villi and crypt. The villi is the residence of well-differentiated 
enterocytes, goblet cells, and endocrine cells where vertical cell migration takes place only to be 
eliminated at the villus apex, and the crypt where multipotent stem cells unique to intestinal 
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epithelia reside and downward migration of anti-microbial Paneth cells are permitted45,46. This 
structural and compartmental organization set small intestinal epithelium apart from colonic 
epithelium in that villi and Paneth cells do not exist in the colon47.  
Intricate organization of villus arises from the cohesive migration of new enterocytes 
toward the apical brush border.  This upward migration also allows the microvilli to maximize its 
nutrient absorption, digestion, and micronutrient metabolism48. In addition, this migration takes 
place synchronically while uncompromising the tight adhesion between the adjacent cells of the 
monolayer and the cell polarity, which is highly dependent on the cytoskeletal protein 
organization48.  This well-organized orchestration of migrating cells along the axis also allows 
mature enterocytes to migrate from the base of villi, differentiating from the niche of multipotent 
stem cells found at the base of the crypt48–50. Differenial compartmentalization is reflected in the 
gradient profile of enzymatic activites (brush-border proteins involved in digestion process) seen 
during the development of villus-crypt axis and cell differentiation49,51.  The facilitation allows for 
defining the compartments of villus and crypt. Enzymatic protein contents such as maltase, lactase 
and alkaline phosphatase showed differential activity level along the axis from post-natal to adult 
stage development51.  For example, during the active development and cell organization of villus-
crypt axis of IE between post-natal days of 13 to 24, maltase activity was heightened in the 
intermediate axis region where villus and crypt reside51 in which the peak maltase activity shifted 
to upper villus region in adult IE.  Similar pattern of decreased enzymatic activities in crypt was 
also seen for lactase and alkaline phosphatase. In contrast, the staining of proliferating cell nuclear 
antigen marker indicated differential cell division activity in crypt (55%), midsection (32%), and 
upper villus region (8%)49, where crypt demonstrated increased DNA synthesis, as assessed by the 
incorporation of 3H-thymidine52.   
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2.3 CD98 
CD98, also known as SLC3A2, is a 120-kDa heterodimer composed of a heavy chain (80 
kDa) that bears extracellular, transmembrane, and cytosolic domains, and a light chain (40 kDa) 
which is an L-type amino acid transporter (LAT)53,54. This glycoprotein was first identified as a 
surface marker in lymphocyte53 and activated immune cells53,55 but was later identified in various 
tissue culture and cell lines, especially in the kidney and intestinal epithelial cells56–59.   
The heavy chain of the heterodimer or CD98hc is linked to the light chain LAT with a di-
sulfide bond60.  LAT, as name suggests, transports essential amino acids such as tryptophan, 
phenylalanine, leucine, and histidine and triggers cell metabolism and growth signals61. The 
protein is ubiquitously expressed in various tissues and colocalizes with CD9854. The 
transmembrane component of CD98hc interacts with β-integrin62,63, which consist of α and β 
subunits to co-facilitate signaling pathways associated with cell survival, migration, and 
adhesion62,64,65. 
2.3.1 CD98 and intestinal inflammation 
RNA and/or protein expression of CD98 is ubiquitously found in all major organs of the 
human body such as brain, airway, endocrine tissue, pancreas, gastrointestinal tract, urinary 
system,  reproductive organs, and skin66–70. In the intestine, it is chiefly expressed in the basolateral 
membrane and has been shown to colocalize as a heterodimer with LAT-271, interact with β-
integri62,63, and crosslink with other basolateral membraneous proteins such as ICAM-172. In the 
event of inflammation induced by IFN-γ in colonic cells, CD98 expression was enhanced73.  
Polarity expression was lost and a diffusive expression in the intracellular compartment and in the 
sub-apical membranes was seen. Similar enrichment of CD98 expression was also evident in the 
colitis animal model induced by DSS (dextran sodium sulfate)73.   
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In patients affected with intestinal inflammation, greater number of circulating CD98-
positive mononuclear cells7 and CD98 mRNA levels74 were detected.  Biopsied colonic intestinal 
epithelial cells (IECs) of IBD patients also showed increased CD98 protein expression8,9.  As 
dysregulation of CD98 expression has been associated with clinical features of IBD, investigation 
of CD98 using in vitro and animal models has also implicated further involvement of the protein 
in intestinal inflammation. CD98s are expressed on the basolateral membrane of polarized Caco2-
BBE IECs and murine small intestinal and colonic IECs57,74,75.  Not only the augmented expression 
of IEC-specific CD98 aggravated the experimental colonic inflammation, the transgenic mice 
overexpressing CD98 were also more susceptible to the development of colitis-associated colon 
cancer76,77.  Indeed, presence of  CD98  expression was greater in the adenomas of intestinal 
epithelium (IE) compared with non-adenomatous IE in the experimental mice78 as CD98 has been 
implicated in the cell growth and survival due to its association with amino acid transportation and 
β-integrin signaling79.  
One of the defense mechanisms of intestinal epithelium toward inflammation is the proper 
epithelial barrier function. Tight adherence to its adjacent cells and proper organization of 
junctional proteins keeps the single-layer epithelium impermeable to the penetration of 
microorganisms from the lumen to the lamina proria.  Homeostatic expression of CD98 on the 
epithelial cell is critical for this purpose. Greater expression of CD98 on the brush border of 
intestinal epithelium increased the adherence of microorganism C. rodentium on the mucosal layer 
without compromising the integrity of intestinal mucosa70, eliciting proinflammatory response by 
increasing neutrophil infiltration and greater expression levels of IL-6, IL-17α, TNF-α, and IFN-
γ70.  Indeed, the role of homeostatic epithelial expression of CD98 in inflammatory response was 
also evident in the assessment of greater mRNA levels of CD98 in the nasal epithelium of patients 
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of rhinitis compared to healthy subjects68. An increase in the level of Staphylococcal enterotoxin 
B in the nasal epithelium was seen, in line with the evidence that CD98 may promote increased 
adherence of enteropathogens to the mucosal lining of the epithelium. An enhanced expression of 
CD98 in intestinal epithelial cells alone increased the barrier permeability in a transgenic murine 
model that overexpresses tissue specific CD9877.   
2.3.2 Integrin and IE 
Cell migration and elimination and the self-renewal process through which stem cells at 
the crypt base differentiate and proliferate to give rise to the specialized intestinal epithelial cells 
(IECs), without the disruption to the integrity of adherence to neighboring cells and interaction 
with matrix proteins, require strict regulation of integrin system80,81.   
Integrin recognition of basement membrane components such as laminin and collagen is 
important for the organization and assembly of cytoskeletons for epithelial cell polarity, cell 
migration, and cell adhesion properties80,82,83. Variant integrin β1 (α6β1, α2β1, α3β1, α5β1, α6β1, 
and α6β4) and α subunits are known to be expressed on the epithelial cells80. In normal adult small 
intestinal epithelial cells, various compositions of integrin alpha subunits are also differentially 
expressed: alpha(α)5beta(β)1 in the base of enterocytes; various gradient of α1β1, α2β1, and α3β1 
along the crypt-villus axis; and along the basement membrane to maintain epithelial cell surface 
and matrix interaction 80,84.  
Conditional loss of systemic β1 gene expression leads to abnormal growth in embryonic 
development and incomplete cell migration, differentiation, and proliferation 85 and cell to cell 
contact86..While studies in intestinal tissue-specific loss of β1 gene expression is lacking, available 
evidence from Cre-mediated deletion of β1 gene indicate an abnormally large intestinal stroma, 
muscularis, and extracellular matrix87. In addition, the intestinal crypts and villi were expanded in 
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its histological appearance with dysplastic crypts and defective enterocyte differentiation.  
Interestingly, in contrast to the previously known role of β-integrin in cell proliferation and cell 
survival88, the same study did not show any failure of cell adhesion or membrane anchorage of the 
IECs with the systemic functional loss of β187.  
2.3.3 CD98 and integrin 
In polarized columnar cells of villi, β-integrin has been shown to colocalize with CD9875. 
Studies have implicated CD98 to have a modulatory role in elevating the integrin ligand-binding 
affinity89,90 by potentially modifying the surface expression of β1 integrin91. Overexpression of 
CD98 increases the β1-integrin expression on the surface along the lumen-facing well-
differentiated brush-border cells of the epithelium in colon70.  Potentiating an increase in β1 
integrin activities, CD98 can modify the stimulation of PI-3-kinase-dependent pathway to prevent 
apoptosis81.  Moreover, the coupling can enhance integrin-dependent FAK, Rac, and Akt pathways 
associated with cell adhesion, migration and spreading59,91,92.   
2.4 Diet and IBD 
US diets typically consist of foods that are high in glycemic index (carbohydrates), fat, 
and sugar which have been shown in animal studies to increase body weight, adipose tissue 
percentage, expression of pro-inflammatory markers, and result in hyperglycemia, hyper-
triacylglycerolaemia compared to animals fed with standard diet93.  Americans receive food 
energy that are primarily composed of carbohydrate (51.8%), fat (32.8%), and protein (14.4%), 
but also deficient in micronutrients94. Such diet typifies a part of Western lifestyle that has been 
linked to the development of metabolic syndrome and obesity in children of developing countries 
outside of US95,96 and associated with increasing incidences of inflammatory diseases such as 
autoimmune disease, as well as IBD97–101. 
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2.4.1 The Effect of food on IBD 
Several macronutrients and food intake have been shown to positively link with IBD. 
However, the lack of finding consistent association between dietary intake and risk for IBD and 
diverging effect of diet102,103 on CD and/or UC active/inactive disease state103 have made research 
on the influence of food on IBD elusive. IBD risk to has been shown to increase with a high intake 
of total fats, polyunsaturated fatty acids, omega-6 fatty acids, and sturated fat104 highly influenced 
by the consumption of meat37,103,105. In a small cohort study, augmenting the intake of omega-3 
fatty acids in IBD patients has demonstrated a potential benefit of essential fatty acid oils in the 
course of disease increasing the remission state compared to those taking the placebo106. 
Furthermore, meat consumption was positively associated with risk for an active disease state of a 
small cross-sectional cohort study103. Meta review of studies of association between fat intake and 
IBD has also found increased risk for IBD with high consumption of omega-6 and total 
polyunsaturated fatty acids98. A systemic review on the benefits of intake of dietary fiber via means 
of high vegetable and fruit consumption on CD and UC has been reported rather 
inconsistently37,98,104. While high intake of fruit and vegetables is inversely correlated with a 
decrease in overall systemic inflammation by mitigating the expression of C-reactive protein107, 
its effect on the risk of developing IBD was inconclusive98,103. Nevertheless, decreasing the intake 
of short-chain carbohydrates from various fruits and vegetables has shown to alleviate 
gastrointestinal symptoms of both UC and CD patients, in which the benefit was highly linked to 
diet adherence108. Proteins derived from animals and dairy has been positively associated with an 
increased risk of UC and CD104. In IBD patients, a decreased level of trimethylamine-N-oxide 
(TMAO), an animal meat-derived protein component associated with protective function at the 
cellular level, has been found in IBD patients109. While there are evidences linking consumption 
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of animal meat with increased systemic inflammation, the results pertaining to the intake of 
proteins from meat and its association with IBD risk is not well elucidated. Consumption of high-
sugar food items such as soda drinks, gum, chocolate has been shown to positively associate with 
increased odds of CD and UC development110. Accompanying this high intake of sugar and soft 
drink with low intake of complex carbohydrates and fiber from vegetables seem to significantly 
increase the UC risk111. Interestingly, the negative effect of high sugar and soft drink intake on UC 
risk was not seen among those who had higher intake of vegetables and dietary fibers.  
Collectively, evidence suggest that certain food and diet consumption is associated with 
the risk of either CD or UC, while most available dietary guidelines offer ways to cope with 
gastrointestinal flares associated with IBD103,112–115. Indeed, list of foods to avoid along with food 
that can be alternatively taken for nutritional support are assessible for patients inflicted by IBD113. 
Food intake regimens outlined in low-FODMP diet, specific carbohydrate diet, the paleolithic diet, 
and anti-inflamatory diet have been reported to assist in disease symptom management114.  In the 
light of differential effect of food on IBD risk and symptom management, diet intake among IBD 
patients seem partially self-directed by their personal experience in the effect of foods on varing 
gut symptoms108,112,115–119.  
2.4.2 miRNA and IBD 
miRNAs are small-noncoding RNAs that target 3’ end of the untranslated regions of their 
target mRNAs to destabilize gene and protein expression10,11. As part of the RNA-induced 
silencing complexes (RISCs), mature form of miRNAs suppress protein synthesis by tethering at 
the binding site of 3’-UTR of the target gene and joining to one of the transcription initiation factor 
to block translation initiation and/or facilitate the deadenylation and decapping process10,120.   By 
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base-pairing in varying homology in sequence to target gene, miRNA induce gene instability,  
compromising the expression of post-transcriptional downstream target10.  
Most of the studies examining the association of miRNA and IBD have focused on the role 
of miRNA in inflammation and in the mechanisms of pathogenesis121.  miRNAs have been shown 
to influence lymphocyte development and further modify immune responses by targeting signaling 
pathways involving NOD2, NFB, and TLRs and the regulation of pro-inflammatory 
cytokines122,123.  An assessment of the biopsy samples of colonic tissues from the active UC 
patients has revealed the localization of miRNA-192 to the colonic IE and the negative correlation 
of its decreased expression with the increased expression of its target gene encoding for epithelial-
derived chemokines124. The study identified these target genes to contain the binding sites for the 
miRNAs which seem to negatively regulate inflammatory responses. In addition, miRNAs found 
in the colonic mucosa of IBD patients have been identified to associate with innate and adaptive 
immunity such as regulation and maturation of B and T cells and other biological processes 
including cell proliferation, apoptosis, extracellular matrix organization, cell adhesion, and cell 
surface marker gene expression, oxidative stress, and cellular stress response122,125. Furthermore, 
changes in certain miRNAs in non-inflamed mucosal tissue seem to heighten the risk for severe 
inflammation and cellular changes by associating with genes of cell division, autophagy, apoptosis, 
ECM organization, cell adhesion, and unfolded protein response125.  
Due to differential expressions of miRNAs in IBD patient biopsy samples in different 
disease state, potential use of miRNA as biomarker for disease diagnosis has been explored121,126.  
Indeed, variety of miRNAs has been detected in human plasma and serum in stable expression and 
found to be resistant to RNase, rendering them to be protective of digestion by potentially 
circulating enzymes127. In this study, miRNAs were also compared amongst patients of different 
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chronic diseases and found expression profile to be drastically different from one disease to the 
other and from healthy controls127. Potential use of circulating peripheral blood miRNAs as a 
biomarker to distinguish CD and UC has also been tested by Wu et al as they identified differential 
expression of miRNAs associated with CD, their subtypes, and UC128. Morever, Viennois et al., 
has suggested the use of miRNAs as a signature for an indicator of intestinal inflammation for the 
diagnosis of ulcerative colitis129. Assessment of serum miRNAs in mice that modeled various 
colitis types (IL10-/- spontaneous, DSS-induced, and TLR5-/-) has indicated 9 miRNAs to be  
differentially altered, suggesting unique set of miRNAs as a signature to distinguish each colitis 
type.  
2.4.3 Food-derived miRNA 
The effect of diet on the risk of IBD and the influence of particular diets on clinical 
symptoms of the disease are explored by researchers in attempt to determine the role 
environmental factor has on IBD etiology and pathogenesis.  Nevertheless, the gap of 
information on the underlying mechanism of differential effect of food has been on IBD 
contributes to incomplete and inconsistent understanding of such influence.  In healthy subjects, 
expression profile of human gene transcripts obtained from peripheral blood mononuclear cells 
were found to be variedly different based on types of diet patterns -mainly high intake fruits and 
vegetables and whole grains versus Westernized diets that are high in sugar, refined 
carbohydrates, and processed meat130. Association of diet and chronic diseases has been widely 
noted, thus this study by Bouchard-Mercier et al.130 introduces the novel concept of foods having 
a potential modulatory role in host gene expression.  Furthermore, a different study by Tarallo et 
al., has found differential expression of various miRNAs (miR-92a, -16, -21, -34a, -222) in both 
plasma and stool samples in healthy subjects (n=24) with different dietary habits131.  Hence, 
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there seem to be, at the least, a link between food and change in the gene expression of the food 
consumer.  
In 2014, Zhang et al., have demonstrated the detection of non-mammalian miRNA-168a 
derived from plant in human serum and plasma132.  As this plant-derived miRNA-168a is 
distinguishable from human host miRNA due to 2’-O-methylated terminal and strong resistence 
to RNase, the study identified this high level of systemic detection is due to participants’ 
consumption of diet that consist mainly of rice132. Putative gene target of miRNA-168a is 
LDLRAP1 (low-density lipoprotein receptor adapter protein 1)132 which is expressed on 
hepatocytes to sequester plasma LDL. Additional exploration of mechanism of miRNA-168a on 
its putative target in in vitro has found no change in the LDLRAP1 mRNA expression , but 
decreased level of protein; in vivo functional analysis has shown exogenous miR-168a intake 
elevated the plasma level of LDL132. In different studies, MiR-2911, a miRNA derived from a 
decoction of herb honeysuckle, was shown to target influenza A viral genes, PB2 and NS1, to 
limit virus replication and were detected in the lung of a mouse infected with the virus133. 
Similarly, other studies have shown miR-2911 from the same herb decoction targeting the genes 
IE62 of varicella-zoster virus134 and VP1 of enterovirus 71135. In addition, for food-derived 
miRNAs miR-21, -16, -155, and miR-168, while varying concentrations of these miRNAs were 
found in various meats and dairy products, miRNAs were selectively present in either blood or 
feces of healthy subjects consuming either vegetarian or meat-rich diet136.  The same study found 
plant derived miRNA-168 in healthy human gastrointestinal mucosa and also in diseased colonic 
mucosa from colorectal cancer subjects136.  
Nevertheless, the feasibility of detecting meaningful concentration of miRNA that is 
functionally relevant in human physiology continue to present challenges.  Snow et al., in their 
15 
attempt to recapture the findings of Zhang et al., was unsuccessful in detecting the presence of 
conserved miRNAs that were abundantly present in food sources such as meat (miR-21) and 
fruits and pollen (miR-156a, -159a, -169a) in the plasma of healthy human subjects and in 
plasma or organ tissue in miR-21 KO mice or honeybee137. Assessment of studies pertaining to 
identifiying dietary miRNAs in animal plasma or tissue has yielded significant amount of studies 
registering significantly less amount of copies of miRNAs138, questioning the dose needed to 
achieve the functionally relevant concentration for the passive uptake of miRNAs by cells.  
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3.1 Abstract 
CD98 has been implicated in the experimental model of inflammatory bowel disease. We 
have previously shown that IEC-specific overexpression of CD98 mediates intestinal 
inflammation and intestinal epithelial barrier dysfunction. Mice overexpressing CD98 exhibited 
severe colitis and a greater susceptibility to CAC. Here we demonstrated CD98 overexpression to 
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dysregulate homeostatic gradient profile of miRNA and protein expression along the ileal villus-
crypt axis.  Using miRNA-target gene prediction module, we observed differentially expressed 
miRNAs to target proteins of villus and crypt profoundly affected by CD98 overexpression. We 
have utilized online bioinformatics as methods to further scrutinize the biological meanings of 
miRNA-target data.  We identified significant interactions among the differentially regulated 
proteins targeted by altered miRNAs in Tg mice. The biological processes affected by the predicted 
targets of miRNAs deviate from the homeostatic functions of the miRNA-gene-protein axis of the 
wildtype mice. Our results emphasize a dynamic perturbation of miRNA and protein expression 
in villus-crypt contributing to potential biological consequences of altering CD98 expression. Our 
findings also suggest the need for a consideration of arrays of interacting biological entities (i.e. 
miRNAs-mRNAs, protein-protein interaction) or a combination comparison for a better 
understanding of the disease pathology which is necessary for an effective therapeutic target 
development 
3.2 Introduction 
CD98, a heterodimer of an L-type amino acid transporter (LAT) and β-integrin63, has been 
implicated in the experimental colitis model that mirrors the clinical symptoms of inflammatory 
bowel disease (IBD). Initially detected in activated immune cells53,55, CD98 is constitutively 
expressed on the epithelial cells of various tissues56–58,139. During chronic intestinal inflammation, 
a greater number of CD98-positive mononuclear cells7 and higher CD98 mRNA levels are found 
in circulation74. Moreover, increased CD98 protein expression8,9 is detected in the colonic biopsies 
of IBD patients. We previously reported that mice with intestinal epithelial cell (IEC)-specific 
overexpression of CD98 exhibited an exacerbations of colitis and increased susceptibility to 
colonic tumorigenesis compared to the wild-type mice (WT)140,141. This augmented expression of 
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CD98 in the intestinal epithelium (IE) increased intestinal barrier permeability, upregulated pro-
inflammatory cytokines, elevated the phosphorylation of proteins associated with β-integrin 
signaling, and enhanced the expressions of proliferation markers in the small intestine and colonic 
epithelium141. In addition, CD98 overexpression in IE resulted in the aggressive formation of larger 
and more numerous tumors, suggesting that CD98 may be involved in oncogenesis27. In a mouse 
model that spontaneously develops intestinal carcinomas, greater CD98 expression in IECs 
enhanced the incidences of small intestinal and colonic tumors, increased cell proliferation, and 
decreased cell apoptosis78.  
We speculate the dysregulation of protein expression along the IE upon changes in CD98 
expression to be facilitated by microRNAs (miRNAs), which have been implicated in regulating 
the inflammatory conditions of IBD and various cancers123,142,143. miRNAs are small-noncoding 
RNAs that target 3’ end of the untranslated regions of their target mRNAs to destabilize gene and 
protein expression10,11. Studies of colonic mucosa of IBD patients have demonstrated miRNA 
regulation of cellular and humoral immunity122–124 and cellular processes such as proliferation, 
apoptosis, extracellular matrix (ECM) organization, cell adhesion, cell surface marker gene 
expression, oxidative stress, and cellular stress responses125. In the colonic biopsies of ulcerative 
colitis patients,  the expression level of miRNA-192 was negatively associated with that of the 
expression of target genes encoding epithelial-derived chemokines124, whereas a dysregulation of 
miRNAs related to apoptosis has been detected in colonic epithelial cells during experimental 
colitis144. Furthermore, changes in certain miRNAs in non-inflamed mucosal tissue seem to 
heighten the risk for severe inflammation and cellular changes by associating with genes of cell 
division, autophagy, apoptosis, ECM organization, cell adhesion, and unfolded protein 
response125.  
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CD98 modulates the expression levels of certain miRNAs and mRNA products during 
experimental colitis. An augmentation of IEC-specific CD98 expression levels  have an 
insignificant effect on the basal miRNA expression profile in colon, but differentially modify 
certain miRNAs under DSS (dextran sulfate sodium) treatment145, perhaps synergizing with a 
preexisting or accompanying aggravator, as such as DSS or inflammation. As IBD and intestinal 
inflammation are not exclusive to the colon, it is not unconventional to suspect the contribution of 
altered miRNA and protein expression in various parts of the gastrointestinal tract to the IBD-
associated inflammation and pathology. Together with the phenomena of aggravated inflammation 
in colon and increased incidence of colitis-associated cancer (CAC) under the influence of CD98 
overexpression in the experimental setting, a closer look at the effect of CD98 on miRNA-gene-
protein axis in IE is needed.  Here, we used publicly available online bioinformatics to 
comprehensively examine novel data obtained from the mass profiling of gene and protein 
expression of the ileal villus and crypt under IEC-specific CD98 overexpression.  
3.3 Results 
Overexpression of CD98 in IECs alters the expression level of proteins associated with villus 
and crypt  
We previously characterized a mouse model genetically modified to express human CD98 
(hCD98) in IECs to study experimental colitis and CAC141. Phenotypically, these FVB villin-
hCD98 transgenic (Tg) mice were generally healthy; however, they were leaner than FVB WT 
mice and were found to have smaller microvilli  under the electron microscopy141. High level of 
hCD98 (by immunohistochemistry) is strongly expressed in the differentiated cells of the villus 
and terminally differentiating cells of the crypt of the small intestine141.  CD98 protein is also 
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abundantly expressed in all sections of the small intestine (duodenum, jejunum, ileum) as indicated 
by western blot141.  
To evaluate the successful isolation of villus and crypt from the IE, a procedure was 
modified146 (Fig. 1a). The presence of villus and/or crypt in fractions were visualized and 
confirmed by light microscopy (Fig. 1b). Collected fractions exhibited a gradient of villus, villus-
crypt, and crypt. Total RNA was isolated from all fractions (Number of animals: Tg, n=6; WT, 
n=6), and real-time PCR was used to determine the presence of primary villus and crypt markers, 
mPepT1 and Lgr5, respectively (Fig. 2a, b, d, e). In ileal IE, PepT1 is highly expressed among 
micro-villus-enriched cells but far more weakly in crypt cells147,148. Figures 2b and 2e show 
representative findings for the relative mRNA expression levels of mPepT1 and Lgr5, respectively, 
in all 13 fractions from WT and Tg ileum. The mRNA expression of mPepT1 was greater in WT 
than Tg across all fractions, with more drastic differences seen in the earlier than the later fractions 
(Fig. 2a). The mRNA expression pattern of Lgr5 across all fractions was similar in WT and Tg 
(Fig. 2d). Overall, mPepT1 (villus marker) expression was more evident in the earlier fractions, 
while Lgr5 (crypt marker) expression was more detectable in the later fractions. When selected 
fractions were grouped as villus or crypt, we found significant between-region differences for both 
WT and Tg mice in the analyses of mPepT1 (Fig. 2b, n=6; WT villus vs. WT crypt: t=3.095, 
P<0.0102; Tg villus vs. Tg crypt: t=8.346, P<0.001) and Lgr5 (Fig. 2e, n=6; WT villus vs. WT 
crypt: t=3.046, P<0.0111; Tg villus vs. Tg crypt: t=3.541, P<0.0046). Furthermore, there was no 
significant statistical difference in the Lgr5 mRNA expression between the crypts of two genotypes 
(n=6, t-statistics=1.492, p-value=0.150, data not shown). These results indicate that villus and 
crypt samples were successfully isolated from the ileal IE of WT and Tg. Notably, other markers 
associated with villus and crypt cells exhibited alterations in Tg (Fig. 2c, Cdx2; 2f, mCD98; 2g, 
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hCD98; 2h, Muc2; 2i, Villin), suggesting disruption to protein expression in villus and crypt due 
to CD98 overexpression in IE.  
There is a distinctive protein profile along the ileal villus-crypt axis in WT mice  
To investigate the protein expression profile along the villus-crypt axis in mouse ileum, we 
used 2D-DIGE to analyze protein expression in the pooled villus or crypt samples (n=4 for WT 
and Tg) within the genotype WT or Tg (i.e. villus vs. crypt) and between WT and Tg (i.e. WT 
villus vs. Tg villus). For clarification, expression “villus-crypt axis” or “axis” is used when 
referring to the analysis within the same genotype. As opposed to the conventional expression of 
“crypt-villus” axis, the term is adopted for this paper due to measurements reflecting the expression 
in the villus relative to crypt.  
Compared spots exhibiting a volume ratio difference of ≥ or ≤ 2-fold difference in any 
comparisons were considered differentially expressed, and thus included in the analysis. Gel image 
analysis was performed using the Differential In-Gel Analysis and Biological Variation Analysis 
modules of the DeCyder software. The following results were obtained for the number of 
differentially expressed gel spots for each comparison (Supplementary Table S1): 115 
upregulated and 106 downregulated spots in WT villus-crypt axis; 140 upregulated and 226 
downregulated spots in Tg villus-crypt axis; 30 upregulated and 63 downregulated spots in Tg 
villus compared to WT villus; 39 upregulated and 30 downregulated spots in Tg crypt compared 
to WT crypt (cropped gel images in Supplementary Fig. S1.1; Originals in Supplementary Fig. 
S1.2). 
Due to the sheer abundance of a number of differentially expressed proteins and the 
limitation of spot selection such as the wide range of fold differences qualified for analysis 
consideration and/or the location in 2D gel, we sought to qualitatively decrease the pool of spots 
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that would be considered for further analysis. Exclusion/inclusion criteria were based first on 
identifying the spots that had undergone a potential protein modification and/or spots that were 
present or absent in gel comparisons.  Of a total of 719 spots that were differentially expressed 
across various comparisons, we selected 318 spots using the above criteria. From them, 20 spots 
common to both axial (within-genotype) comparisons, 8 spots from the villus comparison, and 7 
spots from the crypt comparisons were chosen based on their fold changes and location in the gel 
(Supplementary Table S1, Fig. S2, and S3). Some spots were common to all comparisons. In 
total, 32 independent spots were picked from all four comparisons for further evaluation.  
To identify the putative proteins corresponding to the 32 selected spots, we performed LC-
MS. The search returned 27 putative uncharacterized proteins and 133 accession IDs that 
corresponded to 101 different proteins. We selected the top two putative proteins identified for 
each spot (unless only one was identified), as ranked by protein score and the number of unique 
peptides. This analysis yielded 62 proteins, several of which were identified multiple times (Table 
1.1-1.3, Supplementary Table S2.1-S2.2). From the four comparisons, we identified 34 different 
putative proteins (Table 1.1-1.3, Fig. 3, labeled as their encoding genes). When a protein was 
repeatedly identified, we included only the candidate with the highest score in relevant tables and 
figures. To determine the distribution of the selected putative proteins along the axis, we examined 
their levels in villus relative to its crypt. Of the 34 proteins, 19 were downregulated and 5 were 
upregulated in the villus compared to crypt in the WT (Table 1.1-1.3, Fig. 3a), and 10 showed 
only minimal changes of less than 2-fold difference (plots located inside the 2-fold threshold dotted 
lines, Fig. 3a). Our results indicate that WT ileal epithelium exhibits a certain distribution gradient 
of specific proteins along the villus-crypt axis.  
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Overexpression of CD98 in IECs disturbs protein expression along the villus-crypt axis of the 
ileal epithelium  
To investigate the effect of IEC-specific CD98 overexpression along the IE on protein 
expression, we scrutinized the same 34 putative proteins along the axis of Tg mice. Of them, 26 
were downregulated and 2 were upregulated in the villus compared to its crypt in Tg, (Table 1.1-
1.3, Fig. 3b), while 6 showed only minimal changes (Fig. 3b). An overlay of differentially 
expressed proteins in the axes of WT and Tg showed, that villus expression level of 9 proteins 
were above (red circles to the left of black triangle plots) and 24 proteins were below (red circles 
to the right of black plots) in the Tg villus-crypt axis compared to that of WT axis (Supplementary 
Fig. S4). Targets Capza1 and P4hb showed minimal CD98 overexpression-related changes along 
the axis (Supplementary Fig. S4).  
The relative expression levels in villus compared to its crypt has revealed disruption to the 
protein distribution between WT and Tg. While Cndp2, Aldh18a1, Pm20d1, Gpi1, Tfrc, Taldo1, 
Alb, Krt78, and Rpsa remain minimally varied in its gradient expression along the WT axis, there 
is a differential expression in Tg axis. On the other hand, differential expression of Calr, Krt2, 
Hspa5, Mlec, and Mptx2 is shown to be leveled in Tg axis compared to WT axis. These results 
demonstrate that IEC-specific CD98 overexpression disrupts the homeostatic expression gradients 
of numerous proteins found along the ileal villus-crypt axis. 
Overexpression of CD98 in IECs changes protein expression levels in villus and crypt cells  
To investigate the effect of CD98 overexpression on protein expression in villus and crypt, 
we compared the levels of 34 identified putative proteins in these regions of WT versus Tg mice. 
We found that four candidates were upregulated and 15 were downregulated in Tg villus compared 
to WT villus (red dots outside the 2-fold change threshold line, Fig. 3c). In crypt, overexpression 
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of CD98 upregulated seven putative proteins and downregulated four such proteins in Tg versus 
WT mice (Fig. 3d). The expression levels of 15 and 23 putative proteins in villus and crypt, 
respectively, were minimally affected by the genotypic difference (Fig. 3c, 3d). These results 
reveal that CD98 overexpression has specific effects on protein levels in the cells of villus and 
crypt contributing to the differential distribution along the villus-crypt axis we have identified so 
far.  
The expression profile of intestinal miRNAs differs between ileal IECs of the villus and crypt  
To determine if overexpression of CD98 dysregulates the expression patterns of miRNAs 
in IECs along the axis, we examined a panel of miRNAs from the total RNAs extracted from 
selected villus and crypt fractions of WT and Tg mice. On average, we detected 243 miRNAs per 
sample. Across all comparisons (between villus and crypt within the same genotype or between 
WT and Tg), 214 miRNAs were differentially expressed (cutoff p-value of 0.05). A principal 
component analysis of the top 50 miRNAs with the largest variation for each group showed a 
distinct separation of the villus and crypt within WT and Tg, but partial overlaps in clusters when 
the data by region were plotted (Supplementary Fig. S5a). Two-way hierarchical clustering of 
the miRNAs further confirmed distinct cluster formations for villus or crypt within a given 
genotype (Supplementary Fig. S5b).   
Overexpression of CD98 in IECs dysregulates the miRNA expression profile along the villus-
crypt axis  
To determine if miRNA expression profile along the axis differs between the two 
genotypes, we first examined the differences in normalized miRNA expression (expressed in 
figures as Log2 (fold change, 2
-∆∆CT)) in villus versus crypt for each genotype, resulting in a villus-
crypt axial miRNA expression profile for that genotype. We then compared these profiles between 
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the WT and Tg. Comparison revealed uniquely distributed 119 miRNAs along the villus-crypt axis 
(Fig. 4). In the ileal epithelium, 76 miRNAs in WT and 80 miRNAs in Tg were differentially 
expressed in the villus relative to its crypt (Fig. 4). Among them, 37 miRNAs were similarly 
distributed along the axis in both Tg and WT, while 39 and 43 miRNAs were unique to the WT 
and Tg, respectively. Of the 37 miRNAs that were similarly expressed in the axis of WT and Tg, 
13 were downregulated and 24 were upregulated (Fig.4, Supplementary Fig. S6) in the villus 
relative to crypt. We also identified miRNAs that were uniquely regulated in the axes of WT and 
Tg (Fig. 5). Of the 39 miRNAs uniquely regulated in WT villus, 24 were downregulated and 15 
were upregulated (Fig. 4, Fig. 5a, 5c). Of the 43 miRNAs uniquely regulated in the villus versus 
crypt of Tg mice, 21 were downregulated and 22 were upregulated (Fig. 4, Fig. 5b, 5d). These 
results suggest that CD98 overexpression in ileal IECs can alter the distributions of some miRNAs 
while leaving others relatively unchanged.  
Overexpression of CD98 in IECs alters miRNA expression levels in both villus and crypt cells 
To determine if CD98 overexpression altered the miRNA expression profiles in cells of 
villus and/or crypt, we compared the relative miRNA expression levels of these tissues between 
WT and Tg animals (Fig. 6, Supplementary Table S3). Twenty miRNAs were differentially 
expressed in Tg villus relative to WT; of them, 11 were downregulated and 9 were upregulated 
(Fig. 6a). In crypt, 38 miRNAs were differentially expressed; of them, 26 were downregulated and 
12 were upregulated in Tg relative to WT (Fig. 6b). Of the 58 miRNAs identified from these 
comparisons, 19 and 37 were unique to the villus and crypt comparisons, respectively (the lone 
shared miRNA was miR-134-5p). These results suggest that CD98-overexpressing mice have 
different miRNA expression profiles in their villus and crypt regions, relative to WT mice, 
contributing to the genotype-related differences observed in miRNA distributions along the axis. 
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Putative proteins that are differentially expressed in villus and crypt of Tg mice are targeted by 
the miRNAs that are uniquely affected by CD98 overexpression 
Next, the target genes of 119 miRNAs found to be differentially expressed along the axis 
were predicted using the Predicted Target Module (microRNA-gene targets) of miRWalk 2.0149. 
Then we examined for any overlaps between the potential targets with the differentially expressed 
34 putative proteins selected above. Of the 119 miRNAs, seven let-7-related miRNAs were 
excluded from the target assessment. According to our analysis, 63 miRNAs were predicted to 
target 29 of the 34 putative proteins identified in our proteomic analysis. The 5 that did not yield 
any matches were those encoded by Cct7, Aldh18a1, Alb, Rps12, and Mptx. Among the 63 
miRNAs, 32 had a single genomic target, while 31 had multiple targets from the list of 29 proteins 
in the table (Table 2). Seventeen of the 24 miRNAs that were uniquely downregulated in WT 
villus versus crypt targeted 20 proteins; Ten of 15 upregulated miRNAs targeted 13 proteins in 
these mice (Table 3, left). In Tg, 12 of the 21 miRNAs that were uniquely downregulated in villus 
versus crypt targeted 12 proteins, while 7 of 22 upregulated miRNAs targeted 12 proteins (Table 
3, right). Among the miRNAs that were similarly distributed in both axes, 4 of 13 miRNAs 
downregulated in the villus targeted 6 proteins, and 13 of 24 upregulated miRNAs targeted 11 
proteins (Table 3, center).  
Having identified potential target proteins in the axes of WT and Tg, we next examined for 
the presence of protein-protein interaction. To predict and identify functional or physical networks 
among the proteins, we utilized STRING150. The goal was to identify the presence of interactions 
and the strength of their association in a network based on the evidence curated from various 
databases employed by the tool.  From this analysis, we extracted the information such as the 
number of interactions (edges) among the proteins targeted by the differentially expressed 
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miRNAs, the strength of each association (network edge confidence), an average measure of the 
tendency of each protein to connect with other proteins in the network (average clustering 
coefficient, ACC; 1=highest, 0=lowest), and the contribution of proteins to a known biological 
processes (enrichment p-value) (Fig. 7). Out of 20 putative targets of 17 miRNAs downregulated 
in WT villus-crypt axis, 16 proteins (connected nodes) were determined to interact with each other 
(Fig. 7a). This network had a total of 31 interactions among the individual proteins, an ACC of 
0.466, and an enrichment p-value of 4.11E-11. Of the 13 predicted targets of 10 miRNAs 
upregulated in WT axis, 7 proteins showed 10 different interactions to form a network with an 
ACC of 0.454 and an enrichment p-value of 2.99E-5 (Fig. 7b). Of the 12 proteins targeted by 12 
miRNAs downregulated in Tg axis, 14 interactions were seen among 10 proteins (Fig. 7c). The 
network had an ACC of 0.528 and an enrichment p-value of 2.15E-5. Of 12 proteins targeted by 7 
miRNAs upregulated in Tg axis, 9 were predicted to interact (Fig. 7d). This network had a 
relatively low ACC of 0.153, but a significant enrichment p-value of 2.05E-6. Among the miRNAs 
that were similarly upregulated in the villus versus crypt in both WT and Tg, 4 miRNAs targeted 
6 proteins, 4 of which interacted (Fig. 7e). These 4 proteins had only 3 interactions among them, 
with a modest ACC of 0.500 and an insignificant enrichment p-value of 1.18E-1. Of the miRNAs 
that were downregulated to similar degrees in the villus versus crypt in both WT and Tg, 13 
miRNAs targeted 11 proteins, 8 of which showed interactions that were separated into 2 clusters 
(Fig. 7f). This network had a modest ACC of 0.515 and a significant enrichment p-value of 8.76E-
3. Together, our findings regarding the predicted interactions among proteins targeted by miRNAs 
that were differentially expressed in the axes of WT or Tg mice suggest that these targeted 
downstream products have substantial association. These collective findings may help explain the 
biological consequences of widespread protein interactions due to CD98 overexpression in IECs.     
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Overexpression of CD98 in IECs modulates biological processes by dysregulating multiple 
miRNA-gene interactions  
To investigate biological processes affected by the above-described interactions, we used 
DAVID151,152 to perform functional annotation clustering, which was stratified according to the 
genotype and the directional changes of miRNA expression in the villus of the axis in question. 
The analysis of the interacting proteins targeted by miRNAs that were altered in WT villus versus 
crypt yielded 4 and 2 clusters for the downregulated and upregulated miRNAs, respectively 
(Supplementary Table S3). Determined putative targets of the miRNAs downregulated in the 
WT axis were strongly associated with cadherin binding, cell-cell adhesions and junctions, 
isopeptide bonds, mitochondria, and endoplasmic reticulum (ER) activities, among others. 
Associations with cytoplasm, extracellular exosomes, poly(A)-RNA binding and acetylation, ER 
activities, and melanosomes were found for the putative targets of miRNAs upregulated in the WT 
axis (Supplementary Table S3).  
In Tg villus, the analysis yielded 5 and 3 clusters of interacting proteins targeted by 
miRNAs that were downregulated and upregulated, respectively (Supplementary Table S4). 
Functions enriched by the proteins most affected by the downregulated miRNAs were strongly 
associated with protein folding, chaperones, poly(A)-RNA binding, the cytosol, and Ubl 
conjugation, among others. Three clusters enriched by the interacting proteins targeted by the 
upregulated miRNAs were considerably associated with metabolic processes, mitochondria, and 
proton acceptor and metal ion binding (Supplementary Table S4). 
Biological processes enriched by the miRNAs of similar expression levels in villi of both 
WT and Tg formed 1 and 2 functional clusters of weak association targeted by up- and 
downregulated miRNAs, respectively (Supplementary Table S5). These results indicate that 
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IEC-specific CD98 overexpression perturbs various biological processes by potentially altering 
homeostatic miRNA-gene interaction which consequently leads to changes in protein-to-protein 
interaction.  
3.4 Discussion 
Our study demonstrates IE to exhibit a unique distribution of miRNA and protein 
expression along the villus-crypt axis for intestinal homeostasis. This homeostatic expression, 
however, is vulnerable to dynamic perturbation due to an altered expression of CD98, a protein 
implicated in the pathogenesis of IBD both experimentally and clinically. We have previously 
shown a dysregulation of miRNAs and protein expression levels along the ileal villus-crypt axis 
with a knockout of a single gene PepT1, which codes for a peptide transporter in IEC, contributing 
to the molecular changes associated with cell death and proliferation153. The molecular and 
functional impact of a gene deletion, or gene overexpression as in current study, is highlighted by 
the comprehensive undertake in identifying miRNAs and proteins selectively affected by the target 
genes, potentially contributing to the changes in IE function 67,68,139 and inflammation140,141,153–155 
in experimental colitis.  
Emergence of computational biology and its evolvement into bioinformatics with user-
friendly interfaces and the access to public databases have enabled non-computational researchers 
to process biological information obtained from high-throughput approaches151. Here, we have 
applied bioinformatics as a research tool to better understand and exploit data obtained from the 
miRNA PCR panel and proteomics analyses. This approach compares in parallel a differentially 
expressed miRNA and protein signatures in the same tissue obtained from the mouse ileal 
epithelium. We then elucidated the interactions among the dysregulated proteins targeted by the 
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differentially expressed miRNAs with potential consequences that may relate to the functional 
changes characterized in experimental colitis and CAC. 
CD98 (SLC3A or 4F2) is a regulator of β1-integrin in the IE69,156 and is covalently linked 
to one of the light chains of LAT,  rendering it as a facilitator of cellular processes involved in 
nutrition and metabolism63,156–158.  Therefore, a consequential biological outcome of altering CD98 
expression on the cell surface is potentially pervasive, predisposing the cell for changes deviant 
from the homeostatic regulation.  Here we show that an alteration to CD98 expression in IECs 
modulates miRNA expression in the intestinal villus-crypt axis that may potentiate widespread 
post-transcriptional changes affecting various networks of genes and target proteins.  
A miRNA may target a single or multiple protein-encoding genes while a downstream 
product of mRNA may be the consequence of being modified by a single or multiple 
miRNAs122,159,160. Our study demonstrates miRNAs having single or multiple putative targets 
dysregulated by CD98 overexpression.  A gene coding for elongation factor-2, Eef2, is targeted by 
five miRNAs (miR-322-5p, -497-5p, -709, -326-3p, -484), of which three also targeted other 
genes, whereas a gene coding for carbamoyl-phosphate synthetase-1, Cps1, is the sole target of 
miR-151-5p that has no influence on other dysregulated proteins. In addition, our present study 
has observed a region-specific (villus or crypt) regulation of a protein-coding gene by varying sets 
of miRNAs.  In WT villus, for example, downregulated expression of miR-455-3p and miR-326-
3p influenced the expression of Atic (Bi-functional purine biosynthesis protein).  However, a 
decreased expression of the same genomic target in CD98 overexpressing villus is regulated by 
miR-30e-3p. Such phenomena are evident with other differentially expressed miRNAs and their 
targets in this study.  These results suggest that such control of genomic targets by miRNAs are 
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incongruent and that the regulation may be unique to the function or the characteristics of the 
cell/tissue, in addition to the disease pathology.  
Moreover, our study highlights the complexity of post-transcriptional regulation by 
miRNAs, as we have demonstrated here that merely decreased or increased miRNA expression 
levels do not translate directly to up or downregulated target protein expression levels, 
respectively.  The mechanisms by which miRNAs facilitate mRNA translation activities are 
multifaceted, and the process encompasses destabilization and degradation of the genomic target 
through various mechanisms, where in certain conditions stimulate protein synthesis161.  Indeed, 
an examination of the changes in the expression levels of miRNAs and putative targets in this 
study did not always show an inverse association (cross-examination of Figs. 3 and 5, 
Supplementary Fig. S6, and Table 3). We speculate such dynamic modification enabled by the 
miRNAs to contribute to the unique gradient profile of target proteins we were able to establish 
for the ileal villus-crypt axis for the maintenance of homeostasis and CD98 gene modification in 
WT and Tg.  Likewise, not all differentially expressed putative genomic targets in our study were 
targeted by variably expressed miRNAs, suggesting susceptibility to distribution perturbation via 
other means, contributing considerably to a certain aspect of disease development, independent of 
altered miRNA expression.  
We have taken our analysis further to determine potential presence of interactions among 
the significantly expressed proteins in which their protein-coding genes are influenced by 
miRNAs.  Moreover, these interacting proteins were analyzed for its functional implication that 
may provide additional insights pertaining to the disease or its mechanism. Herein, we show that 
the biological processes mostly, but not exclusively, affected by the interacting proteins are 
metabolism, cell-cell adhesion and junction, protein processing in ER, ECM, and exosome.  
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Perhaps it isn’t implausible to speculate the dysregulation of CD98 expression to “precondition” 
the cell to exhibit an exacerbation of disease pathology in presence of an aggravator by altering 
the villus-crypt axis miRNA and protein expression profile. We have previously reported greater 
CD98 expression in IEC to have an insignificant effect on the basal miRNA expression profile in 
colon, while profoundly influencing the signature of some of the colonic miRNAs in exposure to 
DSS145.  In presence of DSS-induced colitis, greater CD98 expression lead to a more profound 
disruption to the intestinal epithelial barrier function perpetuating the inflammatory cell infiltration 
and the exacerbation of colitis and CAC in the affected mice141.  Implication of CD98 in certain 
aspects of tumor development and cell transformation is also evident due to its intimate coupling 
to β-integrin. By increasing the activation of focal adhesion kinase and stimulating its downstream 
pathways91,141,158,162 and encouraging cellular interaction with the microenvironment and 
aggregation through adhesion signaling163, CD98 support cell survival and proliferation. In a 
separate study, increased CD98 expression was identified in the intestinal adenomas of a ApcMin/+ 
(model of spontaneous adenoma development), in which the incidence of intestinal tumors were 
also increased when CD98 were overexpressed in their IE78.  Clinically, positive CD98 staining 
and increased expression of CD98 in various cancer specimens were correlated with late cancer 
stages, cancer malignancies and metastasis, and poor patient survival outcomes64,164,165.  Indeed, 
CD98 heavy chain augmentation in cells in vitro showed failure to initiate cell cycle arrest and 
apoptosis under nutrient-deprived condition166 and promotion of tumorigenic characteristics167.  
Our results are only applicable to the CD98-overexpressing Tg model and the analyses 
used in the study despite our effort to compare morphologically similar fractions of ileal cells. The 
study does not assume the role or lack thereof the impact CD98 overexpression primarily in villus 
has on the stem cell niche in crypt and its subsequent effect during differentiation. Unfortunately, 
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interpretation of our results is also limited by the absence of accompanying mRNA gene 
expression information. Nevertheless, our comprehensive approach elucidates a deviation in the 
miRNA-protein axis in ileal villus and crypt due to an altered expression of a surface protein 
associated with intestinal inflammation; such breadth of information is difficult to ascertain by the 
means of simple assays for a single target protein and/or miRNA(s).   
In summary, an overexpression of CD98 in IEC potentiates the modulation of miRNA 
expression along the axis, thereby creating a unique gene and protein expression profile apart from 
what is required for the maintenance of epithelial homeostasis. We have applied the use of various 
bioinformatics to determine differential dysregulation of gene network and their putative target 
proteins in an attempt to provide insight to the biological processes affected by a single gene 
modification in the IEC as a prelude to further understand the role of CD98 in intestinal 
inflammation.  
3.5 Materials and Methods 
Animals 
Female FVB wild-type (WT) and hCD98 transgenic (Tg) mice of 6-9 weeks of age were 
used for the following experiments.  Transgenic CD98 mice were previously characterized141. 
DNA extraction from the tail or ear punch for genotyping was done using RED Extract (Sigma 
XNAT) following the manufacturer’s protocol.  Primers used to determine the Tg mice were as 
follows: Villin Forward 5’-GGCTGTGATAGCACACAGGA-3’; hCD98 Reverse: 5’-
CCTTGGACAGGCCCGTGAACTTA-3’. DNA amplification of the target gene was obtained 
under the following condition: 94° C for 2 minutes, 94° C for 30 seconds, 62° C for 30 seconds, 
72° C for 40 seconds and 72° C for 10 minutes for a total of 40 cycles. All animals were housed 
in the animal facility under 12:12 (light:dark) hour cycle where food and water were provided ad 
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libitum.  All procedures and use of mice were performed in accordance with and approved by the 
Georgia State University Institutional Animal Care and Use Committee (Atlanta, GA).   
Isolation of crypt and villus from the small intestine 
Epithelium isolation procedures have been adopted and modified from the previous 
method146 and illustrated in Figure 1a.  Briefly, ileum of the small intestine (SI) from WT (n=6) 
and Tg (n=6) was removed and cleaned with cold HBSS. Luminal surface was exposed, cut into 
smaller pieces, and further washed in 150 ml cold HBSS+0.5 mM DTT for 10 minutes at 4°C with 
constant stirring at 200 rpm. Detached epithelium in the solution was decanted and collected as 
Fraction1 (Step 1).  The remaining tissue was then washed in 100-ml cold chelating buffer for 40 
min at 4°C with constant stirring at 200 rpm. Detached epithelium in this solution was decanted 
and collected as Fraction 2 (Step 2). The remaining tissue was then transferred to a fresh 20-ml 
chelating buffer and manually inverted 60 times.  Detached epithelium in this solution was 
decanted and collected in a new 50-ml conical tube.  The manual invert was repeated three times 
and collectively assigned as Fraction 3 (Step 3). The washing of the remaining tissue and decanting 
and collecting the epithelium (Steps 2-3) were repeated, with 20 minutes of stirring, four times for 
the subsequent fractions (Fractions 4, 5, 6, 7, 8, 9, 10, 11).  Lastly, after the collection of Fraction 
11, the remaining tissues were added to a fresh 20-ml cold chelating buffer and shaken vigorously 
for 1 minute, where the epithelial cells in the solution were collected as Fraction 12 (Step 4).  This 
step was repeated to yield Fraction 13. All collected fractions were centrifuged at 2500 x g for 5 
minutes to yield pellets of epithelial cells.  The pellets were then washed and re-suspended in 
HBSS.  Confirmation of crypt and villus were made through microscopy using Nikon Eclipse 
TS100 (4X and 10X magnification) and RT-PCR.  Samples were stored in -80°C until further use. 
RNA isolation and real-time PCR 
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Total RNA were extracted from all of the tissue fractions using miRCURY RNA Isolation 
Kit (Exiqon, Woburn, MA) or Purelink Mini RNA Kit (Invitrogen) according to the manufacturer 
protocol for purifying RNA from animal tissues.   First-strand cDNA synthesis and real-time PCR 
for the total RNA were performed using Maxima First-strand cDNA synthesis and Maxima SYBR 
Green/ROX qPCR Master Mix kit (Thermo Scientific), respectively.   
cDNA synthesis and real-time PCR for miRNA were performed using NCode miRNA 
First-strand cDNA synthesis (#MIRC-50, Sigma) and NCode SYBR GreenER qPCR SuperMix 
Universal (MIRQER-100). mRNA expression levels were calculated using Ct methods. 
 
 
miRNA expression analysis 
Total RNA samples (50 ng/µl) from WT and Tg villus (n=4 for each genotype) and crypt 
(n=4 for each genotype) underwent PCR reactions conducted by Exiqon Services (Exiqon 
Services, Vedvack, Denmark).  
The samples underwent quality control using several spike-ins (UniSp6, UniSp3) provided 
by Exiqon Services. Normalization of the data was also performed by applying the average of the 
assays detected in all samples (n=20) as a suitable method for stable normalization52. The method 
included 134 assays and used the Normfinder software53. The equation used to measure normalized 
Ct value is the following:  
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝐶𝑡 = 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝐶𝑡 (𝑛 = 20) − 𝑎𝑠𝑠𝑎𝑦 𝐶𝑡 (𝑠𝑎𝑚𝑝𝑙𝑒) 
miRNA qRT-PCR 
Reverse transcription was done using miRCURY LNATM Universal RT microRNA PCR, 
Polyadenylation and cDNA synthesis kit (Exiqon). cDNA was diluted 100x and assayed in 10 µl 
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PCR where each microRNA was assayed once by qPCR on the microRNA Ready-to-Use PCR, 
Mouse&Rat panel I+II using ExiLENT SYBR® Green master mix. Amplification was performed 
in a LightCycler® 480 RealTime PCR System (Roche) in 384-well plates. The amplification 
curves were analyzed using the Roche LC software, both for determination of Ct (with the second 
derivative method) and for melting curve analysis.  
miRNA data analysis and potential target prediction 
Assays were inspected and checked for melting curves and Tm, using the algorithm 
designated for the calculation of amplification efficiency. Moreover, only the assays detected with 
Ct's below 37 and 5 Ct's less than the negative control were included in the data analysis. Data 
deviant from these criteria were omitted from further analysis. Ct was calculated as the 2nd 
derivative. For the normalization of the data, average of assays detected in all samples (average – 
assay Ct) determined by NormFinder was applied.  Predicted potential target genes of identified 
miRNAs were determined using miRSearch V3.0 algorithms (http://www.exiqon.com/mirsearch; 
Exiqon, Woburn, MA). 
Proteome analysis and protein expression 
Total protein from the tissue samples villus (n=4 for each genotype) and crypt (n=4 for 
each genotype) of WT and Tg was isolated and pooled. Concentrations were determined using 
ToPI-DIGE (Differential In-Gel Electrophoresis) kit and ToPA kit and further processed using 
ITSIPrep ToPrep Kit (ITSI Biosciences, LLC, Johnstown, PA).    
Protein separations and image analysis 
Fluorescent dyes Cy3 or Cy5 in 200 picomole were used to label pooled samples of WT 
villus, WT crypt, Tg villus or Tg crypt.  Universal internal control (S) was achieved by pooling 
the same amount of proteins (50 µg) from all samples which were labeled with dye Cy2 and added 
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to each gel as a reference for quantitative comparisons of all samples. Labeled samples were 
combined as the following for two gels:  Gel 1 – WT Villus (Cy3), WT Crypt (Cy5), S (Cy2); Gel 
2 – Tg villus (Cy3), Tg Crypt (Cy5, S (Cy2).  For the 1st dimension separation, samples each 
labeled with dye Cy2, Cy3, or C5, were mixed and loaded to a single 24 cm IEF strip, pH 3-10 
NL.  The strips were then rehydrated for 12 hours at 30 volts, followed by 65,000 volt hours of 
focus. For 2nd dimension separation, focused strips were loaded onto a 24 cm x 20 cm, 12.5% SDS-
PAGE gel and ran for 4 hours. Thereafter, the gels were exposed to three wavelengths and scanned 
with a Typhoon DIGE-Enabled Digital Imager to capture the emitted signals from the dyes.  Image 
analysis was performed using the Differential In-Gel Analysis (DIA) and Biological Variation 
Analysis (BVA) modules of DeCyder software (GE Healthcare).  Spot volumes from 2D-DIGE 
gels were compared as follows: 1) WT villus vs. WT crypt; 2) Tg villus vs. Tg crypt; 3) Tg villus 
vs. WT villus; 4) Tg crypt vs. WT crypt. Spot volume ratio greater than 2 fold was considered 
differentially expressed, thus included as a candidate protein.  Accession number obtained from 
FASTA databases for mouse from Uniprot. Gene symbol and Protein name from Uniprot and MGI 
databases. Score, number of unique peptides, MW [kDA], and Protein pI are the parameters 
obtained from peptide digest result for the identified proteins. Genes are of Mus musculus.  
 
Gel spot picking and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis 
2D-DIGE gels were stained with Lava Purple Gel stain to increase spot map accuracy.  In 
total, 32 spots were chosen to undergo tryptic digestion by spot handling robots. Spots were then 
de-stained and digested overnight.  Digested extracts were then re-suspended and desalted with a 
Zip tip and dried again in a Speed Vac.  Samples underwent another resuspension in 2% 
acentonitrile/0.1% formic acid and subjected to nanospray column mass spec analysis using LTQ 
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XL mass spectrometer (Thermo Scientific).  Digested peptide sequences were searched against 
FASTA databases for Mouse from Uniprot using Proteome Discoverer 1.4 (Thermo Scientific) 
and the SEQUEST algorithm.   
miRNA target prediction 
Predicted miRNA-gene targets were investigated using miRWalk 2.0 
(http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/, Germany).  A family of six let-7 
miRNAs was excluded from the target assessment of 119 miRNAs. Potential genomic targets of 
112 miRNAs were matched against 62 genes identified through Uniprot that are responsible for 
encoding the putative proteins found to be differentially expressed from the proteomics analysis. 
 
Functional annotation clustering and protein interaction 
Investigation of protein-protein interaction was performed using STRING v10.0 (Search 
Tool for the Retrieval of Interacting Genes/Proteins, http://string-db.org).  Degrees of interaction 
amongst the 29 proteins (in Mus musculus) were identified and visualized using the interaction 
network view. The Edge Confidence indicates the confidence of functional association or 
interaction based on the evidence from experimental and knowledge-based databases used by 
STRING. Nodes (colored circle) represent proteins where large size indicates an evidence of 
known or predicted 3-dimensional protein structure.   
Database for Annotation, Visualization and Integrated Discovery (DAVID 6.8, 
https://david.ncifcrf.gov/summary.jsp) bioinformatics annotation tool bioinformatics analysis 
tool was used to generate Functional Annotation Clustering report for the proteins shown to 
interact with each other from the STRING analysis. Proteins with enrichment scores ≥ 1.0 were 
selected, and their “GOterm_direct” categories were used to search for GO (Gene Ontology) terms. 
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The strength of enrichment for the annotation categories were identified with p-value (EASE score 
p-value; modified Fisher’s Exact Test 3), which reflect the threshold probability of biological 
significance. Classification stringency for generating annotation clustering was set at “medium.”, 
in which GO terms in Enriched Functional Group Gene Annotation/Function with p-values ≥ 0.05 
were omitted from the analysis.  
Data Analysis 
The threshold for significance was set at 0.05. For the miRNA data analysis, two-sample 
t-test was used to determine the levels of miRNAs differentially expressed between the groups. 
For the mRNA expression data, two-sided Paired t-test was used.  
 
Data Availability 
The datasets generated or analyzed during the present study are available from the 
corresponding author on reasonable request.  
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Table 3.1 Distinctive protein profile along the ileal villus crypt axis 
 
Of the repeated protein candidates, only the putative protein with highest score is shown in this table. Repeats are shown in Supplementary Table 
S2.1-S2.2. Average fold change in axis refers to changes in villus compared to its respective crypt within same genotype. Average fold change 
between the villi or the crypt refers to changes between two different genotypes. (-) sign refers to downward fold change. 
 
  
Spot 
No.a 
Accession IDb Protein Name Gene Scorec 
No. of 
Unique 
Peptidesd 
MW 
[kDa] 
Protein 
pIe 
Relative expression                            
    Log2 (Spot Volume Ratio) 
WT         
Villus-
Crypt 
Axis 
Tg         
Villus-
Crypt 
Axis 
Between 
Villus       
(Tg : 
WT) 
Between 
Crypt            
(Tg : 
WT) 
719 Q3UWP8 Calreticulin (calregulin) Calr  10.40 2 42.20 4.74 -3.66 -0.93 1.69 -1.03 
719 B2RTP7 Krt2 protein  Krt2  10.97 2 70.90 8.06 -3.66 -0.93 1.69 -1.03 
619 Q3UDR2 
Prolyl 4-hydroxylase, beta 
polypeptide 
P4hb  122.95 10 56.60 4.89 -3.22 -4.02 -1.80 -1.00 
550 P30416 
Peptidyl-prolyl cis-trans 
isomerase FKBP4  
Fkbp4  41.62 5 51.50 5.72 -2.83 -1.75 0.99 -0.09 
150 P58252 Elongation factor 2  Eef2  294.38 26 95.30 6.83 -2.60 -4.55 -1.74 0.20 
726 P56480 
ATP synthase subunit beta, 
mitochondrial  
Atp5b  96.05 7 56.30 5.34 -2.59 -1.04 0.79 -0.77 
726 Q922R8 
Protein disulfide-isomerase 
A6  
Pdia6  53.55 6 48.10 5.14 -2.59 -1.04 0.79 -0.77 
263 Q8CBU4 Ezrin (cytovillin) Ezr  15.91 2 50.20 5.80 -2.47 -1.03 0.59 -0.85 
263 Q9Z1R9 
MCG124046  (Protease, 
Serine, 1) 
Prss1  26.44 1 26.10 4.94 -2.47 -1.03 0.59 -0.85 
143 Q6IWE2 Beta-actin (Fragment)  Actb  14.51 1 8.60 4.49 -1.99 -3.75 -1.65 0.11 
424 Q9CWJ9 
Bifunctional purine 
biosynthesis protein PURH  
Atic  104.14 10 64.20 6.76 -1.82 -2.71 -0.55 0.35 
aSpot Number: Spot identity in gel 
bAccession ID: Unique identifier of the protein based on FASTA database 
cScore: Total score of the protein based on individual peptides 
dUnique peptides: Number of peptide sequence unique to the protein group 
eProtein pI: Theoretical isoelectric point based on protein molecules 
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Table 3.2 Distinctive protein profile along the ileal villus crypt axis 
Spot 
No.a 
Accession IDb Protein Name Gene Scorec 
No. of 
Unique 
Peptidesd 
MW 
[kDa] 
Protein 
pIe 
Relative expression                            
    Log2 (Spot Volume Ratio) 
WT         
Villus-
Crypt 
Axis 
Tg         
Villus-
Crypt 
Axis 
Between 
Villus       
(Tg : 
WT) 
Between 
Crypt            
(Tg : 
WT) 
144 O08601 
Microsomal triglyceride 
transfer protein large subunit  
Mttp  45.99 8 99.00 7.62 -1.46 -3.26 -1.52 0.28 
526 P52480 Pyruvate kinase PKM  Pkm  65.83 7 57.80 7.47 -1.36 -4.04 -2.15 0.53 
313 P20029 Heat shock protein 5 Hspa5  104.65 9 72.40 5.16 -1.19 0.33 2.06 0.54 
399 Q8BMF4 
Dihydrolipoyllysine-residue 
acetyltransferase component 
of pyruvate dehydrogenase 
complex, mitochondrial 
Dlat  120.64 9 67.90 8.57 -1.13 -2.55 -1.16 0.26 
399 E9Q800 
Mitochondrial inner 
membrane protein 
Immt  13.63 3 75.60 7.80 -1.13 -2.55 -1.16 0.26 
436 P80317 T-complex protein 1 subunit 
zeta  
Cct6a  44.40 4 58.00 7.08 -1.05 -2.27 -0.92 0.30 
436 Q99KE1 
Malic enzyme 2, 
mitochondrial NAD-
dependent 
Me2  39.24 6 65.80 7.61 -1.05 -2.27 -0.92 0.30 
527 A0A0N4SV00 T-complex protein 1 subunit 
eta  
Cct7  138.27 11 55.00 7.83 -1.04 -3.18 -1.98 0.17 
581 Q9D1A2 
Cytosolic non-specific 
dipeptidase  
Cndp2  85.77 10 52.70 5.66 -0.68 -2.96 -2.32 -0.04 
556 Q9Z110-2 
Isoform Short of Delta-1-
pyrroline-5-carboxylate 
synthase  
Aldh18a1 28.93 4 87.00 7.55 -0.66 -2.61 -2.59 -0.64 
556 Q8C165 
Probable carboxypeptidase 
PM20D1  
Pm20d1  63.73 7 55.60 6.43 -0.66 -2.61 -2.59 -0.64 
88 B2RXT5 
Glucose-6-phosphate 
isomerase  
Gpi1  1.56 1 38.30 8.48 -0.40 -3.53 -3.32 -0.18 
178 Q8C872 Transferrin receptor protein 1  Tfrc  5.22 1 57.30 6.48 -0.30 -2.18 0.07 1.95 
aSpot Number: Spot identity in gel 
bAccession ID: Unique identifier of the protein based on FASTA database 
cScore: Total score of the protein based on individual peptides 
dUnique peptides: Number of peptide sequence unique to the protein group 
eProtein pI: Theoretical isoelectric point based on protein molecules 
 
Of the repeated protein candidates, only the putative protein with highest score is shown in this table. Repeats are shown in Supplementary Table 
S2.1-S2.2. Average fold change in axis refers to changes in villus compared to its respective crypt within same genotype. Average fold change 
between the villi or the crypt refers to changes between two different genotypes. (-) sign refers to downward fold change.  
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Table 3.3 Distinctive protein profile along the ileal villus crypt axis 
Spot 
No.a 
Accession 
IDb 
Protein Name Gene Scorec 
No. of 
Unique 
Peptidesd 
MW 
[kDa] 
Protein 
pIe 
Relative expression                            
Log2 (Spot Volume Ratio) 
WT         
Villus-
Crypt 
Axis 
Tg         
Villus-
Crypt 
Axis 
Between 
Villus       
(Tg : 
WT) 
Between 
Crypt            
(Tg : 
WT) 
1031 Q93092 Transaldolase 1 Taldo1  34.64 4 37.40 7.03 0.25 -1.19 -2.05 -0.61 
1025 P47753 
F-actin-capping protein subunit 
alpha-1  
Capza1  39.84 4 32.90 5.55 0.27 0.22 -2.15 -2.10 
176 P07724 Serum albumin  Alb  17.61 2 68.60 6.07 0.89 -2.45 -1.67 1.67 
1336 A1L0X5 Krt78 protein (Fragment)  Krt78  17.62 1 54.70 6.30 0.96 -2.24 0.21 3.41 
1336 B2CY77 Laminin receptor (Fragment)  Rpsa  45.76 4 32.80 4.87 0.96 -2.24 0.21 3.41 
167 Q561M8 Cps1 protein (Fragment)  Cps1  6.81 1 32.20 9.25 1.56 -1.53 -0.63 2.46 
501 P35564 Calnexin  Canx  29.94 3 67.20 4.64 1.64 3.27 1.17 -0.45 
1847 P63323 40S ribosomal protein S12  Rps12  12.78 1 14.50 7.24 3.12 1.69 -0.99 0.43 
1406 Q6ZQI3 Malectin  Mlec  17.11 2 32.30 6.05 3.69 0.48 0.20 3.42 
1406 D3YYJ7 Pentaxin  Mptx2  5.58 1 24.50 8.90 3.69 0.48 0.20 3.42 
aSpot Number: Spot identity in gel 
bAccession ID: Unique identifier of the protein based on FASTA database 
cScore: Total score of the protein based on individual peptides 
dUnique peptides: Number of peptide sequence unique to the protein group 
eProtein pI: Theoretical isoelectric point based on protein molecules 
 
Of the repeated protein candidates, only the putative protein with highest score is shown in this table. Repeats are shown in Supplementary Table 
S2.1-S2.2. Average fold change in axis refers to changes in villus compared to its respective crypt within same genotype. Average fold change 
between the villi or the crypt refers to changes between two different genotypes. (-) sign refers to downward fold change. 
 
 
43 
Table 3.4 Differentially expressed miRNAs and putative targets 
 
Putative targets 
miRNAs targeting the putative target gene # of 
miRNAs Single Target   Multiple Targets 
  Prss1     miR-17-3p 1 
  Gpi1     miR-425-5p, miR-150-5p 2 
  
Eef2 
miR-322-5p, miR-
497-5p 
  miR-709, miR-326-3p, miR-484 5 
  
Actb 
miR-132-3p, miR-
1a-3p 
  miR-18a-5p, miR-802-5p 4 
  Mttp     miR-30a-5p, miR-30e-5p 2 
  Cps1 miR-151-5p     1 
  
Krt78 
miR-31-5p, miR-
134-5p 
  miR-199a-5p 3 
  
Tfrc 
miR-7a-5p, miR-
221-3p, miR-365-3p, 
miR-7b-5p 
  miR-30a-5p, miR-30e-5p, miR-130b-5p 7 
  Ezr     miR-17-3p 1 
  
Hspa5 
miR-374b-5p, miR-
350-3p 
  
miR-130b-3p, miR-301a-3p, miR-351-5p, miR-130a-
3p, miR-148a-3p, miR-152-3p, miR-125a-5p, miR-
125b-5p, miR-150-5p, miR-351-5p 
12 
  Immt miR-191-3p   miR-342-3p, miR-802-5p, miR-203-5p 4 
  
Dlat 
miR-191-5p, miR-
194-5p, miR-872-3p 
  miR-421-3p 4 
  
Atic 
miR-30e-3p, miR-
455-3p 
  miR-18a-5p, miR-342-3p, miR-709, miR-326-3p 6 
  
Me2 
miR-106a-5p, miR-
17-5p, miR-93-5p 
  
miR-351-5p, miR-101a-3p, miR-144-3p, miR-125a-5p, 
miR-125b-5p, miR-203-5p 
9 
  
Cct6a 
miR-26a-5p, miR-
26b-5p 
  miR-101a-3p, miR-144-3p, miR-7a-1-3p, miR-130b-5p 6 
  
Canx     
miR-130b-3p, miR-301a-3p, miR-130a-3p, miR-144-
3p, miR-148a-3p 
5 
  P4hb     miR-199a-5p, miR-484 2 
  Pkm miR-378a-5p   miR-130b-5p 2 
  Atp5b     miR-23a-3p 1 
  
Fkbp4 
miR-21a-3p, miR-
137-3p 
  miR-181a-5p, miR-181d-5p 4 
  Pm20d1     miR-143-3p, miR-674-3p 2 
  
Cndp2     
miR-351-5p, miR-709, miR-125a-5p, miR-125b-5p, 
miR-351-5p, miR-674-3p 
6 
  Krt2     miR-23a-3p 1 
  Calr miR-22-5p   miR-709, miR-148a-3p, miR-152-3p, miR-143-3p 5 
  
Pdia6 
miR-106b-5p, miR-
20a-5p 
  miR-181a-5p, miR-181d-5p, miR-23a-3p 5 
  
Capza1     
miR-181a-5p, miR-181d-5p, miR-23a-3p, miR-30a-5p, 
miR-30e-5p, miR-7a-1-3p 
6 
  Taldo1 miR-19b-3p   miR-130b-3p, miR-301a-3p, miR-130a-3p 4 
  Rpsa     miR-425-5p 1 
  Mlec miR-399-5p   miR-421-3p, miR-674-3p 3 
TOTAL 29 32   31   
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miRNAs listed in each row represents miRNAs targeting the putative target gene listed in the corresponding 
row. miRNAs listed under “Single Target” refer to miRNAs that solely target the gene in the same row, 
whereas the miRNAs listed under “Multiple Targets” refer to miRNAs targeting genes listed elsewhere in 
the table, including the one it is listed under. Values in very far right panel refer to the number of miRNAs 
targeting the putative gene in the corresponding row. 
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Table 3.5 Directional changes of miRNA expression and the genomic targets in each comparison 
 
Unique to WT axis 
  
Similarly expressed in WT and Tg 
  
Unique to Tg axis 
    
Genomic 
targetsa 
miRNAs   
Genomic 
targetsb 
miRNAs   
Genomic 
targetsa 
miRNAs   
Genomic 
targetsb 
miRNAs   
Genomic 
targetsa 
miRNAs   
Genomic 
targetsb 
miRNAs 
Actb miR-802-5p   Calr miR-152-3p   Actb miR-132-3p   Actb miR-18a-5p   Actb miR-1a-3p   Cct6a miR-130b-5p 
Atic miR-455-3p     miR-148a-3p   Atic miR-709   Atic miR-18a-5p   Atic miR-30e-3p   Cndp2 miR-674-3p 
  miR-326-3p   Canx miR-148a-3p     miR-342-3p   Canx miR-301a-3p   Calr miR-143-3p   Cps1 miR-151-5p 
Atp5b miR-23a-3p   Capza1 miR-7a-1-3p   Calr miR-709     miR-130b-3p   Cndp2 miR-351-5p   Dlat miR-421-3p 
Calr miR-22-5p     miR-30a-5p   Cndp2 miR-709   Dlat miR-191-5p     miR-125b-5p   Eef2 miR-484 
Canx miR-144-3p     miR-181d-5p   Eef2 miR-709   Ezr miR-17-3p     miR-125a-5p   Immt miR-203-5p 
  miR-130a-3p   Cct6a miR-7a-1-3p     miR-322-5p   Hspa5 miR-374b-5p   Eef2 miR-497-5p   Me2 miR-203-5p 
Capza1 miR-30e-5p   Dlat miR-872-3p   Immt miR-342-3p     miR-301a-3p   Fkbp4 miR-137-3p   Mlec miR-674-3p 
  miR-23a-3p   Fkbp4 miR-181d-5p   6c 4d     miR-130b-3p   Gpi1 miR-150-5p     miR-421-3p 
  miR-181a-5p   Gpi1 miR-425-5p         Me2 miR-93-5p   Hspa5 miR-351-5p     miR-339-5p 
Cct6a miR-26b-5p   Hspa5 miR-152-3p           miR-17-5p     miR-350-3p   P4hb miR-484 
  miR-26a-5p     miR-148a-3p           miR-106a-5p     miR-150-5p   Pkm miR-130b-5p 
  miR-144-3p   Immt miR-191-3p         Pdia6 miR-20a-5p     miR-125b-5p   Pm20d1 miR-674-3p 
  miR-101a-3p   Mttp miR-30a-5p           miR-106b-5p     miR-125a-5p   Tfrc miR-130b-5p 
Dlat miR-194-5p   Pdia6 miR-181d-5p         Prss1 miR-17-3p   Krt78 miR-199a-5p   12c 7d 
Eef2 miR-326-3p   Rpsa miR-425-5p         Taldo1 miR-301a-3p     miR-134-5p       
Fkbp4 miR-21a-3p   Tfrc miR-365-3p           miR-19b-3p   Me2 miR-351-5p       
  miR-181a-5p     miR-30a-5p           miR-130b-3p     miR-125b-5p       
Hspa5 miR-130a-3p     miR-221-3p         Tfrc miR-7a-5p     miR-125a-5p       
Immt miR-802-5p   13c 10d         11c 13d   P4hb miR-199a-5p       
Krt2 miR-23a-3p                     Pm20d1 miR-143-3p       
Krt78 miR-31-5p                     12c 12d       
Me2 miR-144-3p                               
  miR-101a-3p                               
Mttp miR-30e-5p                               
Pdia6 miR-23a-3p                               
  miR-181a-5p                               
Pkm miR-378a-5p                               
Taldo1 miR-130a-3p                               
Tfrc miR-7b-5p                               
  miR-30e-5p                               
20c 17d                               
                                  
aGenomic targets of downregulated miRNAs;  bGenomic targets of upregulated miRNAs;  cTotal number of genomic targets;  dNumber of different miRNAs 
 
 
;  
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Ileal epithelial cells were isolated from villi and crypt of FVB (WT) and FVB Villin-hCD98 (Tg) mice at 
6-9 weeks of age using a previously described method with modification (a). Removed tissue were washed 
in series of buffer and collected to yield fractions with gradient presence of villi, villi-crypt, or crypt. 
Fractions were visualized by light microscopy at 10x magnification (b, scale bar: 100 µm).  
 
  
Figure 3.1 Isolation of ileal epithelial cells from villus and crypt fractions 
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Total RNA were extracted and pooled from ileal villi and crypt fractions from IEC-specific hCD98 
overexpressing transgenic (Tg) and FVB wildtype (WT) mice. Expression levels of villus marker, mPepT1, 
were examined from different villus and crypt fractions (b, n=6; WT villus vs WT crypt: t=3.095, P<0.0102; 
Tg villus vs Tg crypt: t=8.346, P<0.001) with representative expression levels shown across all fractions 
(a). Expression level of crypt marker, Lgr5, was also assessed (e, n=6; WT villus vs WT crypt: t=3.046, 
P<0.0111; Tg villus vs Tg crypt: t=3.541, P<0.0046) with representative expression levels shown across all 
fractions (d). Other markers associated with villus and crypt were also examined across all fractions 
collected (c, Cdx2; f, mCD98; g, hCD98; h, Muc2; i, Villin). 
 
 
 
 
  
Figure 3.2 Proteins associated with villus and crypt are disrupted in CD98 overexpressing mice.  
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Figure 3.3 Distribution of differentially expressed proteins is altered in CD98 overexpressing mice.  
Putative proteins from 32 spots were identified using LC-MS and were considered differentially expressed 
if the level fold change is ≥ 2. Collectively from all four comparisons, 34 different putative proteins (labeled 
in figure as genes responsible for encoding them) were identified where, among the repeats, only the 
putative protein with the highest score is included. Putative proteins in the villus of WT (a) and Tg (b) were 
compared to its respective crypt to determine their distribution profile along the axis.  Cross-comparison 
between the genotypes were also made between the villi of WT and Tg (c) and between the crypt of WT 
and Tg (d). Dotted lines indicate the threshold for 2 fold change. Upper = (+) 2-fold change; Lower = (-) 2-
fold change. Filled circles between the threshold lines indicate proteins with less than 2 fold change, thus a 
minimal expression difference, for the comparison. Y-axis is in Log2 (Spot volume ratio) scale.   
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miRNAs listed were found to be differentially expressed using a cutoff p-value of < 0.05. A total of 119 
miRNAs were differentially expressed along the villus-crypt axis of WT and Tg ileal IECs. Among them, 
there was an overlap of 37 miRNAs found to be similarly expressed in both genotypes while 39 miRNAs 
and 43 miRNAs were uniquely distributed along the axis to either WT or Tg, respectively. miRNAs listed 
reflect the directional expression found in villus compared to crypt along the axis of the same genotype. 
The left column of each grouping is the downregulated miRNAs, whereas the right column represents 
upregulated miRNAs in the villus. 
 
 
  
Figure 3.4 CD98 overexpression in IECs alter unique miRNAs associated with villus-crypt axis profile.  
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. 
Relative fold change (2-∆∆CT) of miRNAs differentially affected by CD98 overexpression is shown. All 
miRNAs listed were found to be differentially expressed using a cutoff p-value of < 0.05. These miRNA 
expressions are unique to the axis of either genotype. In WT, 24 miRNAs were downregulated (a) and 15 
miRNAs were upregulated (c) in the villus compared to its crypt. In Tg villus-crypt axis, 21 miRNAs were 
downregulated (b) and 22 miRNAs were upregulated (d) in the villus compared to its crypt. Y-axis is shown 
in Log2 (Relative expression) scale.  
 
 
 
  
Figure 3.5 Expression levels of certain miRNAs are uniquely affected by the overexpression of CD98 in 
IECs 
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Relative fold change (2-∆∆CT) of miRNAs detected in either villus or crypt of WT and CD98 Tg ileal IECs 
is shown. To determine if there was a regional variation in miRNA expression profile due to genotypic 
difference, Tg villi were compared with WT villi (a) and Tg crypt were compared with WT crypt (b). Of 
the 58 miRNAs identified from these comparisons, with the exclusion of miR-134-5p, -19 and -37, miRNA 
profile signature is unique to the villus or crypt. Y-axis is shown in Log2 (Relative expression) scale. 
 
Figure 3.6 Villus and crypt harbor unique miRNA expression profile which is altered by CD98 
overexpression.  
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Visual representation of STRING network for putative proteins targeted by miRNAs differentially 
regulated in the ileal villus-crypt axis of WT and Tg is shown. Representation of interactions via network 
edge lines are shown among proteins/genes targeted by uniquely downregulated or upregulated miRNAs in 
WT villus (a, b, respectively) or Tg villus (c, d, respectively). Interaction is also shown among the 
proteins/genes targeted by similarly expressed miRNAs in two genotypes (e and f). Spheres of different 
colors represent nodes (proteins).  While large nodes are indicative of a presence of a known of predicted 
Figure 3.7 Overexpression of CD98 in IECs dysregulates the interaction of proteins expressed in villus 
and crypt.  
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3D structure, protein structures for the small nodes are currently unknown. The lines between nodes 
represent “edges” or protein-protein associations. The thickness and darkness of those edges represent 
confidence score that is indicative of likeliness of a true interaction based on available evidence. Evidence 
is ranked 0 to 1 with 1 being the highest likeliness of protein-protein interaction. The location of nodes or 
the length of edges between the nodes does not indicate the strength of association with the connecting or 
neighboring nodes. 
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Supplementary Table S1 Number of 2D-DIGE gel spots with volume ratio greater than 2-fold difference 
for each comparison 
 
 
 
 
 
 
 
 
 
 
 
Number of 2D-DIGE  
Gel Spots 
WT 
Villus-
Crypt Axisa 
Tg 
Villus-Crypt 
Axisb 
Between 
Villusc 
(Tg : WT) 
Between 
Cryptd 
(Tg : WT) 
Volume ratio ≥ 2.0 115 140 30 39 
Volume ratio ≤ 2.0 106 226 63 30 
Total 221 366 93 69 
Selected for analysis 20 8 7 
aExpression in WT villus relative to WT crypt 
bExpression in Tg villus relative to Tg crypt 
cExpression in Tg villus relative to WT villus 
dExpression in Tg crypt relative to WT crypt 
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Supplementary Table S2 Distinctive protein profile along the ileal villus-crypt axis 
 
  
Spot 
No.a 
Accession 
IDb 
Protein Name Gene Scorec 
No. of 
Unique 
Peptidesd 
MW 
[kDa] 
Protein 
pIe 
Relative expression                                    Log2 
(Spot Volume Ratio) 
WT         
Villus-
Crypt 
Axis 
Tg         
Villus-
Crypt 
Axis 
Between 
Villus       
(Tg : 
WT) 
Between 
Crypt            
(Tg : WT) 
424 P07724 Serum albumin  Alb  13.32 1 68.6 6.07 -1.82 -2.71 -0.55 0.35 
1031 Q9CWJ9 
Bifunctional purine biosynthesis 
protein PURH  
Atic  15.09 1 64.2 6.76 0.25 -1.19 -2.05 -0.61 
619 P56480 
ATP synthase subunit beta, 
mitochondrial  
Atp5b  78.96 8 56.3 5.34 -3.22 -4.02 -1.80 -1.00 
526 P56480 
ATP synthase subunit beta, 
mitochondrial  
Atp5b  20.4 3 56.3 5.34 -1.36 -4.04 -2.15 0.53 
550 P80313 T-complex protein 1 subunit eta  Cct7  50.22 5 59.6 7.84 -2.83 -1.75 0.99 -0.09 
1025 Q6KAT3 
Cytosolic non-specific 
dipeptidase  
Cndp2  14.16 1 44.3 5.38 0.27 0.22 -2.15 -2.10 
143 Q6P9L9 Eef2 protein (Fragment)  Eef2  96.21 8 93.5 6.83 -1.99 -3.75 -1.65 0.11 
313 Q6P9L9 Eef2 protein (Fragment)  Eef2  74.83 4 93.5 6.83 -1.19 0.33 2.06 0.54 
144 Q6P9L9 Eef2 protein (Fragment)  Eef2  39.39 4 93.5 6.83 -1.46 -3.26 -1.52 0.28 
1847 P58252 Elongation factor 2  Eef2  20.49 4 95.3 6.83 3.12 1.69 -0.99 0.43 
178 Q6P9L9 Eef2 protein (Fragment)  Eef2  13.67 3 93.5 6.83 -0.30 -2.18 0.07 1.95 
167 Q6P9L9 Eef2 protein (Fragment)  Eef2  6.79 2 93.5 6.83 1.56 -1.53 -0.63 2.46 
1769 Q61509 Elongation factor 2 (Fragment)  Eef2  4.55 1 29.9 6.64 1.47 -0.11 -2.81 -1.23 
591 B2RTP7 Krt2 protein  Krt2  10.28 1 70.9 8.06 -1.53 -2.57 -0.95 0.10 
1016 B2RTP7 Krt2 protein  Krt2  8.83 1 70.9 8.06 1.81 3.23 0.34 -1.07 
aSpot Number: Spot identity in gel 
bAccession ID: Unique identifier of the protein based on FASTA database 
cScore: Total score of the protein based on individual peptides 
dUnique peptides: Number of peptide sequence unique to the protein group 
eProtein pI: Theoretical isoelectric point based on protein molecules 
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Supplementary Table S3 Distinctive protein profile along the ileal villus-crypt axis 
Spot 
No.a 
Accession 
IDb 
Protein Name Gene Scorec 
No. of 
Unique 
Peptidesd 
MW 
[kDa] 
Protein 
pIe 
Relative expression                                    
Log2 (Spot Volume Ratio) 
WT         
Villus-
Crypt 
Axis 
Tg         
Villus-
Crypt 
Axis 
Between 
Villus       
(Tg : 
WT) 
Between 
Crypt            
(Tg : 
WT) 
176 A1L0X5 Krt78 protein (Fragment)  Krt78  16.25 1 54.7 6.3 0.89 -2.45 -1.67 1.67 
1001 A1L0X5 Krt78 protein (Fragment)  Krt78  12.99 1 54.7 6.3 1.13 -1.19 -0.39 1.94 
505 Q99KE1 
Malic enzyme 2, mitochondrial 
NAD-dependent 
Me2  28.3 4 65.8 7.61 -1.62 -3.42 -1.90 -0.10 
501 Q3UDR2 
Prolyl 4-hydroxylase, beta 
polypeptide 
P4hb  71.78 7 56.6 4.89 1.64 3.27 1.17 -0.45 
1016 Q3TT76 
Prolyl 4-hydroxylase, beta 
polypeptide 
P4hb  21.24 2 43 5.14 1.81 3.23 0.34 -1.07 
505 P52480 Pyruvate kinase PKM  Pkm  53.98 6 57.8 7.47 -1.62 -3.42 -1.90 -0.10 
527 P52480 Pyruvate kinase PKM  Pkm  27.16 4 57.8 7.47 -1.04 -3.18 -1.98 0.17 
581 P52480 Pyruvate kinase PKM  Pkm  19.32 3 57.8 7.47 -0.68 -2.96 -2.32 -0.04 
563 Q8C165 
Probable carboxypeptidase 
PM20D1  
Pm20d1  18.18 3 55.6 6.43 -2.26 -5.13 -2.86 0.01 
563 Q9Z1R9 
MCG124046  (Protease, Serine, 
1) 
Prss1  16.74 1 26.1 4.94 -2.26 -5.13 -2.86 0.01 
1001 Q9Z1R9 
MCG124046  (Protease, Serine, 
1) 
Prss1  13.3 1 26.1 4.94 1.13 -1.19 -0.39 1.94 
88 Q9Z1R9 
MCG124046  (Protease, Serine, 
1) 
Prss1  12.94 1 26.1 4.94 -0.40 -3.53 -3.32 -0.18 
150 Q9Z1R9 
MCG124046  (Protease, Serine, 
1) 
Prss1  12.66 1 26.1 4.94 -2.60 -4.55 -1.74 0.20 
aSpot Number: Spot identity in gel 
bAccession ID: Unique identifier of the protein based on FASTA database 
cScore: Total score of the protein based on individual peptides 
dUnique peptides: Number of peptide sequence unique to the protein group 
eProtein pI: Theoretical isoelectric point based on protein molecules 
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Supplementary Table S4 Differently expressed miRNAs in Tg compared to WT 
 
 
  
Tg compared to WT Villus comparison Crypt comparison 
Upregulated miRNAs  
let-7c-5p 
let-7a-5p 
miR-25-3p 
miR-30e-5p 
miR-215-5p 
miR-140-5p 
miR-185-5p 
miR-26b-5p 
miR-22-5p 
let-7a-1-3p 
miR-200a-3p 
miR-148a-3p 
miR-125b-5p 
miR-99a-5p 
miR-146a-5p 
miR-133a-3p 
miR-181c-5p 
miR-142-5p 
miR-142-3p 
miR-1a-3p 
miR-150-5p 
 
 Downregulated miRNAs 
miR-124-3p 
miR-291b-5p 
miR-29b-1-5p 
miR-193b-3p 
miR0466f-3p 
miR-1198-5p 
miR-134-5p 
miR-149-5p 
miR132-3p 
miR-26a-1-3p 
miR-30e-3p 
 
let-7d-5p 
let-7f-1-3p 
miR-203-5p 
miR-33-3p 
miR-1983 
miR-20a-3p 
miR-148a-5p 
miR-674-3p 
miR-130b-5p 
miR-134-5p 
miR-1949 
miR-194-2-3p 
miR-423-3p 
miR-324-5p 
 
miR-324-5p 
miR-7a-5p 
miR-128-3p 
miR-484 
miR-182-5p 
miR-200b-5p 
miR-674-5p 
miR-148b-3p 
miR-151-5p 
miR-103-3p 
miR-191-5p 
miR-21a-5p 
miR-301-3p 
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Supplementary Table S5 Enriched functional clusters in WT villus-crypt axis 
  
Annotation 
Clustera 
Enrichment 
Score 
Term Count Genes 
1 3.29 Cadherin binding, cell-cell adhesion 5 
Pkm, Atic, Capza1, Eef2, 
Hspa5, Fkbp4   
Cell-cell adherens junction 5 
    Isopeptide bond 4 
2 2.46 Mitochondrion 8 Pkm, Me2, Immt, Atic, 
Atp5b, Fkbp4, Dlat, Hspa5     Transit peptide 4 
3 2.32 Smooth endoplasmic reticulum 4 
Fkbp4, Pdia6, Cct6a, Calr, 
Canx, Hspa5, Actb 
  Protein folding 5 
  Chaperone 5 
  Uunfolded protein binding 4 
  Chaperone-mediated protein folding 3 
  Prevents secretion from ER 3 
  Glycoprotein binding 3 
  
Protein processing in endoplasmic 
reticulum 4 
  Melanosome 3 
  Endoplasmic reticulum lumen 3 
  Protein complex 4 
    Endoplasmic reticulum 4 
4 2.22 Extracellular matrix 7 
Pkm, Actb, Immt, Atp5b, 
Capza1, Eef2, Cct6a, Hspa5, 
Calr, Canx, Fkbp4, Taldo1 
  Ubl conjugation 6 
  Protein binding 10 
  Methylation 5 
  Nucleotide-binding 6 
  ATP binding 6 
  Cytoplasm 8 
    Isopeptide bond 4 
5 1.9 Carbon metabolism 4 
Pkm, Me2, Taldo1, Dlat, 
Atic 
  Pyruvate metabolism 3 
  Biosynthesis of antibiotics 4 
  Metabolic process 4 
    Catalytic activity 4 
Annotation 
Clusterb 
Enrichment 
Score 
Term Count Genes 
1 3.54 Extracellular exosome 7 
Rpsa, Fkbp4, Pdia6, Cct6a, 
Hspa5, Calr, Canx 
  Poly(A) RNA binding 5 
  Acetylation 6 
    Cytoplasm 6 
2 2.51 Smooth endoplasmic reticulum 4 
Pdia6, Hspa5, Calr, Canx, 
Cct6a 
  Unfolded protein binding 4 
  
Protein processing in endoplasmic 
reticulum 
4 
  Prevents secretion from ER 3 
  Glycoprotein binding 3 
  Melanosome 3 
  Endoplasmic reticulum lumen 3 
    Endoplasmic reticulum 4 
aBiological processes associated with putative targets of DOWNREGULATED miRNAs in WT villus-crypt axis 
bBiological processes associated with putative targets of UPREGULATED miRNAs in WT villus-crypt axis 
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Supplementary Table S6 Enriched functional clusters in Tg villus-crypt axis 
 
 
 
  
Annotation 
Clustera 
Enrichment 
Score 
Term Count Genes 
1 2.39 Protein folding 3 
P4hb, Fkbp4, Eef2, Calr   Chaperone 3 
    Poly(A) RNA binding 4 
2 2.27 Cytosol 6 
Actb, Cndp2, Fkbp4, Eef2, 
Hspa5, Gpi1, Calr   
Ubl conjugation 5 
    Cytoplasm 6 
3 1.86 Extracellular matrix 4 
P4hb, Eef2, Hspa5, Calr, 
Actb 
  Prevents secretion from ER 3 
  Focal adhesion 4 
  Endoplasmic reticulum lumen 3 
    
Protein processing in endoplasmic 
reticulum 3 
4 1.85 Extracellular matrix 4 
P4hb, Eef2, Hspa5, Calr, 
Actb, Fkbp4, Gpi1 
  Response to endoplasmic reticulum stress 3 
  Ubl conjugation 5 
    Myelin sheath 3 
5 1.46 Ubl conjugation 5 Actb, Fkbp4, Eef2, Hspa5, 
Gpi1 
     
Annotation 
Clusterb 
Enrichment 
Score 
Term Count Genes 
1 2.72 Metabolic process 6 
Pkm, Me2, Cndp2, Pm20d1, 
Dlat, Cps1 
  Carbon metabolism 4 
  Allosteric enzyme 3 
  Pyruvate metabolism 3 
  Transit peptide 3 
  Catalytic activity 3 
  Transit peptide_Mitochondrion 3 
    Mitochondrion 4 
2 2.49 Metabolic process 6 
Pkm, Me2, Cndp2, Pm20d1, 
Dlat, Cps1   
Proton acceptor 3 
    Metal ion binding 5 
3 1.50 Extracellular matrix 4 
Pkm, P4hb, Cndp2, Pm20d1, 
Eef2, Cct6a, Cps1 
  Extracellular exosome 6 
  Poly(A) RNA binding 4 
    Nucleotide-binding 4 
aBiological processes associated with putative targets of DOWNREGULATED miRNAs in Tg villus-crypt axis 
bBiological processes associated with putative targets of UPREGULATED miRNAs in Tg villus-crypt axis 
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Supplementary Table S7 Enriched functional clusters effected in both genotypes 
 
 
 
Annotation 
Clustera 
Enrichment 
Score 
Term Count Genes 
1 1.6 Extracellular exosome 4 
Actb, Atic, Eef2, Calr   
Acetylation 4 
  Cytosol 3 
    Membrane 4 
Annotation 
Clusterb 
Enrichment 
Score 
Term Count Genes 
1 1.72 Smooth endoplasmic reticulum 3 
Pdia6, Hspa5, Canx 
  Melanosome 3 
  
Protein processing in endoplasmic 
reticulum 3 
    Endoplasmic reticulum 3 
2 1.21 Extracellular exosome 6 Actb, Taldo1, Ezr, Pdia6, 
Hspa5, Canx     Focal adhesion 3 
aBiological processes associated with putative targets of DOWNREGULATED miRNAs expressed in villus-crypt axis of WT and 
Tg 
bBiological processes associated with putative targets of UPREGULATED miRNAs expressed in villus-crypt axis of WT and Tg 
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2D-DIGE gel image was analyzed using Biological Variation Analysis modules of DeCyder 
software. Only the spots identified with a volume ratio difference of ≥ 2.0 between any of the 
comparisons (a vs. b; c vs. d; a vs. c; b vs. d) were considered differentially expressed or 
abundant. Gel images are cropped but spots present in each panel display are all inclusive and no 
spots were left discarded. Uncropped, and untouched original gel images of the corresponding 
gels are present in Supplementary Figure S1.2.  
 
  
Supplementary Figure S1 Overexpression of CD98 in IE yields irregularity in the expression of 
abundance in proteins in the villus and crypt. 
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2D-DIGE gel image was analyzed using Biological Variation Analysis modules of DeCyder 
software.  Displayed images are the original uncropped and untouched images of the 
corresponding gels in Supplementary Figure S1.1.  
 
  
Supplementary Figure S2 Overexpression of CD98 in IE yields irregularity in the expression of 
abundance in proteins in the villus and crypt (Untouched) 
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2D-DIGE gel image was analyzed using Biological Variation Analysis modules of DeCyder 
software. Of the 318 spots identified, 20 spots with volume ratio ≥ 2.0 common to axial 
comparisons (a vs. b for WT villus-crypt axis; c vs. d for Tg villus-crypt axis) were chosen for 
further analysis. The images are uncropped and correspond to the original image with minor 
exposure adjustments under the same setting for all images for better visualization of the spots.  
Supplementary Figure S3 CD98 overexpression selectively alters the expression levels of proteins 
common to villus-crypt axis of ileal epithelium.  
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Supplementary Figure S4 CD98 overexpression disturbs protein expression distribution that is unique to 
villus and crypt, contributing to the differential villus-crypt axial protein expression profile. 
 
2D-DIGE gel image was analyzed using Biological Variation Analysis modules of DeCyder 
software. Of the 318 spots, 8 spots from the villus comparison (a vs. c) and 7 spots from the crypt 
comparison (b vs. d) were randomly chosen based on a fold change and location on the gel. The 
images are uncropped and correspond to the original image with minor exposure adjustments under 
the same setting for all images for better visualization of the spots. 
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An overlay of differentially expressed proteins in the axis of WT and Tg has shown 9 proteins 
above and 24 proteins below the expression level that of the WT in the axis of Tg.  Only one 
protein Capza1 (F-actin-capping protein subunit alpha-1) showed no change in the expression level 
along the axis due to CD98 overexpression (overlap of red circle and black triangle). Dotted lines 
indicate the threshold for 2-fold change. Y-axis is in Log2 (Spot volume ratio) scale.  
 
 
  
Supplementary Figure S5 Differentially expressed protein distribution along the axis is affected by 
CD98 overexpression 
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Top 50 miRNAs (normalized to ∆Ct) with the largest variations for each group has been plotted 
for the analysis based on the expression profile to visualize variations in miRNA between the two 
Supplementary Figure S6 miRNA distribution and variation profile is different in WT and CD98 Tg 
IECs 
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genotypes using Principal Component Analysis (PCA; PC1: Largest component in variation; PC2: 
Second largest component in variation, a) as an overview. A differential clustering of miRNA 
expression can be seen based on the groups. There is a distinct separation of villus and crypt for 
each genotypes but partial overlap in the clustering based on villus or crypt. The miRNA clustering 
tree of the heat-map diagram (b) is shown on left while sample clustering is shown on top.  
Clustering is performed on all samples and on the top 50 miRNAs with highest standard deviation. 
Each row represents one microRNA, and each column represents one sample. Color scale 
represents relative expression level about the mean of miRNAs across all samples. 
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Supplementary Figure S7 Distribution of certain miRNAs were minimally influenced by CD98 
overexpression 
Relative fold change (2-∆∆CT) of similarly expressed miRNAs in villus-crypt axis of WT and CD98 
Tg ileal IECs is shown.  All miRNAs listed were found to be differentially expressed using a cutoff 
p-value of < 0.05.  A total of 37 miRNAs were similarly distributed in both WT and Tg villus-
crypt axis, of which 13 were downregulated (a, b) and 24 were upregulated (c, d) in villus 
compared to crypt.  Y-axis is in Log2 (Relative expression) scale. 
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4.1 Abstract 
BACKGROUND: Consumption of Western diets has been implicated as one of the environmental 
factors associated with inflammatory bowel disease (IBD/colitis). Patients are often recommended 
nutritional guidelines to help manage disease symptoms and prevent relapses. However, current 
food consumption behavior of US adults with IBD that are nationally representative is unclear.  
METHODS: National Health Interview Survey 2015 was used to characterize estimated US adults 
with IBD and examine their food intake and consumption frequency using bivariate/multivariate 
logistic regression.  
RESULTS: Over 3.08 million US adults currently have IBD. People with IBD were more likely 
to eat Fries, drink less 100% Fruit Juice, and eat more Cheese and Cookies. Intake of Fries (OR 
1.60, 95% CI 1.14-2.25) and Sports/Energy Drinks (OR 1.46, 95% CI 1.07-1.97) and drinking 
more Soda/Pop were significantly associated with IBD, while Popcorn (OR 0.73, 95% CI 0.548-
0.971) and Milk (OR 0.70, 95% CI 0.497-0.998) lowered the IBD odds adjusting for covariates. 
Increase in intake of Popcorn and Whole Grain Bread lowered the odds of IBD in people already 
consuming < median rate. The benefit of increase in Vegetable intake was more profound in people 
already consuming > median rate.  
CONCLUSION: Eating behavior in US population with IBD was mostly unremarkable from the 
general non-colitic population. It is unclear whether the results reflect potential diet modification 
in IBD population long before the survey interview. Foods typically labeled as junk food was 
positively associated with the colitis but eating more popcorn and drinking more 100% fruit juice 
was associated with lower odds. To further determine whether consumption of such food increases 
the risk of developing IBD and whether certain food items are protective, a future research with 
detailed survey questions representative of US population is needed.     
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4.2 Introduction 
Inflammatory bowel disease (IBD) is a chronic condition of the gastrointestinal tract of which 
approximately 3.1 million adults in the United States are affected by the disease, according to the 
National Health Interview Survey (NHIS) data from 201512,13. This is a profound increase from 
‘1.8 million’ previously reported few years ago assessed from NHIS 1999 data14. The two most 
common conditions of IBD is ulcerative colitis (UC) and Crohn’s disease (CD).  While the disease 
is prevalent across all ages, disease onset peaks at early adulthood15–17 and persists throughout life 
with interim remission with surgery being the last resort upon ineffectiveness of available therapy. 
Relapsing symptoms of diarrhea, abdominal pain, intestinal bleeding, and malnutrition and weight 
loss due to nutrient malabsorption1,2 can be increasingly debilitating, potentially reducing the 
quality of life and the ability to thrive physically1 and socially39. A definitive cause of IBD is 
unknown.  However, IBD has been strongly associated with genetic predisposition, gut microbiota 
composition, altered innate and adaptive immune responses37,168–170.  Just as the etiology of IBD 
is multi-faceted, studies over the years have unveiled environmental factors such as, diet, lifestyle, 
and social factors as part of a critical component contributing to the disease risk26,38. Regardless of 
different attributable risks associated with the disease, conventional approach to treat IBD 
primarily targets inflammation driven by T-cell mediated cytokine production and other pro-
inflammatory effectors40,41, as there is no known cure, with the goal of preventing relapses and 
controlling the symptoms. Compounded by the chronic inflammation presented by the disease, a 
patient with clinically diagnosed IBD is at an increased risk for developing colon cancer, third 
leading cancer for new cases and related deaths for both men and women in US4–6,42, deepening 
the burden to public health care and associated costs171,172.  
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The literature suggests an association of diet and nutrients with the risk of developing 
IBD104,173,174. Often times, however, nutritional guidelines are given to prevent or manage flares 
of disease symptoms upon  IBD diagnosis103,112–115.  Due to symptoms inflicted by IBD and 
compromised functions of small intestine for proper nutrient absorption153,175–177,  diet and nutrient 
recommendation are provided to remedy the nutrient deficiency and related morbidities, such as 
anemia due to iron deficiency, experienced by IBD patients. Indeed, according to Crohn’s & 
Colitis Foundation of America, certain fluids, selective sources of fiber and whole grains, fruits 
and vegetables, proteins, and calcium are recommended while avoiding certain foods within the 
same food group113 for disease management.  A systemic review of the literature evaluating a 
potential link between diet intake and IBD development has identified high consumption of total 
fat, polyunsaturated fatty acids, omega-6 fatty acids, saturated fats, and meats to be associated with 
increased risk for IBD, while greater intake of fruits and fiber were associated with decreased risk 
for Crohn’s disease, but not for ulcerative colitis104. Moreover,  cross-sectional studies on IBD 
patients have found evidence of positive association of meat consumption and disease 
development 103,105 but also saw nutrient deficiency105 and diet change as a result of the disease or 
disease state116,178.  With the urbanization and globalization of economy, increasing incidences of 
inflammatory diseases, such as autoimmune disease and obesity-related health conditions as well 
as IBD97–101, is being linked to the adoption of westernized lifestyle and diet104,179–181. However, a 
definitive relationship in the role of diet in disease etiology or symptom management still need 
much elucidation.  
To our current knowledge, a relationship between diet consumption and prevalence of IBD in 
US population has not been studied using a national health survey. Here, we used NHIS 2015 and 
Cancer Control Supplement to characterize sample US adults who were ever told by the health 
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professional of having IBD and their demographic and lifestyle information and food consumption 
behavior.  
4.3 Methods 
Survey and datasets 
Analysis was performed using 2015 National Health Interview Survey (NHIS), which has 
the quinquennial Cancer Control Module (CCM)38 as a supplemental assessment. NHIS is a cross-
sectional household survey conducted yearly since 1960. For the survey year of 2015, a total of 
103,789 individuals were recruited in various areas of 32 states and DC (District of Columbia).  
They are interviewed face-to-face with computer assistance about their health/disease status, 
health behavior and health care access, as well as their demographic and socioeconomic status, 
and other supplemental variables.  The questionnaire consists of six sections: Household, Family, 
Person, Sample Child, Injury Episode, and Sample Adult. For the current analysis, data from 
Person file, Sample Adult file, and Sample Adult Cancer file from CCM were primarily used in 
addition to Imputed Income files for the analysis of family income to poverty threshold ratio. All 
the responses pertaining to current analysis are self-reported. To account for disproportionate 
sampling of the participants and nonresponse rate inherent to the survey design and proper 
representation of US population, survey weights (wtfa_sa, strat_p, psu_p) derived from the 
estimates of 2010 census-based population182 were applied for each appropriate analysis.  
Keeping of predictors and merging of datasets 
Imputed income data files For the imputed income data files, a dictionary in the Stata format was 
created for each income file to read the original *.dat file format with fixed column width. For all 
5 imputed income data files, three unique identifiers- hhx, fmx, fpx- and variable povrati3 (income 
to poverty threshold ratio) was kept. Each dataset was sorted by the unique identifiers before 
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merging was initiated via many to one merge command merge m:1, which resulted in one income 
data file.  
Person, Sample Adult, Sample Adult Cancer files The three unique identifiers were kept for 
each of the Person, Sample Adult, and Sample Adult Cancer files. In addition, predictors of interest 
included in the files were kept: Ethnicity (origin_i), Race (racerpi2), Age (age_p), Gender (sex), 
Alcohol consumption (alcstat), Body Mass Index (bmi), Region (region), Tobacco use status 
(smkev, cigarev, pipev1, smklstob), Ulcerative colitis/Crohn’s disease (ulccolev), and frequency 
and rate of the Diet and Nutrition predictors (described below).   
Merging of income file with other files 
Before merging, each data file was sorted by hhx, fmx, fpx, which are the three unique 
identifiers. First, the Person file was designated as the master file.  Using the command merge m:1 
hhx fmx fpx, income data file was merged onto the Person file.  Second, using the same command, 
the Sample Adult file was merged onto the resulting file from step 1. Third, using the same 
command, the Sample Adult Cancer file was merged onto the resulting file from step 2.  
Completion of merging yielded a working datafile that contained all the predictor and response 
variables.   
Study variables  
Demographic predictors  
The sample consisted of non-institutionalized adults between the ages of ≥ 18 to ≤ 85 who 
answered NHIS survey and CCM concurrently. There was a total of 33,672 sample adults for the 
2015 survey.  
Race and Ethnicity Participants who self-reported their gender as Male (M) or Female (F) were 
analyzed. Ethnicity was categorized to either Hispanic or Non-Hispanic. Race was categorized as 
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follows: “White only”; “Black or African-American”; “American-Indian or Alaska Natives”; 
“Asian only”; “Multiple race”; “Race Unknown”.   
Age Continuous age variables were classified into categories of ages between 18 and 24 years old, 
ages between 25 and 34 years old, ages between 35 and 44 years old, ages between 45 and 54 years 
old, ages between 55 and 64 years old, ages between 65 and 74 years old, and ages between 75 
and 85 years old.   
Poverty status Family income to poverty threshold ratio (IPR) was applied to all members of the 
household at the time of interview regardless of age. IPR was obtained following the imputed 
income data analysis guideline provided by CDC183. Briefly, as the imputed income files are 
separated into 5 individual files, the datafiles were first merged using a common identifier.  Once 
applied, combined point estimates from the 5 data sets were averaged. To isolate and analyze only 
the adults and their corresponding IPR, a dummy variable was created, and subsequently 
categorized based on the IPR as Poor (Less than 100% of poverty threshold), Near Poor (100% to 
less than 200% of poverty threshold), or Not Poor (200% of poverty threshold or greater). Region 
of the participants’ residence at the time of the interview was also included.  
Lifestyle predictors  
Body Mass Index Participants body mass index (BMI) information was categorized into the 
following groups: Underweight (BMI less than 18.5); Healthy (BMI between 18.5 to less than 25); 
Overweight (BMI between 25 to 30); Obese (BMI of 30 and greater).  
Smoking Participant was categorized as having ever smoked, if he/she self-reportedly “smoked at 
least 100 cigarettes in his/her entire life”; “ever used smokeless tobacco products even one time”; 
“ever smoked a regular cigar, cigarillo, or a little filtered cigar even one time”; “ever smoked a 
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pipe filled with tobacco-either a regular pipe, water pipe, or hookah even one time”. To be 
considered having never smoked, the participant must have answered "No" to all four questions. 
Alcohol Alcohol use information was subdivided into two categories to identify the user status 
and consumption status. User status was categorized as the following based on their self-reported 
drinking habits: Abstainer (Any adult over the age of 18 whose alcohol consumption is less than 
12 times in lifetime); Former (Any adult over the age of 18 whose alcohol consumption is greater 
than 12 times in lifetime but none in past year); Current (Any adult over the age of 18 whose 
alcohol consumption is greater than 12 in lifetime and consumed at least 1 drink in the past year). 
Alcohol consumption status was categorized as the following: Abstainer (consumed less than 12 
times in lifetime); Infrequent (consumed less than or equal to 12 times a year); Regular or Light 
(consumed greater than 12 times a year but less than or equal to 3 a week in the past year); 
Moderate (consumed 3-14 times a week for males, 3-7 times a week for females); Heavy 
(consumed greater than 14 times a week for males; greater  than 7 times a week for females).  
Diet variables 
From CCM, the following diet and nutrition information from Dietary Screener 
Questionnaire was assessed: Hot or cold cereal, popcorn, brown rice/whole grains, whole grain 
bread, fries or any other fried potatoes, green leaf or lettuce salad or any kind, 100% pure fruit 
juice, vegetables, non-fried potato, pizza, fruits, tomato sauce, salsa made with tomatoes, beans, 
cow milk, cheese (excluding cheese from pizza), ice cream or frozen desserts, processed meat, red 
meat, cookies (including pies, cakes, brownies), donuts/pastries/muffins, candy or chocolate, 
sports and energy drinks, regular soda or pop, sugar or honey sweetened coffee or tea, and sugar 
added fruit drinks. From here onward, the word “food” and “diet” are used interchangeably.  
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For the diet variables, participants were asked “During the past month, how often did you 
have/eat [diet item]? You can tell me per [day, week, or month]”. Subsequently, the responses to 
nutrition and diet questions were subdivided into two parts: number of units of consumption (i.e. 
3 times) and the consumption rate (i.e. per day, per week, per month). To streamline the analysis, 
we have converted the values to reflect the monthly consumption. To create a binary response of 
whether the participant consumed the food item in the past month or 30 days, any participants who 
self-reported such consumption, regardless of the frequency, was considered having consumed the 
food item.  Likewise, who responded “Never” to the question was considered not having consumed 
the food item in the past month.  
Due to the nature of responses based on recalls and self-reports, responses to the food 
consumption rate included unusually large values that seem unreasonable from the practical point 
of view. Nevertheless, these responses were considered extreme but probable, therefore not edited 
in the survey. In order to address its potential effect on the overall data, per recommendation and 
methods addressed by National Cancer Institute, the maximum frequency value for extreme values 
in each diet item was applied (For more details: https://epi.grants.cancer.gov/nhis/2015-
screener/scoring/)184. Any observations for the diet variable exceeding the maximum frequency 
value allowed were top-coded accordingly to prevent being lost/excluded in the analysis. Summary 
statistics and modeling are based on this change.  
Response variable 
For 2015 NHIS, Crohn’s disease/ulcerative colitis was included as one of the health 
assessments for sample adults.  Adults who self-reported to the question “Have you ever been told 
by a doctor or other health professional that you had Crohn’s disease or ulcerative colitis?”  were 
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included in the analysis. From here on forward, participants will be referred to as having “Colitis” 
(colitic) or not having colitis (non-colitic).   
Analysis 
All analysis was performed using Stata/IC 15 (StataCorp LLC, Texas, USA). To apply the 
survey weight and the survey design designation to the working dataset, svyset [pweight=wtfa_sa], 
strata (strat_p) psu (psu_p) was commanded to allow for weighted data analysis. Survey design 
was specified using svy: or svy, subpop for each weighted analysis. Level of significance was set 
at 0.05 for all tests. To test the difference in proportions of categorical responses, F-statistics was 
performed using svy: prop followed by test (Adjusted Wald Test) to test the null hypothesis of 
equal proportions. Independence of two categorical variables was tested using svy: tab Pearson 
Design-based F-statistics to test the null hypothesis of no association.  To estimate the likelihood 
of colitis as an outcome with the consumption of individual food item, svy: logistic dv iv was used 
to yield odds ratio (OR) and 95% Confidence Interval (95% CI) for the bivariate analysis. 
Multivariate regression analysis performed for models with more than one food item controlled 
for demographic variables, or lifestyle variables, or all demographic and lifestyle variables.  The 
order of diet items included in the full model is based on unweighted, unadjusted association found 
for each item with the outcome colitis using either Pearson Chi-Square test (Categorical variables) 
or Wilcoxon Mann-Whitney Test (Continuous variables).  
To characterize the prevalence of colitis between those who consumed the food item above (> 
Median) and below or equal (≤ Median) to the median value, binary dummy variables were created 
using the median as a cutoff value. Point prevalence of colitis within subpopulation with different 
consumption behavior was estimated using svy: tab dv iv, or svy: prop var1, over(var2), or 
proportion var1 [weight], over[var2]. Test of variable independence and the test of proportions 
80 
 
 
were performed as described above. To determine the odds of colitis as an outcome for those eating 
> Median or ≤ Median consumption value, svy: logistic [vars] was used. To characterize the odds 
of having colitis eating certain food items within the subpopulation, svy, subpop (if 
[var1==condition]): logit [vars], or was used.  
4.4 Results 
Characteristics of survey participants (Unweighted) 
Total survey population was 103,789 (Table 1.1). There was a total of 33,672 adults aged 
between ≥ 18 and ≤ 85. Among the adults, 44.76% were Males and 55.24% were Females.  The 
least amount of people participating in the survey were in the age group of 18-24 and 75-85, with 
8.58% and 10.94%, respectively. Ethnicity was reported as 83.40% as Non-Hispanic and 16.60% 
as Hispanic. Most participants were White in racial background (76.71%), followed by Black or 
African-American (13.88%), Asian (5.89%), Multiple race (2.08%), and American Indian or 
Alaskan Natives (1.16%). Race was unknown for less than half a percent of the participants. 
Participants were recruited from the regions of South (34.59%), West (27.75%), Midwest 
(21.09%), and Northeast (16.57%). According to the family income to poverty threshold ratio 
(IPR), 15.86% of the participants were considered Poor, 20.85% were considered Near Poor, and 
over 63% were considered Not Poor. While smoking status was unknown for 3.77% of the survey 
participants, about 50% has ever smoked and about 46.17% never smoked. When the alcohol user 
status was assessed, about 62.52% were Current drinkers and 15.60% were Former drinkers, while 
20.58% of the participants abstained from drinking. When the alcohol frequency was assessed, 
about 35.63% drank regularly or lightly, 22.52% drank infrequently, 14.66% drank moderately, 
and 4.99% drank heavily. Alcohol use and the consumption rate was unknown for less than 2% of 
the survey participants. According to body mass index (BMI), 1.79% was Underweight, 32.26% 
81 
 
 
had Healthy BMI, 32.80% were Overweight, and 29.75% were considered Obese. Amongst the 
survey participants, 454 responders or 1.35%, were ever told by health professionals or medical 
doctors that they have colitis (ulcerative colitis/Crohn’s disease).  
Characteristics of estimated population with colitis 
Among estimated population with colitis Females were more likely to have colitis than Males 
(Table 1.2, Fig. 8A; 57.41% vs. 42.59%, respectively; p-value 0.0234). Adults aged between 18-
24 were least likely to have colitis (4.95%), while late middle to early elderly aged group of 55-64 
years old had the most colitic population (23.13%) but only statistically different when compared 
with colitic 18-24 year old, 35-44 year old, and 75-85 year old groups (vs. 18-24: p-value=0.0009; 
vs. 25-34: p-value=0.0659; vs. 35-44: p-value=0.0028; vs. 45-54: p-value=0.1848; vs. 65-74: p-
value=0.0557; vs. 75-85: p-value=0.0003; data not shown on Table; Fig. 8D).  Non-Hispanic in 
ethnic background were more likely (87.20%) to have been diagnosed with colitis and White 
(88.18%) were also more likely to have been told that they have colitis than people of other races 
(Fig. 8C, 8F). Population with colitis were more likely reside in South (38.32%) compared to those 
living in Northeast (19.35%), Midwest (22.09), or West (20.25%) (Fig. 8E).  Colitis was more 
prevalent amongst population whose poverty threshold was at 200% or greater (66.32%) compared 
to Poor (15.73%) or Near Poor (17.95%) (Fig. 8C). Smokers were more represented than 
nonsmokers in colitic population (Fig. 9C). A greater percentage of people with colitis were 
current drinkers (58.15%) and tend to drink regularly or lightly (Fig. 9A, 9B),   and the disease 
was more common in people with BMI range of 18.5 to < 30 kg/m2 (Fig. 9D).  
Characteristics of diet consumption in estimated population with colitis 
The assessment of number and proportions of sample population and estimated population who 
have consumed food items in the past month is displayed in Table 2.1. Comparing the weighted 
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proportions of colitic and non-colitic population, past 30-day consumption in the Whole Wheat 
Grain group (Fig. 10A) which includes popcorn, hot or cold cereal, brown rice/whole grains, and 
whole grain bread, was similar for both populations (Table 2.2).  Among the food items in the 
Fruits and Vegetables group (Fig. 10D), consumption of fries, including other fried potatoes, was 
significantly greater in colitis population than the general population without colitis (84.73% vs. 
79.75%, F-test=5.78, p-value 0.0168), while consumption of salad, 100% pure fruit juice, 
vegetables, non-fried potatoes, pizza, fruits, tomato sauce, salsa made with tomatoes, and beans 
were similarly consumed. Consumption of Dairy products (cow milk, cheese, pizza, and ice cream 
and other frozen desserts), Meat (processed meat, red meat), Sweetened Food/Drinks (hot or cold 
cereal, cookies, donuts and other pastries, sweetened coffee or tea, sweetened fruity drinks, candies 
and chocolates, sports and energy drinks, regular soda or pop, and ice cream) , and Sugars from 
Drinks (sweetened coffee or tea, sweetened fruity drinks, sports and energy drinks, and regular 
soda or pop) were also similar between the two population groups (Table 2.2, Fig. 10B, Fig. 10C).   
Relationship of diet consumption and colitis 
Binary consumption response 
To determine the odds or likelihood of having colitis based on whether a person has consumed 
the food item in the past month, logistic regression on each individual food item was applied with 
colitis as an outcome, and the results are depicted in Table 2.3.  According to the analysis on 
weighted, but unadjusted data of binary response of food consumption, the odds of having colitis 
was 1.41 times for those who consumed fries in the past month than that of those who did not eat 
fries during the same time period (95% CI [1.030-1.929], p-value=0.032). When adjusted for 
demographic factors such as age, race, poverty status, sex, ethnicity, and region or the lifestyle 
factors such as smoking status, alcohol user status, alcohol consumption rate status, and BMI, the 
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odds remained high at 1.63 (95% CI [1.189-2.245], p-value=0.003) and 1.40 (95% CI [1.022-
1.924], p-value=0.036), respectively, for those who consumed fries in the past month.  This 
observation remained unaltered when both demography and lifestyle factors were accounted for 
in one model (Table 2.3, OR=1.63, 95% CI [1.183-2.238], p-value=0.003). The likelihood of 
having told that one has colitis for sports and energy drink consumers was 1.48 times and 1.50 
times that of non-consumers during the same time period when adjusted for demographic factors 
alone (95% CI [1.099-1.987], p-value=0.010), or with the lifestyle factors in one model (95% CI 
[1.116-2.027], p-value=0.008), respectively, but unremarkable when adjusted for lifestyle factors 
alone. 
When all the food items were included in a weighted but unadjusted full model, having 
consumed popcorn or milk decreased the odds of having colitis to 0.73 (95% CI [0.5445-0.9674], 
p-value=0.029) and 0.67 (95% CI [0.4844-0.9403], p-value=0.020), respectively, to that of those 
who did not consume popcorn or milk in the past 30 days (Table 3).  In contrast, the odds were 
higher for people eating cereal or fries at 1.50 times (95% CI [1.0286-2.1811], p-value=0.035) and 
at 1.48 times (95% CI [1.0468-2.0810], p-value=0.026), respectively, that of those who have never 
consumed the food item in the past month.  Adjusting for demography and/or lifestyle variables, 
decreased odds of having colitis in people eating popcorn or milk and increased odds with fries 
consumption remained unaltered (Table 3).  Sports and energy drink consumption increased the 
odds of having colitis by 43-46% compared to those who did not consume any in the past month, 
and this analysis was significant only when adjusted for demography or demography and lifestyle 
predictors all in one model.  Significance in the effect of cereal consumption on increased odds of 
having colitis was supported only when adjusted for lifestyle predictors.   
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Monthly consumption rate 
To determine the odds of ever having been told that one has colitis by a medical or health 
professional and its association to the food consumption behavior, we fitted the monthly 
consumption rate (number of times per month, continuous variable) responses of each individual 
food items to a logistic regression model with colitis as a dependent variable (Table 4.1) adjusting 
for both demography and/or lifestyle factors. In a weighted, unadjusted analysis, we found a 
statistically significant increase in odds of being colitic with consumption of cheese (OR=1.006, 
95% CI [1.0021-1.0104], p-value=0.003), ice cream (OR=1.011, 95% CI [1.0022-1.0203], p-
value=0.015), and regular soda or pop (OR=1.006, 95% CI [1.00967-1.00969], p-value=0.003). 
When the model was adjusted for demography predictors, consumption of fries, cheese, and soda 
was significantly associated with an increase in odds of having colitis by 0.7-1.1% for every unit 
of increase in those respective food item consumption (Table 4.1). The odds of being colitic was 
statistically significantly greater in those consuming ice cream in an unadjusted (OR=1.011, 95% 
CI [1.0022-1.0203], p-value 0.015) and lifestyle adjusted (OR=1.011, 95% CI [1.0021-1.0201], p-
value 0.016) model.  When adjusted for both demography and lifestyle predictor variables in one 
model, the odds of having colitis increased as the monthly intake of fries (OR=1.011, 95% CI 
[1.003-1.019], p-value=0.005) increased. The observation was similar for those who consumed 
cheese (OR=1.008, 95% CI [1.004-1.012], p-value<0.001) and regular soda or pop (OR=1.007, 
95% CI [1.003-1.011], p-value=0.001).  Inclusion of all food items in one model, in weighted 
unadjusted or adjusted for demography and/or lifestyle predictor variables, has found consumption 
of cheese and regular soda or pop to significantly increase the odds of having colitis with every 
consumption unit increase of that food item (Table 4.2). 
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Next, we characterized the median monthly consumption rate for each food items (Table 
5.1).  Median monthly consumption rate for the sample adult population and weighted general 
adult population, regardless of colitis disease state, was the same for each food item assessed, with 
a minor variation in the point estimates for brown rice or whole grains, fries or other fried potatoes, 
regular soda or pop, and sweetened coffee or tea (Table 5.1). Using the median value identified in 
the weighted analysis as a cut off value, we further stratified colitic and non-colitic subpopulation 
into two groups (Table 5.2): 1) Monthly consumption rate (greater than) > Median; 2) Monthly 
consumption rate (equal to or less than) ≤ Median.  Comparison of proportions of population with 
two different pattern of median monthly consumption rate between people with and without colitis 
has found colitic population are drinking 100% pure fruit juices significantly less often than the 
general non-colitic population. About 44.83% of colitic population were drinking pure fruit juice 
at a rate that is greater than the median compared with 52.25% of general non-colitic population 
(F-test=4.78, p-value 0.0295).  In contrast, more colitic population consumed cheese (53.05% vs 
43.88% in non-colitic population; F-test=8.78, p-value=0.0033) and cookies/pies/cake (53.25% vs 
46.46% in non-colitic population;) at a greater rate in the past month than the general non-colitic 
population (Table 5.2).  We also compared the point prevalence of colitis in each consumption rate 
strata (Supplemental Table S1). The significance coincided with the findings just mentioned. 
Prevalence of colitis was significantly higher in group drinking pure fruit juice below the median 
rate (Point prevalence=1.4892, 95% CI [1.487-1.491]), but lower in group that consumed cheese 
(Point prevalence=1.0833, 95% CI [1.082-1.085]) and cookies/pies/cake (Point 
prevalence=1.4892, 95% CI [1.487-1.491]) less often in the past month (Supplemental Table S1). 
To determine the odds of having colitis in population with a monthly median consumption 
rate of ≤ Median compared to the strata with > Median (base level), we applied logistic regression. 
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After adjusting for both demography and lifestyle predictor variables in a single model, we found 
people eating cheese (OR=0.629, 95% CI [0.491-0.807], p-value<0.0001) or sport and energy 
drinks (OR=0.665, 95% CI [0.493-0.896], p-value=0.008) at or below the median rate to be less 
likely to have been told that they have colitis than that of people consuming greater than the median 
rate (Table 5.3).  
Odds of colitis and monthly median consumption rate 
To identify the odds of having colitis within the subpopulation with different monthly median 
consumption rate, we modeled colitis with overall monthly consumption frequency in logistic 
regression for the subpopulation eating greater than median (> Median). The same was applied to 
the subpopulation of those eating at or below the median consumption rate (≤ Median). In an 
unadjusted model, within those who are already reporting greater than the median (> Median) 
monthly consumption rate, a one-unit increase in their  monthly consumption of vegetable 
decreased the odds of being colitic by 1.2% (95% CI [0.9621-0.9948], p-value=0.001) while eating 
more frequently the non-fried potatoes, ice cream or frozen desserts, sweetened coffee or tea, or 
regular soda or pop slightly, but statistically significantly, increased the odds by 0.4 - 1% (Table 
6.1).  In contrast, those eating at or below the monthly consumption rate of popcorn or whole grain 
bread decreased the odds of being colitis to 62.4% (95% CI [0.4290-0.9087], p-value=0.014) and 
91.3% (95% CI [0.8606-0.9679], p-value=0.002), respectively, per one-unit increase in 
consumption of the same respective food items. Moreover, while increase in consumption of fries 
in those who are already eating more than the median monthly rate had no significant effect on the 
odds of having colitis, consuming fries one-unit more frequently in those who report at or below 
the monthly consumption rate will increase the odds of being colitic by 18.8% (95% CI [1.0511-
1.3433], p-value=0.006, Table 6.1).  
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Adjusting for demography predictors negated the significant effect of increasing consumption 
frequency of non-fried potatoes, ice cream or frozen desserts, and coffee on the odds of being 
colitic in those who already reported greater than the monthly median rate (Table 6.2). However, 
the decreased odds of being colitic remained unchanged with increasing consumption of 
vegetables in those who already consume more than the median monthly rate (OR=0.98, 95% CI 
[0.9622-0.9950], p-value=0.011). Likewise, consuming regular soda or pop more frequently in 
those who already drink more than the median monthly rate increased the odds of being colitic 
(OR=1.01, 95% CI [1.0035-1.0108], p-value< 0.001). Similarly, in those who report consuming 
at or below the median rate, the beneficial effect of more frequent consumption of popcorn and 
whole grain bread, and the negative effect of fries on the odds of being colitic remained unaltered 
(Table 6.2),  When adjusting for lifestyle predictors alone, a further increase in monthly 
consumption for those who already report greater than the median consumption of non-fried 
potatoes, ice cream or frozen desserts, donuts, sweetened coffee or tea, and regular soda or pop 
increased the odds of being colitic, nominally but statistically significantly, by 0.4 -1.14% (Table 
6.3). In contrast, the effect of increase in consumption rate of popcorn and whole grain bread for 
those reporting at or below the median on lower odds of being colitic, and greater odds of colitis 
with increasing consumption of fries in the same subpopulation, remained significant even after 
adjusting for demography and/or lifestyle predictors (Table 6.4); For those who already reported 
greater than median monthly consumption, eating vegetables more frequently decreased the odds 
of colitic by 1.2% while increasing the odds by 0.7% for every unit increase of drinking soda per 
month  (Table 6.4). 
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4.5 Discussion 
In our present study, we evaluated a nationally representative US adults affected by 
inflammatory bowel disease and their estimated intake of food items using NHIS 2015.  We sought 
to: 1) Characterize the estimated population with colitis; 2) Compare the proportions of colitic and 
non-colitic population who have consumed certain food items in the past 30 days included in the 
diet and nutrition screening questionnaire; 3) Determine the likelihood of being colitic based on 
consumption of certain food items and intake frequency; 4) Compare the likelihood of being colitic 
based on the frequency of consumption (>Median or ≤ Median).  
As previously reported12, over 3.08 million US adult population have either ulcerative 
colitis or Crohn’s disease. Our analysis reveals IBD to affect women more so than men, which 
sustains the trend previously reported12,14,185,186. Compared to non-colitic population, adults 
between the age of 55-64 years old were more represented in colitic population.  White is more 
represented in colitic population while Black/African-American and American Indian or Alaska 
Native population affected by the disease are significantly less. While the findings may reflect 
potential disease susceptibility or health disparity due to racial and genetic differences, the 
information may also reflect underestimation or under-representation of disease diagnosis in racial 
minorities attributable to differences in health equity187,188.   
In our assessment of behaviors associated with health risks, we found smoking to be more 
prevalent in colitic population compared to non-colitic general population (57.15% vs 50.88%, 
respectively), which is consistent with recent report by Xu et al185. While greater proportion of 
colitic population was identified as current drinkers than former drinkers, this percentage was 
significantly less compared to the population without colitis. Instead, we found that people with 
colitis were more likely to have been a former drinker (25.68%) than the non-colitic general 
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population (14.06%). Moreover, population with colitis were also more likely to drink infrequently 
than the rest of the non-colitic population. While colitis was least prevalent in underweight (BMI 
< 18.5) population, differential distribution of all levels of BMI in population with colitis was 
unremarkable from the distribution found in general population without colitis.   
Diagnosis of chronic disease often induces changes in health-related behaviors such as 
smoking, drinking, substance use, physical activity, and diet189–191. Cross-sectional and 
longitudinal studies of US men and women diagnosed with chronic illnesses report reduction in 
smoking189,190 and drinking189,190,192 following the diagnosis. Health behavioral change over time 
was also greater in cohort with disease diagnosis than the healthy controls189.  While the historical 
account of smoking effect on disease morbidity and mortality cannot be refuted193, literature hints 
a differential association of smoking on IBD35–37. Review of literatures suggest smoking to be 
negatively associated with the risk of UC while posit associating with CD27. An observation of 
non-smoking as a characteristic of people with UC prompted a study looking at smoking status in 
UC and CD patients194. Here, greater proportion of UC patients were either former smokers or 
abstainers while higher percentages of CD patients were more likely to be a current smoker or 
have ever smoked194. Cessation of smoking was associated with the exacerbation of symptoms and 
increased risk of UC soon after quitting, compared to those who never smoked27,194,195. Lower 
prevalence of current alcohol drinking and less frequent drinking behavior found in our analysis 
comparing colitic population to non-colitic population may reflect probable personal intervention 
to manage IBD, for alcohol consumption has been reported to worsen gastrointestinal 
symptoms196,197. Indeed, alcohol was one of the common foods IBD patients elected to omit due 
to symptom flare ups178. Even so, alcohol consumption in patients with inactive IBD state was 
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comparable to the general population197, and binge-drinking behavior was found to be no 
different185.   
In our study, we found several food items more likely to be consumed by people with colitis 
than people without colitis. Of 26 food items assessed, we found significantly greater proportion 
of estimated colitic population to have consumed fries at least once in the past 30 days than the 
non-colitic population, but with a comparable consumption in all other food items evaluated. 
Popcorn consumption was also less prevalent in colitic population, although this finding in 
weighted but unadjusted analysis was only marginal (p-value = 0.0511).  We also assessed the 
odds of ever being told that a person has colitis with respect to whether he/she has eaten certain 
food items at least once in the past 30 days.  A robust relationship was found between the fries/fried 
potato intake and an increased likelihood of colitis. Such significant association was not affected 
by demography and/or lifestyle factors. Moreover, having ever consumed sports and energy drinks 
in the past 30 days also increased the odds of having colitis compared to those who have never 
drank such drinks during the same time period. But this was only significant when adjusted for 
demography alone or having demography and lifestyle factors in one model, which can be 
explained by reportedly a strong influence of age, sex, and poverty level has on the intake of sports 
and energy drinks198.  We also saw in the multivariate regression analysis, a 1% increase in odds 
of being colitic with one unit increase in the intake of fries, cheese, or regular soda or pop based 
on the recall of past month consumption.  Compared to the general non-colitic population, people 
with colitis were also more likely to consume cheese and cookies more frequently (> monthly 
median).  
Present analysis has also found consumption of certain food items and intake rate to 
decrease the likelihood of being colitic. Having ever had milk or popcorn in the past 30 days and 
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intake of 100% pure fruit juice at greater than monthly median frequency (4.3333 times a month) 
lowered the odds of having colitis.  In addition, consuming cheese less than or equal to 13 times a 
month or not having consumed sport and energy drink during the past month was associated with 
lower odds of colitis compared to those whose intake is greater, regardless of demography and 
lifestyle background.    
In population eating food item at a frequency ≤ (at or below) the monthly median, we 
wanted to see if changing their current eating habit by increasing the intake by one unit would 
affect their likelihood of being colitic. After accounting for covariates, we found greater odds of 
being colitic with an increase in the intake of fries for those who eat less frequently than the 
monthly median. However, this observation was not seen in population whose intake was already 
high (> Median). In addition, increasing the intake of popcorn was associated with lowering the 
odds of being colitic in population whose consumption was already ≤ monthly median, but the 
association was absent in population whose intake was greater than the median rate. As anticipated, 
for people drinking regular soda or pop more than 2 times a month, further increase in frequency 
was even more damaging. However, the lack of negative effect of increasing the intake in people 
who drink less to begin with was unexpected. This selective effect was also seen with the vegetable 
consumption, where the benefit of increasing the frequency of vegetable intake was augmented for 
population already eating greater than 21.67 times a month while the odds of being colitic did not 
change in population whose vegetable intake is less frequent at baseline (≤ Median). 
NHIS 2015 has included Dietary Screener Questionnaire (DSQ) developed by the Risk 
Factor Assessment Branch of National Institutes of Health, National Cancer Institute, Division of 
Cancer Control & Population Sciences199. Food items were included in the survey as a part of diet 
and nutrition assessment of CCM. In present analysis of national survey of over 33,600 sample US 
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adults, the lack of finding the breadth of differential consumption pattern in our estimated colitic 
and non-colitic population was surprising. However, we did see some similarity and differences 
with other literatures in the assessment of dietary intake among cohorts with IBD.  Our analysis 
has shown a marginal decrease in the popcorn intake in colitic population compared to non-colitic 
population while intake of popcorn was associated with the decrease in odds of being colitic. 
Popcorn is part of whole grain food group, a source of dietary fiber200,201 which has shown to 
benefit the gastrointestinal symptom management of IBD and improvement in immune response 
and intestinal lesions in experimental colitis animal model202.  Several studies suggest high 
avoidance of popcorn in people with colitis due to its adverse effect on gastrointestinal flares178,203. 
However, the same study also indicated people with colitis to normally eat popcorn, just not during 
the flare-ups178.  
Our analysis has found a robust positive relationship between having consumed fries and 
odds of colitis.  Fries consumption was also more prevalent in colitic population compared to non-
colitic population but saw no difference in the monthly intake frequency between the two 
population. In contrast, Vagianos et al. found intake of fried potatoes to be significantly less in 
IBD cohort than matched cotrols178 and fried foods in general were perceived by colitic patients to 
worsen their symptoms203.  The health risk associated with fries or fried food consumption have 
been reported by many studies204–208. Recent publication has associated high intake of fried 
potatoes, but not unfried potatoes, with an increase in 8-year mortality rate, but the study was done 
in patients with high risk for osteoarthritis who may have underlying medical conditions204. Potato 
is a vegetable that can be a nutritious part of a balanced diet, and is abundant in micronutrients 
such as potassium, vitamin C, vitamin B6, folate, phosphorous, calcium, magnesium, niacin, and 
others that can assist in meeting daily recommendation of nutrients209,210.  Studies suggest, the food 
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processing such as frying in oil, but not necessarily the food itself, to offset the impact of food on 
health205,211–214 and the nutrient quality211,215–219.  
Odds of being colitic was also influenced by different frequency intakes of cheese, regular 
soda or pop, sports and energy drinks, milk, and 100% pure fruit juice in our analysis.  We found 
marginal benefit of consuming milk in decreasing the odds of being colitic.  Cheese consumption 
was also more prevalent in colitic population and its increase in intake was positively associated 
with the likelihood of being colitic. While several studies have noted milk and milk products to 
exacerbate gastrointestinal symptoms and thus avoided by IBD patients178,203, a systemic review 
on the effect of milk/dairy product on chronic inflammatory disorders has found the consumption 
to be beneficial220 with the effect of cheese being inconsistent and yogurt alleviating disease-
related symptoms103,105,178,203,221. There is a limited evidence on the impact of consumption of sport 
and energy drinks, carbonated beverages such as soda and pop, and 100% pure fruit juice on IBD 
risk or symptom management. We found the intake of soda or pop and sports and energy drinks to 
be very prevalent in colitic population in our analysis, which is consistent with the other 
findings103,105,178,192. Consumption of high-sugar as found in soda and regular sport and energy 
drinks were found to be positively associated with increased odds of CD and UC development110. 
Moreover, high intake of total sugar or in a form of sucrose97 or monosaccharide222 was also 
significantly associated with increased odds of developing IBD222, but more profoundly in UC 
than CD97. In contrary, Cohen et al has found less intake of soda among both UC and CD 
participants due to its association with symptom exacerbation203.  However, the comparison of 
soda intake to non-colitic population was not made in his study.  
From our analysis, certain health behavioral traits and diet intake associated with colitic 
population can be inferred.  The strength of our current study is the utilization of national health 
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survey in which estimations that are representative of US adult population can be made.  To our 
knowledge, current analysis is the first to assess food intake pattern in nationally representative 
IBD population in US. However, because the survey design is not disease specific, several 
limitations arise in the interpretation of our findings. First, the survey does not differentiate the 
two forms (UC or CD) of disease. Second, the survey does not ask disease-specific questions such 
as the duration or the condition of the disease (remission vs relapse) or whether changes in certain 
habits such as health-related behaviors and food consumption behaviors are due to disease 
diagnosis. While dietary recommendation and guidelines exist103,112–114,223–225, whether people 
with colitis adhere to such dietary plans are not well  studied226. As with the change in health-
related behaviors previously described in people with other chronic diseases189–191, modification 
of diet and nutrition intake to better manage gastrointestinal symptoms is also likely. Indeed, a 
cross-sectional study suggest a change of diet in majority of colitic patients is based on their 
perception of or the attitude toward the benefit of the diet in gut symptoms105. However,  they are 
also likely to self-direct in their choice of food items than to follow any type of dietary treatments 
such as low- or high-fiber diet, grain/carbohydrate diet, dairy diet, and low short-chain 
carbohydrate diet116. Same study also found high Food Related Quality of Life (FRQoL) survey 
mean score among IBD patients who follow no diet than those who follow one or more diet in a 
dose dependent manner116. The complexity in assessing the role of diet in IBD risk or symptom 
management is also compounded by reports of differential effects of nutrition and diet intervention 
on the course of disease108,112,115,117–119.  In addition, the dietary questionnaire has innately present 
weakness associated with the dietary recall bias based on the memory of the respondent227–229.  The 
questionnaire lacks details on how the food was consumed (i.e. homecooked or purchased) or 
prepared (i.e. fried or steamed), which can provide further insight on food intake behavior.  One 
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major limitation is the inclusiveness of different food items and their co-intake, as exclusive 
consumption of certain food item(s) would be highly unlikely.  
Consideration of diet as one of the etiological factors in IBD has been secondary to a more 
established link between the disease and adverse immune response37,168–170. Nonetheless, the 
understanding of critical influence the environmental factors such as diet, lifestyle, and social 
factors have on IBD pathology has grown tremendously26,38,168,230,231. Now, there is increasing 
evidence that suggests a critical interaction between diet and microbiota as another etiological 
factor in IBD development. While the elaboration of the role of gut microbiota in IBD is outside 
the scope of this paper, it is worth mentioning a potential influence diet may have on maintaining 
the stable expression of human gut microbiota critical for general health and nutrient 
metabolism232,233.  Recent studies and reviews have begun to suggest a potential contribution of 
diet to the microbiota density variation in human gut and obesity-related health outcomes234–238.  
A review by Viennois et al. suggests that there may be a potential gain in adjusting the diet to 
accommodate the  variability of microbiota composition that exists within population and the 
composition unique to certain inflammatory diseases, including IBD238.  Different metabolic by-
products made available by diverse dietary patterns and foods introduced to the host is thought to 
be critical in the maintenance of the homeostatic microbiota composition throughout the span of 
gastrointestinal tract234. As the pathogenesis of IBD is associated with persistent inflammation 
present in gastrointestinal tract, it is then conceivable to speculate the role of dysregulation of gut 
microbiota in IBD development. Indeed, numerous literature reviews emphasize the importance 
of considering diet as one of the environmental factors driving the microbiome environment, or 
“dysbiosis” that increases the risk for gut inflammatory response103,109,239,240, including 
“westernized” diets that are high in protein, fat, sugar, salt, alcohol, but low in fruit and vegetable 
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consumption109. Furthermore, animal studies have demonstrated the consumption of emulsifiers 
that are widely present in certain food items, to elicit low-grade inflammation due to the thinning 
of the intestine’s primary barrier (mucosal layer) and the displacement of gut microbiota237,241, and 
to promote the development of colitis and colitis-associated cancer241,242. Research linking diet, 
microbiota, and development of IBD need much elucidation. Nevertheless, based on the role of 
diet in inflammatory diseases and evidence of its role in other chronic ailments, a significant 
disruption to healthy gut microbiota via diet modification and eating habits is a very plausible 
pathway toward developing IBD mediated by abnormal gastrointestinal activities, including 
nutrient deficiency, metabolism, and inflammation. 
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Figure 4.1 Demographic characteristics of estimated population with colitis.  
Numbers shown are protions of population with colitis. A) Gender, B) Poverty Status, C) Ethnicity, D) 
Prevalence of colitis and age, E) Prevalence of colitis and region, F) Prevalence of colitis and race. 
*Representation is significantly different from the estimated non-colitic population. 
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Figure 4.2 Lifestyle characteristics of estimated population with colitis.  
Numbers shown are protions of population with colitis. A) Prevalence of colitis and alcohol user 
status, B) Prevalence of colitis and alcohol consumption status, C) Prevalence of colitis and 
smoking, D) Prevalence of colitis and body mass index (kg/m2). *Representation is significantly 
different from the estimated non-colitic population. 
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Figure 4.3 Proportions of estimated colitic population consuming respective food item  
Food items in A) Whole Wheat Grain, B) Sweetened Food or Drinks, C) Dairy and Meat, D) Fruits 
and Vegetables. *Significantly different from estimated non-colitic population.  
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Table 4.1 Survey participant characteristics, NHIS 2015a  
    Unweighted, Unadjusted 
Characteristics 
(Sample total) 
Sub-categories N (Total) Percent 
Sample population   103,789   
  Sample adults (> 18 yrs old) 33,672 32.44 
Sex Male 15,071 44.76 
(N=33,672) Female 18,601 55.24 
Age categories (yrs) 18-24 2,890 8.58 
(N=33,672) 25-34 5,783 17.17 
  35-44 5,284 15.69 
  45-54 5,566 16.53 
  55-64 5,771 17.14 
  65-74 4,695 13.94 
  75-85 3,683 10.94 
Ethnicity Hispanic 5,591 16.60 
(N=33,672) Non-Hispanic 28,081 83.40 
Race White 25,831 76.71 
(N=33,672) Black or African-American 4,673 13.88 
  American Indian or Alaska Native 392 1.16 
  Asian 1,983 5.89 
  Multiple race 699 2.08 
  Unknown 94 0.28 
Region Northeast 5,580 16.57 
(N=33,672) Midwest 7,102 21.09 
  South 11,646 34.59 
  West 9,344 27.75 
Poverty statusb Poor 5,341 15.86 
(N=33,672) Near poor 7,020 20.85 
  Not poor 21,311 63.29 
Ever smokedc Yes 16,853 50.05 
(N=33,672) Never 15,548 46.17 
  Unknown 1,271 3.77 
Alcohol user statusd Abstainer 6,930 20.58 
(N=33,672) Former drinker 5,252 15.60 
  Current drinker 21,053 62.52 
  Unknown 437 1.30 
Alcohol 
consumption statuse Abstainer 6,930 20.58 
(N=33,672) Infrequent drinker 7,584 22.52 
  Regular or Light drinker 11,998 35.63 
  Moderate drinker 4,936 14.66 
  Heavy drinker 1,679 4.99 
  Unknown 545 1.62 
Body Mass Index 
(BMI) Underweight, (< 18.5) 603 1.79 
(N=33,672) Healthy (18.5 to < 25) 10,863 32.26 
  Overweight (25 to < 30) 11,045 32.80 
  Obese (30 and over) 10,016 29.75 
  Missing or Unascertained 1,145 3.40 
Colitis  Yes 454 1.35 
(N=33,672) No 33,172 98.52 
  Refused or Don't Know 46 0.14 
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aUnweighted frequency and their percentages are reported; Data source: Person file, Sample Adult file, Imputed Income 
files, Sample Adult Cancer file from 2015 NHIS Data release source 
(https://www.cdc.gov/nchs/nhis/nhis_2015_data_release.htm) 
bPoverty status: Poor = Less than 100% of poverty threshold; Near Poor= 100% to less than 200% of poverty threshold; 
Not Poor= 200% of poverty threshold or greater 
cAny participants who answered "yes" to any of the following questions:1) Ever smoked a cigarette at least 100 times, in 
life time; 2) Ever smoked a cigar-related product, even once; 3) Ever smoked a pipe filled with tobacco, even once; 4) 
Ever used smokeless tobacco in entire life.  Participant must answer "No" to all four questions to be considered as Never 
smoked. 
dUser status: Abstainer=Any adult over 18 years of age whose alcohol consumption is less than 12 times in lifetime; 
Former= Any adult over 18 years of age whose alcohol consumption is greater than 12 in lifetime but none in past year; 
Current= Any adult over 18 years of age whose alcohol consumption is greater than 12 in lifetime and consumed at least 
1 drink in the past year. 
eConsumption status: Abstainer=Any adult over 18 years of age whose alcohol consumption is less than 12 times in 
lifetime; Infrequent=Any adult over 18 years of age whose alcohol consumption is ≤ 12 time a year; Regular or 
Light=Any adult over 18 years of age whose alcohol consumption is greater than 12 time a year but less than or equal to 
3 a week in the past year; Moderate=Any adult over 18 years of age whose alcohol consumption is 3-14 times a week 
for males or 3-7 times a week for females; Heavy=Any adult over 18 years of age whose alcohol consumption is greater 
than 14 times a week for males or greater than 7 times a week for females.  
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Table 4.2 Weighted characteristics of US adults with IBD, NHIS 2015a  
    Colits = Yes     Colitis = No   
Colitis =Yes                
vs    Colitis =No 
    Weighted, Unadjusted     Weighted, Unadjusted   Adjusted Wald Test  
Characteristics (Population size) Sub-categories N (Total) Percent 
sublevel 
p-value  
  N (Total) Percent 
sublevel p-
value  
F-test p-value 
2010 US Census   308,745,538                 
  Adult Population with IBD 3,087,297 1.00     305,658,241 99.00       
Sex Male 1,314,844 42.59     115,382,951 48.27       
(N=3,087,297) Female 1,772,453 57.41 0.0234*   123,642,500 51.73 <0.0001* 2.96 0.0866 
Age categories (yrs) 18-24 152,761 4.95     29,709,787 12.43   23.95 <0.0001* 
(N=3,086,9977) 25-34 490,389 15.89     42,183,027 17.65   0.52 0.4730 
  35-44 374,639 12.13     39,802,767 16.65   4.56 0.0335* 
  45-54 550,514 17.83     42,257,153 17.68   0.00 0.9498 
  55-64 714,096 23.13     39,509,436 16.53   6.45 0.0116* 
  65-74 489,910 15.87     26,737,037 11.19   4.62 0.0324* 
  75-85 314,688 10.19 <0.0001*   18,826,244 7.88 <0.0001* 1.58 0.2098 
Ethnicity Hispanic 395,237 12.80     37,344,940 15.62   1.84 0.1762 
(N=3,087,297) Non-Hispanic 2,692,060 87.20 <0.0001*   201,680,511 84.38 <0.0001* 1.84 0.1762 
Race White 2,722,501 88.18     188,219,953 78.74   21.67 <0.0001* 
(N=3,087,297) Black or African-American 173,822 5.63     29,592,552 12.38   29.28 <0.0001* 
  American Indian or Alaska Native 7,158 0.23     2,299,505 0.96   15.80 0.0001* 
  Asian 115,964 3.76     14,169,011 5.93   2.54 0.1187 
  Multiple race 67,852 2.20     4,125,180 1.73   0.26 0.6123 
  Unknown 0 0.00 <0.0001*   619,250 0.26 <0.0001*     
Region Northeast 597,260 19.35     41,609,170 17.41   0.46 0.5004 
(N=3,087,297) Midwest 682,066 22.09     53,577,311 22.41   0.01 0.9085 
  South 1,182,933 38.32     88,756,100 37.13   0.13 0.7159 
  West 625,038 20.25 0.0008*   55,082,870 23.04 <0.0001* 1.25 0.2645 
Poverty statusb Poor 485,686 15.73     29,115,793 12.18   2.98 0.0853 
(N=3,087,297) Near poor 554,238 17.95     44,616,806 18.67   0.08 0.7814 
  Not poor 2,047,373 66.32 <0.0001*   165,292,852 69.15 <0.0001* 0.91 0.3405 
Ever smokedc Yes 1,693,976 57.15     116,698,408 50.88   4.14 0.0427* 
(N=3,087,297) Never 1,270,292 42.85     112,655,073 49.12   4.14 0.0427* 
  Unknown 123,029   0.0196*f   9,671,970   0.0426*f     
Alcohol user statusd Abstainer 498,582 16.16     48,787,304 20.69   3.45 0.0641 
(N=3,087,297) Former drinker 792,163 25.68     33,162,768 14.06   17.78 <0.0001* 
  Current drinker 1,793,756 58.15     153,856,388 65.75   5.18 0.0236* 
  Unknown 2,796   <0.0001*f   3,218,991   <0.0001*f     
Alcohol consumption statuse Abstainer 498,582 16.30     48,787,304 20.76   3.31 0.0700 
(N=3,087,297) Infrequent drinker 912,720 29.85     51,469,604 21.90   7.63 0.0061* 
  Regular or Light drinker 1,125,594 36.81     86,100,150 36.64   0.00 0.9523 
  Moderate drinker 411,531 13.46     36,956,901 15.73   0.89 0.3450 
  Heavy drinker 109,688 3.59     11,700,400 4.98   1.71 0.1917 
  Unknown 29,182   <0.0001*f   4,011,092   <0.0001*f     
Body Mass Index (BMI) Underweight, (< 18.5) 82,556 2.76     4,352,640 1.89   0.73 0.3925 
(N=2,987,538) Healthy (18.5 to < 25) 1,017,654 34.06     79,147,619 34.34   0.01 0.9296 
  Overweight (25 to < 30) 1,102,368 36.90     77,736,820 33.73   1.20 0.2738 
  Obese (30 and over) 784,960 26.27     69,264,800 30.05   1.76 0.1853 
  Missing or Unascertained 0   <0.0001*f   0   <0.0001*f     
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aWeighted frequency and their percentages are reported; Data source: Person file, Sample Adult file, Imputed Income files, Sample Adult Cancer file from 2015 NHIS Data release source 
(https://www.cdc.gov/nchs/nhis/nhis_2015_data_release.htm). Weighting and Sampling units are based on population reported on 2010 US Census. 
bPoverty status: Poor = Less than 100% of poverty threshold; Near Poor= 100% to less than 200% of poverty threshold; Not Poor= 200% of poverty threshold or greater 
cAny participants who answered "yes" to any of the following questions:1) Ever smoked a cigarette at least 100 times, in life time; 2) Ever smoked a cigar-related product, even once; 3) Ever 
smoked a pipe filled with tobacco, even once; 4) Ever used smokeless tobacco in entire life.  Participant must answer "No" to all four questions to be considered Never smoked. 
dUser status: Abstainer=Any adult over 18 years of age whose alcohol consumption is less than 12 times in lifetime; Former= Any adult over 18 years of age whose alcohol consumption is greater 
than 12 in lifetime but none in past year; Current= Any adult over 18 years of age whose alcohol consumption is greater than 12 in lifetime and consumed at least 1 drink in the past year. 
eConsumption status: Abstainer=Any adult over 18 years of age whose alcohol consumption is less than 12 times in lifetime; Infrequent=Any adult over 18 years of age whose alcohol 
consumption is ≤ 12 time a year; Regular or Light=Any adult over 18 years of age whose alcohol consumption is greater than 12 time a year but less than or equal to 3 a week in the past year; 
Moderate=Any adult over 18 years of age whose alcohol consumption is 3-14 times a week for males or 3-7 times a week for females; Heavy=Any adult over 18 years of age whose alcohol 
consumption is greater than 14 times a week for males or greater than 7 times a week for females.  
fTest of proportion (Adjusted Wald Test) was performed on the response categories (within sublevels; between Colitis = Yes vs Colitis=No). Unknown, Missing, or Unascertained are present, but 
not included the analysis 
*Statistically significant; Below the significance level of 0.05 
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Table 4.3 Number of adult survey participants and weighted estimated population consuming listed 
food items from Cancer Control Supplement, NHIS 2015a,b 
      Unweighted Weighted, Unadjusted 
      
Sample 
population Estimated population 
Food 
groupsc Food items   N Percent N Percent 
Whole 
wheat grains Popcorn   16,018 50.61 115,866,849 51.10 
  Cereal (hot or cold)f   22,855 71.80 163,222,824 71.56 
  Brown rice   15,372 48.48 113,758,180 50.08 
  Whole grain bread   24,147 76.32 174,334,319 76.89 
Fruits and 
vegetables Fries    24,663 77.71 181,717,511 79.76 
  Salad (green leafy, lettuce)   28,461 89.58 205,419,323 90.22 
  Fruit juices (100% pure fruit juice)   20,989 66.08 150,914,877 66.30 
  Vegetablesd   30,207 95.33 216,930,088 95.53 
  Potato (non-fried)   26,837 84.66 193,387,286 85.12 
  Pizza (frozen, fast food, homemade)f   25,366 79.96 187,697,450 82.58 
  Fruits (fresh, frozen, canned)   29,680 93.43 212,278,941 93.24 
  Tomato sauce   25,831 81.59 188,308,837 83.03 
  Salsa (made with tomatoes)   20,018 63.16 147,990,000 65.19 
  Beans   24,606 77.62 176,203,909 77.61 
Dairy Milk (cow milk, any type)   24,041 75.59 172,634,448 75.75 
  Cheese (excludes cheese on pizza)   29,093 91.87 209,693,652 92.41 
  Pizza (frozen, fast food, homemade)f   25,366 79.96 187,697,450 82.58 
  Ice cream (frozen desserts)f   22,258 70.33 162,222,316 71.56 
Meat Processed meat   23,820 75.22 173,062,848 76.27 
  Red meat   28,814 90.98 207,146,299 91.29 
Sweetened 
food/drinkse Cereal (hot or cold)f   22,855 71.80 163,222,824 71.56 
  Cookies (i.e. cake, pies, brownies)   23,341 73.78 170,612,848 75.27 
  Donut (i.e. Danish, pastries, muffins)   17,336 54.76 127,529,051 56.23 
  Coffee or tea (sugar or honey added)   17,179 54.04 124,517,306 54.66 
  Fruit drinks (sweetened with sugar)   8,833 27.79 63,737,542 27.99 
  Candy (i.e. chocolates)   23,855 75.38 172,588,758 76.13 
  Sports and energy drinks   8,289 26.06 64,492,081 28.30 
  Regular soda or pop   17,403 54.71 127,613,230 55.98 
  Ice cream (frozen desserts)f   22,258 70.33 162,222,316 71.56 
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aWeighted using sample weight [wtfa_sa]; Data source: Sample Adult Cancer file from 2015 NHIS Data release 
source (https://www.cdc.gov/nchs/nhis/nhis_2015_data_release.htm) 
bAdditional details in survey questions can be found in NHIS 2015 Data release website: 
ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2015/cancerxx_layout.pdf 
cFood groups are based on the relationship previously established according the dietary guidelines. Details can be 
found on https://epi.grants.cancer.gov/nhanes/dietscreen/relationship.html.  
dVegetables other than lettuce salads, potatoes, cooked beans in which participant already answered to in previous 
questions. 
eFood items in this group excludes artificially sweetened or sugar-free kinds  
fFood items appear in more than one food groups: Pizza, Ice cream, Cereal 
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Table 4.4 Comparison of weighted proportions of food item consumption in colitic and non-colitic estimated populationa,b 
    Weighted, Unadjusted 
    Colitis = Yes Colitis = No   
Food groupsc Food items N 
Percen
t N Percent F-testf p-value 
Whole wheat grains Popcorn 1,306,270 44.55 114,468,924 51.21 3.840 0.0511 
  Cereal (hot or cold)g 2,198,692 75.34 160,837,887 72.52 1.480 0.2247 
  Brown rice 1,375,009 46.90 112,253,586 50.13 0.930 0.3362 
  Whole grain bread 2,179,865 74.35 171,970,787 76.94 1.080 0.2999 
Fruits and vegetables Fries  2,472,687 84.73 178,827,691 79.75 5.780 0.0168* 
  Salad (green leafy, lettuce) 2,551,381 87.02 202,636,603 90.20 2.660 0.1038 
  Fruit juices (100% pure fruit juice) 1,812,407 61.74 148,915,123 66.36 2.010 0.1576 
  Vegetablesd 2,760,074 94.14 213,878,256 95.55 1.020 0.3142 
  Potato (non-fried) 2,547,714 86.89 190,582,800 85.10 0.730 0.3937 
  Pizza (frozen, fast food, homemade)g 2,375,321 81.01 158,123,747 82.62 0.320 0.5691 
  Fruits (fresh, frozen, canned) 2,700,634 92.22 209,302,985 93.26 0.440 0.5077 
  Tomato sauce 2,395,891 81.82 185,708,495 83.07 0.230 0.6351 
  Salsa (made with tomatoes) 1,873,306 63.89 146,030,331 65.25 0.170 0.6792 
  Beans 2,247,672 76.66 173,734,461 77.62 0.120 0.7334 
Dairy Milk (cow milk, any type) 2,087,082 71.29 170,380,909 75.83 2.180 0.1404 
  Cheese (excludes cheese on pizza) 2,740,059 93.57 206,708,117 92.41 0.660 0.4184 
  Pizza (frozen, fast food, homemade)g 2,375,321 81.01 158,123,747 82.62 0.320 0.5691 
  Ice cream (frozen desserts)g 2,100,989 71.66 159,984,495 71.59 0.000 0.9815 
Meat Processed meat 2,343,122 80.02 170,564,974 76.25 2.370 0.1249 
  Red meat 2,696,761 92.09 204,199,009 91.29 0.280 0.5962 
Sweetened food/drinkse Cereal (hot or cold)g 2,198,692 75.34 160,837,887 72.52 1.480 0.2247 
  Cookies (i.e. cake, pies, brownies) 2,296,673 78.33 168,105,863 75.24 1.250 0.2638 
  Donut (i.e. Danish, pastries, muffins) 1,720,836 58.69 125,706,425 56.23 0.610 0.4355 
  Coffee or tea (sugar or honey added) 1,552,116 52.94 122,830,695 54.69 0.300 0.5868 
  Fruit drinks (sweetened with sugar) 860,899 29.36 62,814,773 27.98 0.280 0.5956 
  Candy (i.e. chocolates) 2,266,853 77.31 170,097,045 76.12 0.170 0.6765 
  Sports and energy drinks 865,600 29.52 63,591,743 28.30 0.200 0.6544 
  Regular soda or pop 1,632,312 55.54 125,886,667 56.02 0.020 0.8899 
  Ice cream (frozen desserts)g 2,100,989 71.66 159,984,495 71.59 0.000 0.9815 
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aWeighted using sample weight [wtfa_sa] for cross-tabulation with Colitis outcome; Data source: Sample Adult Cancer file from 2015 NHIS Data release 
source (https://www.cdc.gov/nchs/nhis/nhis_2015_data_release.htm) 
bAdditional details in survey questions can be found in NHIS 2015 Data release website: 
ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2015/cancerxx_layout.pdf 
cFood groups are based on the relationship previously established according the dietary guidelines. Details can be found on 
https://epi.grants.cancer.gov/nhanes/dietscreen/relationship.html. 
dVegetables other than lettuce salads, potatoes, cooked beans in which participant already answered to in previous questions.  
eFood items exclude artificially sweetened or sugar-free kinds 
fTest of proportion, Adjusted Wald test  
gFood items appear in more than one food groups: Pizza, Ice cream, Cereal 
*Statistically significant; Below the significance level of 0.05 
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Table 4.5 Association of (Oddsh) food consumption and IBD in weighted, estimated population from NHIS 2015a,b  
    Weighted, unadjusted 
Weighted, Adjusted for 
Demographyf Weighted, Adjusted for Lifestyleg 
Weighted, Adjusted for 
Demography and Lifestylef,g 
Food groupsc Food items OR 
p-
value 95% CI OR 
p-
value 95% CI OR 
p-
value 95% CI OR 
p-
value 95% CI 
Whole wheat 
grains Popcorn 0.77 0.053 (0.5838 - 1.0000) 0.78 0.072 (0.5920 - 1.0220) 0.78 0.068 (0.5885 - 1.0190) 0.79 0.089 (0.5975 - 1.0374) 
  Cereal (hot or cold)i 1.22 0.246 (0.8728 - 1.6950) 1.15 0.393 (0.8310 - 1.5950) 1.21 0.249 (0.8720 - 1.6870) 1.15 0.402 (0.8307 - 1.5861) 
  Brown rice 0.88 0.337 (0.6738 - 1.1450) 0.94 0.688 (0.7210 - 1.2400) 0.87 0.318 (0.6682 - 1.1400) 0.93 0.624 (0.7098 - 1.2285) 
  Whole grain bread 0.87 0.283 (0.6716 - 1.1240) 0.90 0.443 (0.6950 - 1.1720) 0.88 0.343 (0.6763 - 1.1460) 0.91 0.474 (0.6943 - 1.1851) 
Fruits and 
vegetables Fries  1.41 0.032* (1.0299 - 1.9290) 1.63 0.003* (1.1890 - 2.2450) 1.40 0.036* (1.0220 - 1.9237) 1.63 0.003* (1.1831 - 2.2375) 
  Salad (green leafy, lettuce) 0.72 0.068 (0.5078 - 1.0200) 0.71 0.057 (0.4930 - 1.0100) 0.73 0.085 (0.5109 - 1.0444) 0.71 0.063 (0.4907 - 1.0189) 
  Fruit juices (100% pure fruit juice) 0.82 0.147 (0.6230 - 1.0730) 0.89 0.417 (0.6778 - 1.1750) 0.82 0.155 (0.6191 - 1.0797) 0.89 0.424 (0.6733 - 1.1814) 
  Vegetablesd 0.75 0.256 (0.4527 - 1.2355) 0.69 0.147 (0.4160 - 1.1400) 0.74 0.243 (0.4474 - 1.2270) 0.68 0.138 (0.4106 - 1.1317) 
  Potato (non-fried) 1.16 0.418 (0.8080 - 1.6700) 1.04 0.818 (0.7256 - 1.5000) 1.24 0.254 (0.8575 - 1.7856) 1.11 0.581 (0.7698 - 1.5940) 
  Pizza (frozen, fast food, homemade)i 0.90 0.556 (0.6262 - 1.2860) 1.02 0.899 (0.7088 - 1.4790) 0.95 0.787 (0.6610 - 1.3680) 1.09 0.644 (0.7539 - 1.5782) 
  Fruits (fresh, frozen, canned) 0.86 0.481 (0.5591 - 1.3150) 0.84 0.418 (0.5500 - 1.2820) 0.91 0.697 (0.5620 - 1.4712) 0.88 0.608 (0.5481 - 1.4225) 
  Tomato sauce 0.92 0.626 (0.6475 - 1.2990) 0.93 0.670 (0.6457 - 1.3250) 0.92 0.661 (0.6491 - 1.3160) 0.93 0.682 (0.6446 - 1.3331) 
  Salsa (made with tomatoes) 0.94 0.676 (0.7118 - 1.2470) 1.11 0.510 (0.8068 - 1.5380) 0.97 0.822 (0.7287 - 1.2859) 1.14 0.442 (0.8195 - 1.5754) 
  Beans 0.95 0.729 (0.6952 - 1.2900) 0.93 0.656 (0.6815 - 1.2700) 0.96 0.804 (0.6977 - 1.3219) 0.93 0.679 (0.6785 - 1.2878) 
Dairy Milk (cow milk, any type) 0.79 0.122 (0.5840 - 1.0640) 0.80 0.134 (0.5910 - 1.0730) 0.80 0.139 (0.5905 - 1.0768) 0.81 0.162 (0.5964 - 1.0910) 
  Cheese (excludes cheese on pizza) 1.19 0.453 (0.7494 - 1.9050) 1.18 0.501 (0.7290 - 1.9040) 1.21 0.419 (0.7596 - 1.9333) 1.18 0.492 (0.7328 - 1.9061) 
  Pizza (frozen, fast food, homemade)i 0.90 0.556 (0.6262 - 1.2860) 1.02 0.899 (0.7088 - 1.4790) 0.95 0.778 (0.6601 - 1.3647) 1.09 0.644 (0.7539 - 1.5782) 
  Ice cream (frozen desserts)i 1.00 0.982 (0.7570 - 1.3290) 1.02 0.906 (0.7670 - 1.3470) 1.01 0.966 (0.7536 - 1.3434) 1.02 0.894 (0.7649 - 1.3593) 
Meat Processed meat 1.25 0.149 (0.9230 - 1.6800) 1.25 0.166 (0.9119 - 1.7064) 1.32 0.088 (0.9597 - 1.8049) 1.31 0.097 (0.9516 - 1.8033) 
  Red meat 1.11 0.612 (0.7380 - 1.6700) 1.12 0.585 (0.7414 - 1.6970) 1.16 0.488 (0.7591 - 1.7787) 1.17 0.476 (0.7612 - 1.7914) 
Sweetened 
food/drinkse Cereal (hot or cold)i 1.22 0.246 (0.8728 - 1.6950) 1.15 0.393 (0.8310 - 1.5950) 1.21 0.249 (0.8720 - 1.6870) 1.15 0.402 (0.8307 - 1.5861) 
  Cookies (i.e. cake, pies, brownies) 1.19 0.286 (0.8640 - 1.6300) 1.19 0.275 (0.8690 - 1.6340) 1.16 0.363 (0.8403 - 1.6067) 1.16 0.359 (0.8432 - 1.5981) 
  Donut (i.e. Danish, pastries, muffins) 1.11 0.439 (0.8560 - 1.4280) 1.15 0.269 (0.8940 - 1.4900) 1.07 0.634 (0.8171 - 1.3925) 1.12 0.413 (0.8565 - 1.4569) 
  Coffee or tea (sugar or honey added) 0.93 0.586 (0.7220 - 1.2023) 1.01 0.942 (0.7800 - 1.3060) 0.94 0.616 (0.7268 - 1.2084) 1.01 0.925 (0.7837 - 1.3076) 
  Fruit drinks (sweetened with sugar) 1.07 0.590 (0.8357 - 1.3700) 1.21 0.121 (0.9496 - 1.5530) 1.05 0.685 (0.8177 - 1.3577) 1.20 0.156 (0.9318 - 1.5488) 
  Candy (i.e. chocolates) 1.07 0.682 (0.7759 - 1.4700) 1.08 0.642 (0.7839 - 1.4830) 1.09 0.619 (0.7806 - 1.5148) 1.09 0.595 (0.7866 - 1.5184) 
  Sports and energy drinks 1.06 0.651 (0.8200 - 1.3700) 1.48 0.010* (1.0990 - 1.9869) 1.08 0.575 (0.8259 - 1.4100) 1.50 0.008* (1.1159 - 2.0272) 
  Regular soda or pop 0.98 0.890 (0.7440 - 1.2900) 1.13 0.418 (0.8366 - 1.5344) 0.98 0.896 (0.7345 - 1.3099) 1.14 0.410 (0.8325 - 1.5655) 
  Ice cream (frozen desserts)i 1.00 0.982 (0.7220 - 1.2170) 1.02 0.906 (0.7670 - 1.3470) 1.01 0.966 (0.7536 - 1.3434) 1.02 0.894 (0.7649 - 1.3593) 
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aWeighted using sample weight [wtfa_sa]. Logistic regression with Colitis as outcome; Data source: Sample Adult Cancer file from 2015 NHIS Data release (https://www.cdc.gov/nchs/nhis/nhis_2015_data_release.htm) 
bAdditional details in survey questions can be found in NHIS 2015 Data release website: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2015/cancerxx_layout.pdf 
cFood groups are based on the relationship previously established according the dietary guidelines. Details can be found on https://epi.grants.cancer.gov/nhanes/dietscreen/relationship.html. 
dVegetables other than lettuce salads, potatoes, cooked beans in which participant already answered to in previous questions. 
eFood items in this group excludes artificially sweetened or sugar-free kinds 
fEach food item adjusted for demographic factors: Age, race, poverty status, sex, ethnicity, region 
gEach food item adjusted for lifestyle factors: Smoking, alcohol user status, alcohol consumption rate, BMI 
hOdds Ratio: (Odds of being colitic in those consuming food item/Odds of being colitic in those never consumed the food item) 
iFood items appear in more than one food groups: Pizza, Ice cream, Cereal 
*Below the significance level of 0.05 
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Table 4.6 Association (Oddsf) of food consumption (full model) and IBD in weighted, estimated population from NHIS 2015a,b 
  Weighted, Unadjusted 
Weighted, Adjusted for 
Demography Weighted, Adjusted for Lifestyle  
Weighted, Adjusted for 
Demography and Lifestyle 
Food itemsc OR p-value 95% CI OR p-value 95% CI OR p-value 95% CI OR p-value 95% CI 
Milk (cow milk, any type) 0.67 0.020* (0.4844 - 0.9403) 0.69 0.034* (0.4928 - 0.9718) 0.69 0.030* (0.4872 - 0.9638) 0.70 0.049* (0.4969 - 0.9978) 
Salad (green leafy, lettuce) 0.76 0.170 (0.5132 - 1.1257) 0.73 0.112 (0.4885 - 1.0776) 0.76 0.168 (0.5090 - 1.1256) 0.72 0.1080 (0.4828 - 1.0756) 
Popcorn 0.73 0.029* (0.5445 - 0.9674) 0.72 0.025* (0.5407 - 0.9599) 0.73 0.034* (0.5494 - 0.9765) 0.73 0.031* (0.5477 - 0.9710) 
Vegetablesd 0.80 0.412 (0.4740 - 1.3591) 0.74 0.271 (0.4372 - 1.2628) 0.77 0.323 (0.4532 - 1.2987) 0.72 0.2200 (0.4214 - 1.2208) 
Whole grain bread 0.94 0.693 (0.7002 - 1.2677) 0.97 0.843 (0.7192 - 1.3088) 0.95 0.756 (0.6993 - 1.2968) 0.97 0.8730 (0.7139 - 1.3314) 
Fruit juices (100% pure fruit juice) 0.83 0.211 (0.6121 - 1.1151) 0.88 0.408 (0.6493 - 1.1923) 0.83 0.225 (0.6047 - 1.1262) 0.88 0.4140 (0.6412 - 1.2014) 
Cookie (i.e. cake, pies, brownies) 1.18 0.402 (0.8034 - 1.7238) 1.13 0.532 (0.7736 - 1.6421) 1.13 0.518 (0.7762 - 1.6509) 1.08 0.6720 (0.7468 - 1.5721) 
Salsa (made with tomatoes) 0.99 0.939 (0.7247 - 1.3473) 1.17 0.384 (0.8248 - 1.6472) 1.01 0.932 (0.7429 - 1.3830) 1.19 0.3280 (0.8404 - 1.6797) 
Beans 0.96 0.818 (0.7015 - 1.3232) 0.90 0.530 (0.6579 - 1.2410) 0.97 0.852 (0.6954 - 1.3504) 0.90 0.5360 (0.6499 - 1.2519) 
Fruits (fresh, frozen, canned) 1.00 0.999 (0.6080 - 1.6442) 0.97 0.891 (0.5856 - 1.5927) 1.07 0.815 (0.6088 - 1.8775) 1.03 0.9230 (0.5849 - 1.8069) 
Cereal (hot or cold) 1.50 0.035* (1.0286 - 2.1811) 1.40 0.084 (0.9565 - 2.0378) 1.48 0.042* (1.0145 - 2.1491) 1.38 0.0970 (0.9437 - 2.0141) 
Potato (non-fried) 1.20 0.363 (0.8086 - 1.7843) 1.03 0.877 (0.6900 - 1.5444) 1.28 0.217 (0.8636 - 1.9036) 1.10 0.6460 (0.7356 - 1.6398) 
Candy (i.e. chocolates) 1.04 0.826 (0.7112 - 1.5318) 1.00 0.983 (0.6811 - 1.4808) 1.07 0.719 (0.7286 - 1.5813) 1.03 0.8700 (0.6982 - 1.5289) 
Fries  1.48 0.026* (1.0468 - 2.0810) 1.65 0.004* (1.1761 - 2.3275) 1.42 0.044* (1.0100 - 1.9943) 1.60 0.006* (1.1421 - 2.2454) 
Ice cream (frozen desserts) 0.98 0.913 (0.7080 - 1.3621) 0.97 0.860 (0.7009 - 1.3459) 0.98 0.893 (0.7017 - 1.3619) 0.97 0.8360 (0.6944 - 1.3434) 
Pizza (frozen, fast food, homemade) 0.83 0.399 (0.5444 - 1.2750) 0.95 0.806 (0.6191 - 1.4519) 0.89 0.603 (0.5816 - 1.3703) 1.02 0.9100 (0.6664 - 1.5766) 
Regular soda or pope 0.93 0.678 (0.6726 - 1.2948) 1.05 0.781 (0.7470 - 1.4735) 0.93 0.675 (0.6594 - 1.3101) 1.05 0.7830 (0.7372 - 1.4985) 
Red meat 0.98 0.931 (0.6079 - 1.5770) 0.96 0.881 (0.5997 - 1.5514) 1.00 0.996 (0.6157 - 1.6286) 0.99 0.9540 (0.6081 - 1.5982) 
Brown rice 0.92 0.567 (0.7013 - 1.2149) 1.01 0.962 (0.7650 - 1.3247) 0.92 0.534 (0.6919 - 1.2108) 1.00 0.9870 (0.7534 - 1.3212) 
Cheese (excludes cheese on pizza) 1.21 0.448 (0.7401 - 1.9736) 1.13 0.620 (0.6912 - 1.8558) 1.19 0.488 (0.7279 - 1.9411) 1.11 0.6740 (0.6786 - 1.8208) 
Sports and energy drinkse 1.06 0.675 (0.8012 - 1.4076) 1.43 0.021* (1.0549 - 1.9355) 1.08 0.612 (0.8076 - 1.4363) 1.46 0.016* (1.0730 - 1.9746) 
Tomato sauce 0.87 0.484 (0.5797 - 1.2954) 0.84 0.402 (0.5586 - 1.2638) 0.85 0.439 (0.5672 - 1.2795) 0.82 0.3600 (0.5453 - 1.2473) 
Donut (i.e. Danish, pastries, muffins) 1.04 0.804 (0.7739 - 1.3918) 1.03 0.855 (0.7658 - 1.3790) 0.98 0.915 (0.7253 - 1.3341) 0.98 0.8830 (0.7207 - 1.3259) 
Processed meat 1.20 0.321 (0.8392 - 1.7055) 1.14 0.477 (0.7914 - 1.6478) 1.26 0.220 (0.8718 - 1.8116) 1.19 0.3490 (0.8228 - 1.7350) 
Fruit drinks (sweetened with sugar)e 1.04 0.780 (0.7836 - 1.3836) 1.12 0.432 (0.8467 - 1.4738) 1.02 0.900 (0.7624 - 1.3613) 1.10 0.5100 (0.8279 - 1.4616) 
Coffee or tea (sugar or honey added)e 0.96 0.738 (0.7283 - 1.2523) 1.00 0.985 (0.7598 - 1.3092) 0.96 0.787 (0.7346 - 1.2636) 1.00 0.9890 (0.7641 - 1.3139) 
Age       1.24 0.000 (1.1357 - 1.3511)       1.25 0.0000 (1.1460 - 1.3606) 
Race       0.80 0.076 (0.6322 - 1.0234)       0.80 0.0800 (0.6285 - 1.0267) 
Sex       1.41 0.017 (1.0634 - 1.8794)       1.41 0.0180 (1.0610 - 1.8718) 
Ethnicity       0.85 0.422 (0.5746 - 1.2620)       0.89 0.5510 (0.6072 - 1.3056) 
Poverty status       0.82 0.047 (0.6785 - 0.9977)       0.83 0.0640 (0.6849 - 1.0107) 
Region       0.94 0.387 (0.8137 - 1.0834)       0.94 0.4180 (0.8190 - 1.0866) 
Alcohol user status             0.90 0.476 (0.6798 - 1.1980) 0.91 0.5120 (0.6905 - 1.2034) 
Alcohol consumption status             0.99 0.955 (0.8048 - 1.2276) 1.01 0.9260 (0.8241 - 1.2370) 
Smoking             1.07 0.159 (0.9752 - 1.1643) 1.03 0.4970 (0.9383 - 1.1400) 
BMI             0.94 0.462 (0.8071 - 1.1025) 0.91 0.2590 (0.7831 - 1.0682) 
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aWeighted using sample weight [wtfa_sa].  Logistic regression with Colitis outcome; Data source: Sample Adult Cancer file from 2015 NHIS 
Data release source (https://www.cdc.gov/nchs/nhis/nhis_2015_data_release.htm) 
bAdditional details in survey questions can be found in NHIS 2015 Data release website: 
ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2015/cancerxx_layout.pdf 
cOrder of predictors in full model based on Pearson Chi-square test 
dVegetables other than lettuce salads, potatoes, cooked beans in which participant already answered to in previous questions. 
eDiet items excludes artificially sweetened or sugar-free kinds 
fOdds Ratio: (Odds of being colitic in those consuming food item/Odds of being colitic in those never consumed the food item) 
*Statistically significant; Below the significance level of 0.05 
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Table 4.7 Association (Oddsh) of food consumption frequency and IBD in weighted, estimated population from NHIS 2015a,b 
    
Weighted, unadjusted Weighted, Adjusted for Demographyf Weighted, Adjusted for Lifestyleg 
Weighted, Adjusted for  
Demography and Lifestylef,g 
Food groupsc Food items OR p-value 95% CI OR p-value 95% CI OR p-value 95% CI OR p-value 95% CI 
Whole wheat 
grains  Popcorn 0.97 0.943 (0.9472 - 1.0043) 0.97 0.072 (0.9467 - 1.0024) 0.98 0.115 (0.9487 - 1.0058) 0.98 0.094 (0.9479 - 1.0042) 
  Cereal (hot or cold) 1.00 0.524 (0.9955 - 1.0080) 1.01 0.789 (0.9939 - 1.0081) 1.00 0.548 (0.9953 - 1.0089) 1.00 0.807 (0.9937 - 1.0082) 
  Brown rice 0.99 0.430 (0.9746 - 1.0110) 1.00 0.973 (0.9835 - 1.0162) 0.99 0.430 (0.9744 - 1.0111) 1.00 0.959 (0.9831 - 1.0163) 
  Whole grain bread 1.00 0.647 (0.9914 - 1.0050) 1.00 0.423 (0.9897 - 1.0000) 1.00 0.643 (0.9914 - 1.0054) 1.00 0.412 (0.9896 - 1.0043) 
Fruits and 
vegetables Fries  1.01 0.103 (0.9985 - 1.0167) 1.01 0.004* (1.0034 - 1.0184) 1.01 0.124 (0.9980 - 1.0166) 1.01 0.005* (1.0033 - 1.0186) 
  Salad (green leafy, lettuce) 1.00 0.610 (0.9869 - 1.0077) 1.00 0.564 (0.9858 - 1.0078) 1.00 0.683 (0.9876 - 1.0082) 1.00 0.603 (0.9861 - 1.0082) 
  Fruit juices (100% pure fruit juice) 1.00 0.345 (0.9873 - 1.0040) 1.00 0.384 (0.9877 - 1.0048) 1.00 0.366 (0.9872 - 1.0048) 1.00 0.411 (0.9877 - 1.0051) 
  Vegetablesd 0.99 0.101 (0.9878 - 1.0010) 0.99 0.060 (0.9857 - 1.0003) 0.99 0.126 (0.9884 - 1.0015) 0.99 0.075 (0.9862 - 1.0007) 
  Potato (non-fried) 1.01 0.054 (0.9998 - 1.0207) 1.01 0.299 (0.9946 - 1.0178) 1.01 0.031 (1.0010 - 1.0212) 1.01 0.203 (0.9961 - 1.0184) 
  Fruits (fresh, frozen, canned) 1.00 0.463 (0.9924 - 1.0000) 1.00 0.402 (0.9918 - 1.0033) 1.00 0.495 (0.9924 - 1.0037) 1.00 0.419 (0.9916 - 1.0035) 
  Pizza (frozen, fast food, homemade) 0.98 0.308 (0.9359 - 1.0211) 0.99 0.791 (0.9569 - 1.0341) 0.98 0.364 (0.9422 - 1.0222) 1.00 0.964 (0.9640 - 1.0357) 
  Tomato sauce 1.01 0.455 (0.9894 - 1.0240) 1.01 0.278 (0.9925 - 1.0260) 1.01 0.426 (0.9900 - 1.0241) 1.01 0.256 (0.9931 - 1.0264) 
  Salsa (made with tomatoes) 0.99 0.178 (0.9752 - 1.0040) 1.00 0.639 (0.9818 - 1.0113) 0.99 0.213 (0.9761 - 1.0054) 1.00 0.647 (0.9820 - 1.0114) 
  Beans 1.00 0.420 (0.9835 - 1.0069) 1.00 0.628 (0.9840 - 1.0098) 1.00 0.480 (0.9839 - 1.0077) 1.00 0.665 (0.9841 - 1.0103) 
Dairy Milk (cow milk, any type) 1.00 0.463 (0.9887 - 1.0052) 1.00 0.385 (0.9879 - 1.0047) 1.00 0.454 (0.9883 - 1.0053) 1.00 0.388 (0.9876 - 1.0049) 
  Cheese (excludes cheese on pizza) 1.01 0.003* (1.0021 - 1.0104) 1.01 <0.001* (1.0032 - 1.0113) 1.01 0.001* (1.0027 - 1.0107) 1.01 <0.001* (1.0038 - 1.0115) 
  Pizza (frozen, fast food, homemade) 0.98 0.308 (0.9359 - 1.0211) 0.99 0.791 (0.9569 - 1.0341) 0.98 0.364 (0.9422 - 1.0222) 1.00 0.964 (0.9640 - 1.0357) 
  Ice cream (frozen desserts) 1.01 0.015* (1.0022 - 1.0203) 1.01 0.069 (0.9993 - 1.0201) 1.01 0.016* (1.0021 - 1.0201) 1.01 0.070 (0.9992 - 1.0199) 
Meat Processed meat 1.00 0.887 (0.9904 - 1.0112) 1.00 0.680 (0.9921 - 1.0123) 1.00 0.712 (0.9919 - 1.0120) 1.00 0.496 (0.9937 - 1.0130) 
  Red meat 1.00 0.566 (0.9878 - 1.0067) 1.00 0.870 (0.9904 - 1.0082) 1.00 0.668 (0.9889 - 1.0072) 1.00 0.987 (0.9916 - 1.0086) 
Sweetened 
food/drinkse Cereal (hot or cold) 1.00 0.524 (0.9955 - 1.0080) 1.01 0.789 (0.9939 - 1.0081) 1.00 0.548 (0.9953 - 1.0089) 1.00 0.807 (0.9937 - 1.0082) 
  Cookies (i.e. cake, pies, brownies) 1.01 0.064 (0.9996 - 1.0159) 1.01 0.275 (0.9959 - 1.0146) 1.01 0.076 (0.9922 - 1.0160) 1.01 0.296 (0.9956 - 1.0147) 
  Donut (i.e. Danish, pastries, muffins) 1.01 0.283 (0.9940 - 1.0208) 1.01 0.312 (0.9935 - 1.0205) 1.01 0.307 (0.9935 - 1.0208) 1.01 0.329 (0.9932 - 1.0205) 
  Candy (i.e. chocolates) 1.01 0.077 (0.9990 - 1.0119) 1.00 0.171 (0.9980 - 1.0112) 1.01 0.063 (0.9997 - 1.0119) 1.01 0.155 (0.9982 - 1.0112) 
  Sports and energy drinks 1.00 0.458 (0.9832 - 1.0077) 1.00 0.608 (0.9930 - 1.0120) 1.00 0.523 (0.9840 - 1.0083) 1.00 0.538 (0.9937 - 1.0123) 
  Coffee or tea (sugar or honey added) 1.00 0.249 (0.9984 - 1.0063) 1.00 0.307 (0.9982 - 1.0057) 1.00 0.264 (0.9982 - 1.0064) 1.00 0.332 (0.9981 - 1.0058) 
  Fruit drinks (sweetened with sugar) 1.00 0.705 (0.9872 - 1.0087) 1.00 0.950 (0.9908 - 1.0099) 1.00 0.679 (0.9870 - 1.0086) 1.00 0.944 (0.9908 - 1.0100) 
  Regular soda or pop 1.01 0.003* (1.0097 - 1.0097) 1.01 <0.001* (1.0030 - 1.0103) 1.01 0.006* (1.0017 - 1.0097) 1.01 0.001* (1.0029 - 1.0105) 
  Ice cream (frozen desserts) 1.01 0.015 (1.0022 - 1.0203) 1.01 0.069 (0.9993 - 1.0201) 1.01 0.016* (1.0021 - 1.0201) 1.01 0.070 (0.9992 - 1.0199) 
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aWeighted using sample weight [wtfa_sa]. Logistic regression with Colitis as outcome; Data source: Sample Adult Cancer file from 2015 NHIS Data release source 
(https://www.cdc.gov/nchs/nhis/nhis_2015_data_release.htm) 
bAdditional details in survey questions can be found in NHIS 2015 Data release website: 
ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2015/cancerxx_layout.pdf 
cFood groups are based on the relationship previously established according the dietary guidelines. Details can be found on 
https://epi.grants.cancer.gov/nhanes/dietscreen/relationship.html.  
dVegetables other than lettuce salads, potatoes, cooked beans in which participant already answered to in previous questions. 
eFood items in this group exclude artificially sweetened or sugar-free kinds 
fEach food item adjusted for demographic factors: Age, race, poverty status, sex, ethnicity, region 
gEach food item adjusted for lifestyle factors: Smoking, alcohol user status, alcohol consumption rate, BMI 
hOdds of having colitis with every unit increase in consumption of respective food item 
*Statistically significant; Below the significance level of 0.05 
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Table 4.8 Association (Oddsf) of food consumption frequency (full model) and IBD in weighted, estimated population from NHIS 2015a,b 
  Weighted, unadjusted Weighted, Adjusted for Demography Weighted, Adjusted for Lifestyle 
Weighted, Adjusted for  
Demography and Lifestyle 
Food itemsc OR p-value 95% CI OR p-value 95% CI OR p-value 95% CI OR p-value 95% CI 
Popcorn 0.97 0.085 (0.9472 - 1.0035) 0.97 0.061 (0.9464 - 1.0012) 0.98 0.099 (0.9488 - 1.0045) 0.97 0.075 (0.9480 - 1.0026) 
Cereal (hot or cold) 1.00 0.298 (0.9964 - 1.0117) 1.00 0.400 (0.9957 - 1.0109) 1.00 0.305 (0.9964 - 1.0116) 1.00 0.420 (0.9955 - 1.0108) 
Brown rice 0.99 0.563 (0.9776 - 1.0124) 1.00 0.770 (0.9871 - 1.0176) 0.99 0.534 (0.9771 - 1.0121) 1.00 0.818 (0.9866 - 1.0173) 
Whole grain bread 1.00 0.652 (0.9913 - 1.0055) 1.00 0.500 (0.9904 - 1.0047) 1.00 0.595 (0.9910 - 1.0052) 1.00 0.445 (0.9900 - 1.0044) 
Salad (green leafy, lettuce) 1.00 0.834 (0.9882 - 1.0097) 1.00 0.803 (0.9877 - 1.0097) 1.00 0.929 (0.9888 - 1.0103) 1.00 0.875 (0.9881 - 1.0103) 
Salsa (made with tomatoes) 0.99 0.228 (0.9757 - 1.0059) 1.00 0.606 (0.9812 - 1.0111) 0.99 0.248 (0.9762 - 1.0063) 1.00 0.578 (0.9810 - 1.0107) 
Pizza (frozen, fast food, homemade) 0.97 0.167 (0.9210 - 1.0144) 0.98 0.423 (0.9441 - 1.0245) 0.97 0.204 (0.9276 - 1.0162) 0.99 0.568 (0.9517 - 1.0276) 
Fruit juices (100% pure fruit juice) 1.00 0.383 (0.9876 - 1.0048) 1.00 0.415 (0.9878 - 1.0051) 1.00 0.404 (0.9875 - 1.0051) 1.00 0.432 (0.9876 - 1.0054) 
Potato (non-fried) 1.01 0.124 (0.9973 - 1.0226) 1.00 0.531 (0.9909 - 1.0178) 1.01 0.090 (0.9984 - 1.0231) 1.01 0.439 (0.9921 - 1.0184) 
Tomato sauce 1.01 0.285 (0.9923 - 1.0266) 1.01 0.290 (0.9924 - 1.0258) 1.01 0.325 (0.9915 - 1.0260) 1.01 0.344 (0.9914 - 1.0251) 
Beans 1.00 0.443 (0.9824 - 1.0078) 0.99 0.464 (0.9815 - 1.0086) 1.00 0.492 (0.9824 - 1.0086) 1.00 0.507 (0.9815 - 1.0093) 
Fries  1.00 0.427 (0.9936 - 1.0153) 1.01 0.071 (0.9992 - 1.0182) 1.00 0.544 (0.9924 - 1.0145) 1.01 0.088 (0.9988 - 1.0176) 
Fruits (fresh, frozen, canned) 1.00 0.834 (0.9935 - 1.0053) 1.00 0.785 (0.9933 - 1.0051) 1.00 0.808 (0.9931 - 1.0054) 1.00 0.741 (0.9927 - 1.0052) 
Vegetablesd 0.99 0.102 (0.9867 - 1.0012) 0.99 0.083 (0.9858 - 1.0009) 0.99 0.122 (0.9871 - 1.0015) 0.99 0.106 (0.9863 - 1.0013) 
Milk (cow milk, any type) 1.00 0.323 (0.9855 - 1.0048) 1.00 0.310 (0.9856 - 1.0046) 1.00 0.324 (0.9853 - 1.0049) 1.00 0.314 (0.9855 - 1.0047) 
Cheese (excludes cheese on pizza) 1.01 0.001* (1.0035 - 1.0125) 1.01 <0.001* (1.0040 - 1.0130) 1.01 <0.001* (1.0040 - 1.0129) 1.01 <0.001* (1.0046 - 1.0133) 
Ice cream (frozen desserts) 1.01 0.103 (0.9980 - 1.0215) 1.01 0.212 (0.9955 - 1.0204) 1.01 0.127 (0.9974 - 1.0212) 1.01 0.239 (0.9950 - 1.0202) 
Red meat 0.99 0.316 (0.9825 - 1.0057) 1.00 0.433 (0.9844 - 1.0068) 0.99 0.342 (0.9829 - 1.0060) 1.00 0.464 (0.9849 - 1.0070) 
Processed meat 1.00 0.513 (0.9847 - 1.0078) 1.00 0.579 (0.9855 - 1.0082) 1.00 0.681 (0.9861 - 1.0092) 1.00 0.734 (0.9869 - 1.0093) 
Cookies (i.e. cake, pies, brownies) 1.00 0.661 (0.9908 - 1.0146) 1.00 0.921 (0.9882 - 1.0132) 1.00 0.686 (0.9905 - 1.0146) 1.00 0.922 (0.9879 - 1.0135) 
Candy (i.e. chocolates) 1.00 0.375 (0.9957 - 1.0116) 1.00 0.478 (0.9948 - 1.0112) 1.00 0.323 (0.9961 - 1.0118) 1.00 0.461 (0.9948 - 1.0115) 
Coffee or tea (sugar or honey added) 1.00 0.357 (0.9978 - 1.0061) 1.00 0.410 (0.9977 - 1.0056) 1.00 0.383 (0.9976 - 1.0062) 1.00 0.452 (0.9975 - 1.0056) 
Donut (i.e. Danish, pastries, muffins) 1.00 0.772 (0.9861 - 1.0190) 1.00 0.883 (0.9847 - 1.0181) 1.00 0.838 (0.9850 - 1.0188) 1.00 0.964 (0.9834 - 1.0177) 
Sports and energy drinks 0.99 0.417 (0.9826 - 1.0073) 1.00 0.830 (0.9914 - 1.0108) 1.00 0.455 (0.9831 - 1.0077) 1.00 0.797 (0.9917 - 1.0109) 
Regular soda or pop 1.01 0.007* (1.0016 - 1.0101) 1.01 0.003* (1.0022 - 1.0103) 1.01 0.012* (1.0012 - 1.0101) 1.01 0.004* (1.0020 - 1.0104) 
Fruit drinks (sweetened with sugar) 1.00 0.621 (0.9861 - 1.0084) 1.00 0.836 (0.9890 - 1.0090) 1.00 0.571 (0.9855 - 1.0081) 1.00 0.805 (0.9885 - 1.0090) 
Age       1.20 0.000 (1.1120 - 1.2956)       1.21 0.000 (1.1227 - 1.3054) 
Race       0.81 0.089 (0.6379 - 1.0326)       0.81 0.095 (0.6335 - 1.0372) 
Sex       1.30 0.066 (0.9825 - 1.7109)       1.30 0.062 (0.9872 - 1.7206) 
Ethnicity       0.87 0.538 (0.5608 - 1.3533)       0.91 0.685 (0.5951 - 1.4068) 
Poverty status       0.85 0.079 (0.7048 - 1.0195)       0.86 0.104 (0.7092 - 1.0328) 
Region       0.97 0.636 (0.8341 - 1.1175)       0.97 0.706 (0.8420 - 1.1236) 
Alcohol user status             0.90 0.482 (0.6807 - 1.1994) 0.93 0.585 (0.7039 - 1.2195) 
Alcohol consumption status             1.00 0.963 (0.8156 - 1.2380) 1.02 0.860 (0.8350 - 1.2408) 
Smoking             1.06 0.244 (0.9630 - 1.1591) 1.03 0.565 (0.9300 - 1.1418) 
BMI             0.95 0.499 (0.8064 - 1.1108) 0.92 0.300 (0.7834 - 1.0783) 
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aWeighted using sample weight [wtfa_sa]. Logistic regression with Colitis as outcome; Data source: Sample Adult Cancer file from 2015 NHIS Data release 
source (https://www.cdc.gov/nchs/nhis/nhis_2015_data_release.htm) 
bAdditional details in survey questions can be found in NHIS 2015 Data release website: 
ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2015/cancerxx_layout.pdf 
cThe order of each food item in full model are based on its association with colitis found by Wilcoxon-Mann-Whitney test.   
dVegetables other than lettuce salads, potatoes, cooked beans in which participant already answered to in previous questions. 
eFood items in this group exclude artificially sweetened or sugar-free kinds 
fOdds of having colitis with every unit increase in consumption of respective food item 
*Statistically significant; Below the significance level of 0.05 
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Table 4.9 Population size and median monthly consumption frequency of food items for sample adults and estimated adult population, NHIS 
2015a,b 
    Sample Adult Population General Population 
    Unweighted, Unadjusted Weighted, Unadjusted 
Food groupsc Food items  N Median IQR N Median IQR 
Whole wheat 
grains Popcorn 31,649 1.000 (0.000 - 2.000) 226,750,764 1.000 (0.000 - 2.000) 
  Cereal (hot or cold)f 31,831 5.000 (0.000 - 17.333) 228,078,386 5.000 (0.000 - 17.333) 
  Brown rice 31,711 0.000 (0.000 - 4.333) 227,158,212 1.000 (0.000 - 4.333) 
  Whole grain bread 31,640 8.666 (1.000 - 30.000) 226,741,285 8.666 (1.000 - 25.000) 
Fruits and 
vegetables Fries  31,737 4.000 (1.000 - 8.667) 227,462,700 4.333 (1.000 - 8.667) 
  Salad (green leafy, lettuce) 31,770 13.000 (4.333 - 21.666) 227,675,083 13.000 (4.333 - 21.666) 
  Fruit juices (100% pure fruit juice) 31,765 4.333 (0.000 - 15.000) 227,626,105 4.333 (0.000 - 15.000) 
  Vegetablesd 31,687 21.667 (10.000 - 30.333) 227,072,944 21.667 (10.000 - 30.333) 
  Potato (non-fried) 31,700 4.333 (2.000 - 8.666) 227,185,918 4.333 (2.000 - 8.666) 
  Fruits (fresh, frozen, canned) 31,768 21.666 (8.667 - 30.333) 227,663,492 21.666 (8.667 - 30.333) 
  Pizza (frozen, fast food, homemade)f 31,723 2.000 (1.000 - 4.333) 227,304,506 2.000 (1.000 - 4.333) 
  Tomato sauce 31,661 3.000 (1.000 - 4.333) 226,790,518 3.000 (1.000 - 4.333) 
  Salsa (made with tomatoes) 31,695 2.000 (0.000 - 5.000) 227,025,710 2.000 (0.000 - 5.000) 
  Beans 31,702 4.000 (1.000 - 8.666) 227,049,415 4.000 (1.000 - 8.666) 
Dairy Milk (cow milk, any type) 31,804 13.000 (1.000 - 30.333) 227,906,932 13.000 (1.000 - 30.333) 
  Cheese (excludes cheese on pizza) 31,668 13.000 (4.333 - 30.000) 226,905,312 13.000 (5.000 - 30.000) 
  Pizza (frozen, fast food, homemade)f 31,723 2.000 (1.000 - 4.333) 227,304,506 2.000 (1.000 - 4.333) 
  Ice cream (frozen desserts)f 31,646 2.000 (0.000 - 5.000) 226,704,695 2.000 (0.000 - 5.000) 
Meat Processed meat 31,668 4.333 (1.000 - 8.666) 226,915,214 4.333 (1.000 - 8.666) 
  Red meat 31,670 8.666 (4.333 - 17.333) 226,911,625 8.666 (4.333 - 17.333) 
Sweetened 
food/drinkse Cereal (hot or cold)f 31,831 5.000 (0.000 - 17.333) 228,078,386 5.000 (0.000 - 17.333) 
  Cookies (i.e. cake, pies, brownies) 31,635 3.000 (0.000 - 8.666) 226,659,263 3.000 (0.000 - 8.666) 
  Donut (i.e. Danish, pastries, muffins) 31,658 1.000 (0.000 - 4.333) 226,794,796 1.000 (0.000 - 4.333) 
  Candy (i.e. chocolates) 31,646 4.333 (1.000 - 13.000) 226,690,983 4.333 (1.000 - 13.000) 
  Sports and energy drinks 31,805 0.000 (0.000 - 1.000) 227,921,423 0.000 (0.000 - 1.000) 
  Coffee or tea (sugar or honey added) 31,792 4.000 (0.000 - 30.333) 227,814,182 4.333 (0.000 - 30.333) 
  Fruit drinks (sweetened with sugar) 31,785 0.000 (0.000 - 1.000) 227,744,976 0.000 (0.000 - 1.000) 
  Regular soda or pop 31,809 1.000 (0.000 - 13.000) 227,963,515 2.000 (0.000 - 13.000) 
  Ice cream (frozen desserts)f 31,646 2.000 (0.000 - 5.000) 226,704,695 2.000 (0.000 - 5.000) 
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aWeighted using sample weight [wtfa_sa]; Data source: Sample Adult Cancer file from 2015 NHIS Data release source 
(https://www.cdc.gov/nchs/nhis/nhis_2015_data_release.htm) 
bAdditional details in survey questions can be found in NHIS 2015 Data release website: 
ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2015/cancerxx_layout.pdf 
cFood groups are based on the relationship previously established according the dietary guidelines. Details can be found on 
https://epi.grants.cancer.gov/nhanes/dietscreen/relationship.html.  
dVegetables other than lettuce salads, potatoes, cooked beans in which participant already answered to in previous questions. 
eFood items in this group excludes artificially sweetened or sugar-free kinds 
fFood items appear in more than one food groups: Pizza, Ice cream, Cereal 
IQR (Interquartile Range) 
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Table 4.10  Comparison in proportions of estimated subpopulation with different median consumption frequency, NHIS 2015a,b 
    Weighted  Weighted, Unadjusted Weighted, Unadjusted   
  
      Colitis= Yes Colitis= No     
    
Monthly 
medianb > Median <= Median > Median <= Median 
Adjusted Wald 
Testg 
Food groupsc Food items  N Percent N Percent N Percent N Percent F-test P-value 
Whole wheat 
grains Popcorn 1.00 955,904 32.60 1,976,132 67.40 76,826,625 34.37 146,696,044 65.63 0.28 0.5987 
  Cereal (hot or cold)h 5.00 1,392,172 47.70 1,526,191 52.30 106,469,140 47.35 118,408,725 52.65 0.01 0.9175 
  Brown ricef 1.00 1,151,428 39.27 1,780,608 60.73 95,612,663 42.70 128,317,454 57.30 1.25 0.2643 
  Whole grain bread 8.67 1,571,509 53.60 1,360,527 46.40 109,705,733 49.08 113,821,358 50.92 2.12 0.1465 
Fruits and 
vegetables Fries  4.33 1,583,515 54.26 1,334,654 45.74 116,264,228 51.85 107,984,244 48.15 0.55 0.4600 
  Salad (green leafy, lettuce) 13.00 1,107,710 37.78 1,824,326 62.22 88,256,583 39.32 136,190,405 60.68 0.22 0.6375 
  Fruit juices (100% pure fruit juice) 4.33 1,315,828 44.83 1,619,624 55.17 117,252,424 52.25 107,142,170 47.75 4.78 0.0295* 
  Vegetablesd 21.67 1,441,793 49.17 1,490,243 50.83 110,307,851 49.28 113,536,998 50.72 0.00 0.9761 
  Potato (non-fried) 4.33 1,796,601 61.27 1,135,435 38.73 133,460,620 59.59 90,497,203 40.41 0.26 0.6104 
  Fruits (fresh, frozen, canned) 21.67 1,308,944 44.70 1,619,409 55.30 103,834,256 46.26 120,604,824 53.74 0.22 0.6376 
  Pizza (frozen, fast food, homemade)h 2.00 1,148,250 39.16 1,783,786 60.84 96,845,835 43.22 127,230,576 56.78 1.58 0.2099 
  Tomato sauce 3.00 1,408,009 48.08 1,520,344 51.92 104,850,255 46.90 118,715,851 53.10 0.15 0.6996 
  Salsa (made with tomatoes) 2.00 1,332,345 45.44 1,599,691 54.56 99,529,375 44.47 124,268,240 55.53 0.09 0.7640 
  Beans 4.00 1,390,076 47.41 1,541,960 52.59 111,421,107 49.78 112,414,114 50.22 0.54 0.4642 
Dairy Milk (cow milk, any type) 13.00 1,167,197 39.87 1,760,330 60.13 99,933,350 44.48 124,749,996 55.52 2.11 0.1472 
  Cheese (excludes cheese on pizza) 13.00 1,553,612 53.05 1,374,741 46.95 98,156,072 43.88 125,524,828 56.12 8.78 0.0033* 
  Pizza (frozen, fast food, homemade)h 2.00 1,148,250 39.16 1,783,786 60.84 96,845,835 43.22 127,230,576 56.78 1.58 0.2099 
  Ice cream (frozen desserts)h 2.00 1,467,104 50.04 1,464,932 49.96 100,845,000 45.13 122,631,600 54.87 2.28 0.1318 
Meat Processed meat 4.33 1,582,027 54.02 1,346,326 45.98 118,598,914 53.02 105,091,888 46.98 0.10 0.7496 
  Red meat 8.67 1,315,018 44.91 1,613,335 55.09 103,391,312 46.22 120,295,901 53.78 0.18 0.6750 
Sweetened 
food/drinkse Cereal (hot or cold)h 5.00 1,392,172 47.70 1,526,191 52.30 106,469,140 47.35 118,408,725 52.65 0.01 0.9175 
  Cookies (i.e. cake, pies, brownies) 3.00 1,561,285 53.25 1,370,751 46.75 103,811,055 46.46 119,620,113 53.54 4.18 0.0419* 
  Donut (i.e. Danish, pastries, muffins) 1.00 1,206,191 41.14 1,725,845 58.86 95,378,659 42.66 128,188,042 57.34 0.24 0.6213 
  Candy (i.e. chocolates) 4.33 1,729,593 58.99 1,202,443 41.01 125,187,020 56.02 98,275,868 43.98 0.86 0.3540 
  Sports and energy drinksf 0.00 865,600 29.52 2,066,436 70.48 63,591,743 28.30 161,101,585 71.70 0.20 0.6544 
  Coffee or tea (sugar or honey added) 4.33 1,399,154 47.72 1,532,882 52.28 112,756,104 50.21 111,829,983 49.79 0.62 0.4308 
  Fruit drinks (sweetened with sugar)f 0.00 860,899 29.36 2,071,137 70.64 62,814,773 27.98 161,702,108 72.02 0.28 0.5956 
  Regular soda or pop 2.00 1,508,456 51.32 1,430,679 48.68 113,669,535 50.58 111,058,786 49.42 0.05 0.8235 
  Ice cream (frozen desserts)h 2.00 1,467,104 50.04 1,464,932 49.96 100,845,000 45.13 122,631,600 54.87 2.28 0.1318 
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aWeighted using sample weight [wtfa_sa]; Data source: Sample Adult Cancer file from 2015 NHIS Data release source (https://www.cdc.gov/nchs/nhis/nhis_2015_data_release.htm) 
bUnit: Times per month; Additional details in survey questions can be found in NHIS 2015 Data release website: 
ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2015/cancerxx_layout.pdf 
cFood groups are based on the relationship previously established according the dietary guidelines. Details can be found on https://epi.grants.cancer.gov/nhanes/dietscreen/relationship.html.  
dVegetables other than lettuce salads, potatoes, cooked beans in which participant already answered to in previous questions. 
eFood items in this group excludes artificially sweetened or sugar-free kinds 
fThe median for these diet items are 0, or none. Equivalent to having never consumed in past month. 
gTest of proportion compares the proportion of colitic subpopulation eating > Median (or ≤Median) to the non-colitic subpopulation eating > Median (or ≤Median) 
hFood items appear in more than one food groups: Pizza, Ice cream, Cereal 
*Statistically different; Below the significance level of 0.05 
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Table 4.11 Association (Oddsh) of IBD and food intake of ≤ Median monthly rate compared to those consuming > Median monthly rate, NHIS 
2015a,b 
    Weighted, Unadjusted Weighted, Adjusted for Demographyf Weighted, Adjusted for Lifestyleg 
Weighted, Adjusted for  
Demography and Lifestylef,g 
    <=Median <=Median <=Median <=Median  
Food groupsc Food items OR P-value 95% CI OR P-value 95% CI OR P-value 95% CI OR P-value 95% CI 
Whole wheat 
grains Popcorn 1.08 0.603 (0.8015 - 1.4624) 1.09 0.581 (0.8059 - 1.4685) 1.08 0.615 (0.7947 - 1.4742) 1.09 0.597 (0.7983 - 1.4783) 
  Cereal (hot or cold)i 0.99 0.917 (0.7504 - 1.2949) 1.05 0.730 (0.7980 - 1.3794) 1.00 0.977 (0.7582 - 1.3301) 1.07 0.641 (0.8066 - 1.4173) 
  Brown rice  1.14 0.337 (0.8731 - 1.4939) 1.06 0.688 (0.8059 - 1.3862) 1.15 0.318 (0.8767 - 1.4965) 1.07 0.624 (0.8140 - 1.4088) 
  Whole grain bread 0.83 0.148 (0.6528 - 1.0667) 0.86 0.224 (0.6697 - 1.0987) 0.81 0.104 (0.6284 - 1.0446) 0.84 0.170 (0.6468 - 1.0801) 
Fruits and 
vegetables Fries  0.91 0.462 (0.7003 - 1.1759) 0.79 0.091 (0.6083 - 1.0374) 0.92 0.538 (0.7097 - 1.1964) 0.80 0.108 (0.6123 - 1.0499) 
  Salad (green leafy, lettuce) 1.07 0.640 (0.8117 - 1.4033) 1.09 0.558 (0.8192 - 1.4462) 1.04 0.763 (0.7918 - 1.3743) 1.08 0.618 (0.8079 - 1.4309) 
  Fruit juices (100% pure fruit juice) 1.35 0.031* (1.0281 - 1.7648) 1.27 0.087 (0.9660 - 1.6714) 1.36 0.027* (1.0358 - 1.7846) 1.28 0.076 (0.9742 - 1.6910) 
  Vegetablesd 1.00 0.976 (0.7623 - 1.3229) 1.06 0.678 (0.7944 - 1.4240) 0.99 0.969 (0.7552 - 1.3096) 1.05 0.719 (0.7876 - 1.4127) 
  Potato (non-fried) 0.93 0.613 (0.7089 - 1.2253) 1.00 0.990 (0.7632 - 1.3060) 0.91 0.491 (0.6895 - 1.1956) 0.97 0.831 (0.7416 - 1.2717) 
  Pizza (frozen, fast food, homemade)i 1.18 0.217 (0.9058 - 1.5437) 1.03 0.832 (0.7909 - 1.3382) 1.14 0.352 (0.8675 - 1.4886) 0.98 0.856 (0.7477 - 1.2735) 
  Fruits (fresh, frozen, canned) 1.07 0.639 (0.8179 - 1.3870) 1.10 0.469 (0.8439 - 1.4439) 1.07 0.595 (0.8233 - 1.4032) 1.12 0.420 (0.8525 - 1.4651) 
  Tomato sauce 0.95 0.699 (0.7491 - 1.2141) 0.92 0.504 (0.7212 - 1.1748) 0.94 0.641 (0.7369 - 1.2072) 0.91 0.466 (0.7113 - 1.1681) 
  Salsa (made with tomatoes) 0.96 0.764 (0.7446 - 1.2419) 0.80 0.127 (0.5998 - 1.0659) 0.95 0.717 (0.7344 - 1.2368) 0.80 0.134 (0.6008 - 1.0707) 
  Beans 1.10 0.465 (0.8520 - 1.4189) 1.06 0.650 (0.8131 - 1.3929) 1.08 0.575 (0.8277 - 1.4050) 1.05 0.730 (0.7954 - 1.3858) 
Dairy Milk (cow milk, any type) 1.21 0.154 (0.9314 - 1.5672) 1.25 0.087 (0.9670 - 1.6407) 1.23 0.123 (0.9459 - 1.5880) 1.27 0.074 (0.9766 - 1.6557) 
  Cheese (excludes cheese on pizza) 0.69 0.003* (0.5418 - 0.8837) 0.65 0.001* (0.5128 - 0.8366) 0.66 0.001* (0.5136 - 0.8496) 0.63 <0.001* (0.4906 - 0.8069) 
  Pizza (frozen, fast food, homemade)i 1.18 0.217 (0.9058 - 1.5437) 1.03 0.832 (0.7909 - 1.3382) 1.14 0.352 (0.8675 - 1.4886) 0.98 0.856 (0.7477 - 1.2735) 
  Ice cream (frozen desserts)i 0.82 0.131 (0.6358 - 1.0605) 0.84 0.184 (0.6555 - 1.0847) 0.84 0.170 (0.6462 - 1.0804) 0.86 0.226 (0.6653 - 1.1014) 
Meat Processed meat 0.96 0.750 (0.7484 - 1.2324) 0.92 0.537 (0.7129 - 1.1934) 0.93 0.553 (0.7192 - 1.1933) 0.89 0.373 (0.6862 - 1.1520) 
  Red meat 1.05 0.676 (0.8218 - 1.3529) 0.99 0.950 (0.7690 - 1.2796) 1.03 0.841 (0.7962 - 1.3229) 0.96 0.772 (0.7408 - 1.2497) 
Sweetened 
food/drinkse Cereal (hot or cold)i 0.99 0.917 (0.7504 - 1.2949) 1.05 0.730 (0.7980 - 1.3794) 1.00 0.977 (0.7582 - 1.3301) 1.07 0.641 (0.8066 - 1.4173) 
  Cookies (i.e. cake, pies, brownies) 0.76 0.042* (0.5860 - 0.9907) 0.79 0.072 (0.6072 - 1.0220) 0.79 0.079 (0.6062 - 1.0280) 0.82 0.128 (0.6278 - 1.0606) 
  Donut (i.e. Danish, pastries, muffins) 1.06 0.623 (0.8288 - 1.3676) 1.04 0.753 (0.8105 - 1.3367) 1.11 0.439 (0.8543 - 1.4361) 1.08 0.566 (0.8322 - 1.3981) 
  Coffee or tea (sugar or honey added) 1.10 0.431 (0.8615 - 1.4165) 1.05 0.720 (0.8160 - 1.3416) 0.10 0.439 (0.8601 - 4.4136) 1.05 0.704 (0.8191 - 1.3433) 
  Fruit drinks (sweetened with sugar) 0.93 0.590 (0.7299 - 1.1966) 0.82 0.121 (0.6439 - 1.0530) 0.95 0.693 (0.7376 - 1.2245) 0.83 0.156 (0.6457 - 1.0732) 
  Candy (i.e. chocolates) 0.89 0.358 (0.6828 - 1.1485) 0.88 0.327 (0.6801 - 1.1374) 0.88 0.342 (0.6764 - 1.1458) 0.88 0.324 (0.6748 - 1.1393) 
  Sports and energy drinks 0.94 0.651 (0.7282 - 1.2194) 0.68 0.010* (0.5033 - 0.9098) 0.93 0.584 (0.7104 - 1.2129) 0.66 0.008* (0.4933 - 0.8961) 
  Regular soda or pop 0.97 0.824 (0.7470 - 1.2614) 0.84 0.238 (0.6305 - 0.1218) 0.97 0.831 (0.7380 - 1.2766) 0.83 0.236 (0.6182 - 1.1261) 
  Ice cream (frozen desserts)i 0.82 0.131 (0.6358 - 1.0605) 0.84 0.184 (0.6555 - 1.0847) 0.84 0.170 (0.6462 - 1.0804) 0.86 0.226 (0.6653 - 1.1014) 
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aWeighted using sample weight [wtfa_sa]. Logistic regression with Colitis as outcome; Data source: Sample Adult Cancer file from 2015 NHIS Data release source (https://www.cdc.gov/nchs/nhis/nhis_2015_data_release.htm) 
bAdditional details in survey questions can be found in NHIS 2015 Data release website: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2015/cancerxx_layout.pdf 
cFood groups are based on the relationship previously established according the dietary guidelines. Details can be found on https://epi.grants.cancer.gov/nhanes/dietscreen/relationship.html.  
dVegetables other than lettuce salads, potatoes, cooked beans in which participant already answered to in previous questions. 
eFood items in this group excludes artificially sweetened or sugar-free kinds 
fEach food item adjusted for demographic factors: Age, race, poverty status, sex, ethnicity, region 
gEach food item adjusted for lifestyle factors: Smoking, alcohol user status, alcohol consumption rate, BMI 
hOdds Ratio: (Odds of being colitic in those consuming at ≤ Median monthly rate /Odds of being colitic in those consuming at > Medican monthly rate) 
iFood items appear in more than one food groups: Pizza, Ice cream, Cereal 
 *Statistically significant; Below the significance level of 0.05  
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Table 4.12 Association (Oddsh) of IBD and increasing consumption frequency in subpopulation of >Median or ≤Median eating behavior 
(Unadjusted), NHIS 2015a,b 
    Weighted, Unadjusted Weighted, Unadjusted 
    Consumption Rate > Median Consumption Rate ≤ Median 
Food groupsc Food items OR p-value 95% CI OR p-value 95% CI 
Whole wheat 
grains Popcorn 0.97 0.110 (0.9393 - 1.0064) 0.62 0.014* (0.4290 - 0.9087) 
  Cereal (hot or cold)i 1.00 0.535 (0.9951 - 1.0095) 1.08 0.107 (0.9828 - 0.1954) 
  Brown rice  1.00 0.768 (0.9789 - 1.0159) 0.96 0.902 (0.5331 - 1.7420) 
  Whole grain bread 0.99 0.225 (0.9741 - 1.0623) 0.91 0.002* (0.8606 - 0.9679) 
Fruits and 
vegetables Fries  1.01 0.380 (0.9938 - 1.0164) 1.19 0.006* (1.0511 - 1.3433) 
  Salad (green leafy, lettuce) 1.00 0.876 (0.9891 - 1.0129) 0.97 0.127 (0.9413 - 1.0076) 
  Fruit juices (100% pure fruit juice) 1.00 0.636 (0.9952 - 1.0079) 1.07 0.424 (0.9026 - 1.2753) 
  Vegetablesd 0.98 0.010* (0.9621 - 0.9948) 1.01 0.683 (0.9782 - 1.0343) 
  Potato (non-fried) 1.01 0.045* (1.0002 - 1.0206) 1.09 0.329 (0.9207 - 1.2786) 
  Pizza (frozen, fast food, homemade)i 0.98 0.528 (0.9344 - 1.0355) 1.02 0.874 (0.8160 - 1.2699) 
  Fruits (fresh, frozen, canned) 1.00 0.508 (0.9896 - 1.0052) 1.00 0.745 (0.9793 - 1.0296) 
  Tomato sauce 1.01 0.484 (0.9878 - 1.0263) 0.99 0.873 (0.8189 - 1.1849) 
  Salsa (made with tomatoes) 0.98 0.122 (0.9602 - 1.0048) 0.87 0.224 (0.6925 - 1.0904) 
  Beans 1.00 0.564 (0.9849 - 1.0083) 1.04 0.599 (0.8969 - 1.2072) 
Dairy Milk (cow milk, any type) 1.00 0.896 (0.9894 - 1.0094) 0.99 0.749 (0.9520 - 1.0361) 
  Cheese (excludes cheese on pizza) 0.97 0.454 (0.9900 - 1.0045) 1.01 0.508 (0.9758 - 1.0506) 
  Pizza (frozen, fast food, homemade)i 0.98 0.528 (0.9344 - 1.0355) 1.02 0.874 (0.8160 - 1.2699) 
  Ice cream (frozen desserts)i 1.01 0.035* (1.0007 - 1.0187) 0.87 0.299 (0.6747 - 1.1292) 
Meat Processed meat 1.00 0.715 (0.9839 - 1.0112) 1.14 0.118 (0.9670 - 1.3440) 
  Red meat 1.00 0.478 (0.9822 - 1.0085) 1.03 0.322 (0.9750 - 1.0796) 
Sweetened 
food/drinkse Cereal (hot or cold)i 1.00 0.535 (0.9951 - 1.0095) 1.08 0.107 (0.9828 - 0.1954) 
  Cookies (i.e. cake, pies, brownies) 1.00 0.506 (0.9925 - 1.0154) 0.98 0.838 (0.8133 - 1.1827) 
  Donut (i.e. Danish, pastries, muffins) 1.01 0.071 (0.9991 - 1.0225) 1.37 0.107 (0.9338 - 2.0131) 
  Coffee or tea (sugar or honey added) 1.00 0.032* (1.0004 - 1.0082) 1.05 0.696 (0.8327 - 1.3151) 
  Fruit drinks (sweetened with sugar) 1.00 0.500 (0.9808 - 1.0095) n.a n.a n.a 
  Candy (i.e. chocolates) 1.01 0.153 (0.9981 - 1.0124) 1.00 0.974 (0.8445 - 1.1910) 
  Sports and energy drinks 0.99 0.281 (0.9727 - 1.0081) n.a n.a n.a 
  Regular soda or pop 1.01 <0.001* (1.0038 - 1.0111) 1.05 0.748 (0.7884 - 1.3921) 
  Ice cream (frozen desserts)i 1.01 0.035 (1.0007 - 1.0187) 0.87 0.299 (0.6747 - 1.1292) 
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aWeighted using sample weight [wtfa_sa]. Logistic regression with Colitis as outcome; Data source: Sample Adult Cancer file from 2015 NHIS 
Data release source (https://www.cdc.gov/nchs/nhis/nhis_2015_data_release.htm) 
bAdditional details in survey questions can be found in NHIS 2015 Data release website: 
ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2015/cancerxx_layout.pdf 
cFood groups are based on the relationship previously established according the dietary guidelines. Details can be found on 
https://epi.grants.cancer.gov/nhanes/dietscreen/relationship.html.  
dVegetables other than lettuce salads, potatoes, cooked beans in which participant already answered to in previous questions. 
eFood items in this group excludes artificially sweetened or sugar-free kinds 
fEach food item adjusted for demographic factors: Age, race, poverty status, sex, ethnicity, region 
gEach food item adjusted for lifestyle factors: Smoking, alcohol user status, alcohol consumption rate, BMI 
hOdds of having colitis with every unit increase in consumption of respective food item in the subgroup consuming either > Median or ≤Median 
iFood items appear in more than one food groups: Pizza, Ice cream, Cereal 
n.a: The median for these diet items are 0, or none. Equivalent to having never consumed in past month. 
 *Statistically significant; Below the significance level of 0.05  
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Table 4.13 Association (Oddsh) of IBD and increasing consumption frequency in subpopulation of >Median or ≤Median eating behavior 
(Adjusted for demography), NHIS 2015a,b  
    Weighted, Adjusted for Demography Weighted, Adjusted for Demography 
    Consumption Rate > Median Consumption Rate ≤ Median 
Food groupsc Food items OR p-value 95% CI OR p-value 95% CI 
Whole wheat 
grains Popcorn 0.97 0.098 (0.9381 - 1.0055) 0.66 0.030* (0.4497 - 0.9591) 
  Cereal (hot or cold)i 1.00 0.700 (0.9939 - 1.0091) 1.08 0.120 (0.9803 - 1.1870) 
  Brown rice  1.00 0.635 (0.9877 - 1.0204) 0.99 0.969 (0.5401 - 1.8075) 
  Whole grain bread 0.99 0.168 (0.9689 - 1.0055) 0.93 0.012* (0.8724 - 0.9830) 
Fruits and 
vegetables Fries  1.01 0.183 (0.9969 - 1.0164) 1.23 0.001* (1.0923 - 1.3865) 
  Salad (green leafy, lettuce) 1.00 0.874 (0.9890 - 1.0131) 0.97 0.083 (0.9363 - 1.0041) 
  Fruit juices (100% pure fruit juice) 1.00 0.813 (0.9938 - 1.0079) 1.11 0.242 (0.9327 - 1.3164) 
  Vegetablesd 0.98 0.011* (0.9622 - 0.9950) 1.00 0.850 (0.9738 - 1.0327) 
  Potato (non-fried) 1.01 0.179 (0.9965 - 1.0189) 1.05 0.537 (0.8923 - 1.2438) 
  Pizza (frozen, fast food, homemade)i 0.99 0.765 (0.9440 - 1.0433) 1.08 0.498 (0.8593 - 1.3651) 
  Fruits (fresh, frozen, canned) 1.00 0.505 (0.9895 - 1.0052) 1.01 0.603 (0.9821 - 1.0316) 
  Tomato sauce 1.01 0.412 (0.9887 - 1.0280) 0.99 0.887 (0.8090 - 1.2014) 
  Salsa (made with tomatoes) 0.99 0.297 (0.9648 - 1.0111) 0.93 0.544 (0.7244 - 1.1857) 
  Beans 1.00 0.906 (0.9902 - 1.0112) 1.02 0.764 (0.8824 - 1.1857) 
Dairy Milk (cow milk, any type) 1.00 0.868 (0.9893 - 1.0091) 1.00 0.817 (0.9545 - 1.0375) 
  Cheese (excludes cheese on pizza) 1.00 0.610 (0.9913 - 1.0052) 1.02 0.326 (0.9805 - 1.0608) 
  Pizza (frozen, fast food, homemade)i 0.99 0.765 (0.9440 - 1.0433) 1.08 0.498 (0.8593 - 1.3651) 
  Ice cream (frozen desserts)i 1.01 0.200 (0.9961 - 1.0190) 0.90 0.391 (0.6950 - 1.1536) 
Meat Processed meat 1.00 0.814 (0.9857 - 1.0114) 1.13 0.154 (0.9556 - 1.3307) 
  Red meat 1.00 0.468 (0.9826 - 1.0081) 1.03 0.263 (0.9770 - 1.0796) 
Sweetened 
food/drinkse Cereal (hot or cold)i 1.00 0.700 (0.9939 - 1.0091) 1.08 0.120 (0.9803 - 1.1870) 
  Cookies (i.e. cake, pies, brownies) 1.00 0.889 (0.9871 - 1.0151) 1.00 0.982 (0.8280 - 1.2027) 
  Donut (i.e. Danish, pastries, muffins) 1.01 0.082 (0.9987 - 1.0226) 1.47 0.053 (0.9953 - 2.1649) 
  Coffee or tea (sugar or honey added) 1.00 0.159 (0.9989 - 1.0068) 1.11 0.350 (0.8872 - 1.4004) 
  Fruit drinks (sweetened with sugar) 1.00 0.524 (0.9813 - 1.0097) n.a n.a n.a 
  Candy (i.e. chocolates) 1.00 0.297 (0.9963 - 1.0121) 1.01 0.865 (0.8566 - 1.2020) 
  Sports and energy drinks 0.99 0.353 (0.9755 - 1.0089) n.a n.a n.a 
  Regular soda or pop 1.01 <0.001* (1.0035 - 1.0108) 1.10 0.501 (0.8270 - 1.4736) 
  Ice cream (frozen desserts)i 1.01 0.200 (0.9961 - 1.0190) 0.90 0.391 (0.6950 - 1.1536) 
                
                
                
        
125 
 
 
aWeighted using sample weight [wtfa_sa]. Logistic regression with Colitis as outcome; Data source: Sample Adult Cancer file from 2015 
NHIS Data release source (https://www.cdc.gov/nchs/nhis/nhis_2015_data_release.htm)  
  
bAdditional details in survey questions can be found in NHIS 2015 Data release website: 
ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2015/cancerxx_layout.pdf 
  
cFood groups are based on the relationship previously established according the dietary guidelines. Details can be found on 
https://epi.grants.cancer.gov/nhanes/dietscreen/relationship.html.  
  
dVegetables other than lettuce salads, potatoes, cooked beans in which participant already answered to in previous questions.  
  
eFood items in this group excludes artificially sweetened or sugar-free kinds 
  
fEach food item adjusted for demographic factors: Age, race, poverty status, sex, ethnicity, region 
  
gEach food item adjusted for lifestyle factors: Smoking, alcohol user status, alcohol consumption rate, BMI    
hOdds of having colitis with every unit increase in consumption of respective food item in the subgroup consuming either > Median or 
≤Median  
  
iFood items appear in more than one food groups: Pizza, Ice cream, Cereal 
n.a: The median for these diet items are 0, or none. Equivalent to having never consumed in past month.  
*Statistically significant; Below the significance level of 0.05 
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Table 4.14 Association (Oddsh) of IBD and increasing consumption frequency in subpopulation of >Median or ≤Median eating behavior 
(Adjusted for lifestyle), NHIS 2015a,b  
    Weighted, Adjusted for Lifestyle Weighted, Adjusted for Lifestyle 
    Consumption Rate > Median Consumption Rate ≤ Median 
Food groupsc Food items OR p-value 95% CI OR p-value 95% CI 
Whole wheat 
grains Popcorn 0.97 0.146 (0.9414 - 1.0090) 0.64 0.021* (0.4437 - 0.9344) 
  Cereal (hot or cold)i 1.00 0.499 (0.9953 - 1.0097) 1.08 0.105 (0.9832 - 1.1955) 
  Brown rice  1.00 0.915 (0.9813 - 1.0170) 0.99 0.972 (0.5442 - 1.7991) 
  Whole grain bread 0.99 0.174 (0.9705 - 1.0055) 0.90 0.001* (0.8500 - 0.9592) 
Fruits and 
vegetables Fries  1.01 0.374 (0.9939 - 1.0164) 1.19 0.006* (1.0518 - 1.3530) 
  Salad (green leafy, lettuce) 1.00 0.813 (0.9897 - 0.1013) 0.97 0.136 (0.9406 - 1.0084) 
  Fruit juices (100% pure fruit juice) 1.00 0.560 (0.9956 - 1.0082) 1.08 0.402 (0.9047 - 1.2824) 
  Vegetablesd 0.98 0.011* (0.9626 - 0.9950) 1.01 0.504 (0.9811 - 1.0395) 
  Potato (non-fried) 1.01 0.043* (1.0003 - 1.0207) 1.11 0.247 (0.9314 - 1.3166) 
  Pizza (frozen, fast food, homemade)i 0.98 0.517 (0.9336 - 1.0353) 1.06 0.628 (0.8421 - 1.3291) 
  Fruits (fresh, frozen, canned) 1.00 0.558 (0.9899 - 1.0055) 1.01 0.654 (0.9801 - 1.0324) 
  Tomato sauce 1.01 0.535 (0.9871 - 1.0253) 0.98 0.847 (0.8109 - 1.1879) 
  Salsa (made with tomatoes) 0.98 0.141 (0.9603 - 1.0058) 0.89 0.340 (0.7075 - 1.1272) 
  Beans 1.00 0.587 (0.9852 - 1.0085) 1.06 0.463 (0.9081 - 1.2355) 
Dairy Milk (cow milk, any type) 1.00 0.894 (0.9890 - 1.0097) 1.00 0.849 (0.9541 - 1.0395) 
  Cheese (excludes cheese on pizza) 1.00 0.464 (0.9903 - 1.0045) 1.01 0.543 (0.9738 - 1.0517) 
  Pizza (frozen, fast food, homemade)i 0.98 0.517 (0.9336 - 1.0353) 1.06 0.628 (0.8421 - 1.3291) 
  Ice cream (frozen desserts)i 1.01 0.030* (1.0009 - 1.0186) 0.88 0.323 (0.6742 - 1.1393) 
Meat Processed meat 1.00 0.728 (0.9840 - 1.0114) 1.15 0.119 (0.9650 - 1.3669) 
  Red meat 0.99 0.448 (0.9816 - 1.0083) 1.03 0.221 (0.9808 - 1.0872) 
Sweetened 
food/drinkse Cereal (hot or cold)i 1.00 0.499 (0.9953 - 1.0097) 1.08 0.105 (0.9832 - 1.1955) 
  Cookies (i.e. cake, pies, brownies) 1.00 0.411 (0.9937 - 1.0156) 0.98 0.850 (0.8107 - 1.1889) 
  Donut (i.e. Danish, pastries, muffins) 1.01 0.044* (1.0003 - 1.0226) 1.33 0.155 (0.8965 - 1.9853) 
  Coffee or tea (sugar or honey added) 1.00 0.038* (1.0002 - 1.0083) 1.05 0.650 (0.8410 - 1.3196) 
  Fruit drinks (sweetened with sugar) 0.99 0.438 (0.9800 - 1.0088) n.a n.a n.a 
  Candy (i.e. chocolates) 1.01 0.117 (0.9986 - 1.0124) 1.02 0.870 (0.8490 - 1.2135) 
  Sports and energy drinks 0.99 0.325 (0.9746 - 1.0086) n.a n.a n.a 
  Regular soda or pop 1.01 <0.001* (1.0037 - 1.0111) 1.07 0.666 (0.7977 - 1.4233) 
  Ice cream (frozen desserts)i 1.01 0.030* (1.0009 - 1.0186) 0.88 0.323 (0.6742 - 1.1393) 
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aWeighted using sample weight [wtfa_sa]. Logistic regression with Colitis as outcome; Data source: Sample Adult Cancer file from 2015 NHIS Data release source 
(https://www.cdc.gov/nchs/nhis/nhis_2015_data_release.htm)  
bAdditional details in survey questions can be found in NHIS 2015 Data release website: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2015/cancerxx_layout.pdf  
cFood groups are based on the relationship previously established according the dietary guidelines. Details can be found on https://epi.grants.cancer.gov/nhanes/dietscreen/relationship.html.  
dVegetables other than lettuce salads, potatoes, cooked beans in which participant already answered to in previous questions.  
eFood items in this group excludes artificially sweetened or sugar-free kinds   
fEach food item adjusted for demographic factors: Age, race, poverty status, sex, ethnicity, region    
gEach food item adjusted for lifestyle factors: Smoking, alcohol user status, alcohol consumption rate, BMI  
hOdds of having colitis with every unit increase in consumption of respective food item in the subgroup consuming either > Median or ≤Median  
iFood items appear in more than one food groups: Pizza, Ice cream, Cereal 
n.a: The median for these diet items are 0, or none. Equivalent to having never consumed in past month.  
*Statistically significant; Below the significance level of 0.05 
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Table 4.15 Association (Oddsh) of IBD and increasing consumption frequency in subpopulation of >Median or ≤Median eating behavior 
(Adjusted for demography and lifestyle), NHIS 2015a,b  
    
Weighted, Adjusted for  
Demography and Lifestyle 
Weighted, Adjusted for  
Demography and Lifestyle 
    Consumption Rate > Median Consumption Rate ≤ Median 
Food groupsc Food items OR p-value 95% CI OR p-value 95% CI 
Whole wheat 
grains Popcorn 0.97 0.135 (0.9404 - 1.0084) 0.68 0.041* (0.4642 - 0.9837) 
  Cereal (hot or cold)i 1.00 0.660 (0.9942 - 1.0092) 1.08 0.122 (0.9799 - 1.1862) 
  Brown rice  1.01 0.493 (0.9899 - 1.0213) 1.01 0.972 (0.5499 - 1.8581) 
  Whole grain bread 0.98 0.135 (0.9656 - 1.0048) 0.92 0.005* (0.8605 - 0.9738) 
Fruits and 
vegetables Fries  1.01 0.610 (0.9972 - 1.0167) 1.23 0.001* (1.0897 - 1.3941) 
  Salad (green leafy, lettuce) 1.00 0.821 (0.9895 - 1.0133) 0.97 0.085 (0.9349 - 1.0043) 
  Fruit juices (100% pure fruit juice) 1.00 0.721 (0.9943 - 1.0084) 1.11 0.228 (0.9352 - 1.3231) 
  Vegetablesd 0.98 0.012* (0.9628 - 0.9952) 1.01 0.704 (0.9759 - 1.0367) 
  Potato (non-fried) 1.01 0.164 (0.9968 - 1.0192) 1.07 0.410 (0.9051 - 1.2756) 
  Pizza (frozen, fast food, homemade)i 0.99 0.767 (0.9437 - 1.0437) 1.13 0.314 (0.8923 - 1.4240) 
  Fruits (fresh, frozen, canned) 1.00 0.555 (0.9898 - 1.0055) 1.01 0.580 (0.9817 - 1.0335) 
  Tomato sauce 1.01 0.437 (0.9884 - 1.0274) 0.98 0.863 (0.8021 - 1.2030) 
  Salsa (made with tomatoes) 0.99 0.312 (0.9649 - 1.0115) 0.95 0.672 (0.7380 - 1.2165) 
  Beans 1.00 0.882 (0.9903 - 1.0114) 1.04 0.637 (0.8899 - 1.2098) 
Dairy Milk (cow milk, any type) 1.00 0.871 (0.9890 - 1.0094) 1.00 0.944 (0.9574 - 1.0414) 
  Cheese (excludes cheese on pizza) 1.00 0.628 (0.9916 - 1.0051) 1.02 0.413 (0.9766 - 1.0593) 
  Pizza (frozen, fast food, homemade)i 0.99 0.767 (0.9437 - 1.0437) 1.13 0.314 (0.8923 - 1.4240) 
  Ice cream (frozen desserts)i 1.01 0.215 (0.9958 - 1.0189) 0.90 0.403 (0.6929 - 1.1595) 
Meat Processed meat 1.00 0.869 (0.9862 - 1.0118) 1.14 0.146 (0.9563 - 1.3484) 
  Red meat 1.00 0.446 (0.9824 - 1.0079) 1.04 0.198 (0.9815 - 1.0940) 
Sweetened 
food/drinkse Cereal (hot or cold)i 1.00 0.660 (0.9942 - 1.0092) 1.08 0.122 (0.9799 - 1.1862) 
  Cookies (i.e. cake, pies, brownies) 1.00 0.782 (0.9886 - 1.0154) 0.99 0.945 (0.8220 - 1.2006) 
  Donut (i.e. Danish, pastries, muffins) 1.01 0.059 (0.9996 - 1.0226) 1.43 0.081 (0.9562 - 2.1354) 
  Coffee or tea (sugar or honey added) 1.00 0.187 (0.9986 - 1.0070) 1.12 0.319 (0.8952 - 1.4034) 
  Fruit drinks (sweetened with sugar) 0.99 0.468 (0.9804 - 1.0092) n.a n.a n.a 
  Candy (i.e. chocolates) 1.00 0.244 (0.9969 - 1.0122) 1.02 0.810 (0.8564 - 1.2192) 
  Sports and energy drinks 0.99 0.375 (0.9768 - 1.0089) n.a n.a n.a 
  Regular soda or pop 1.01 <0.001* (1.0035 - 1.0110) 1.12 0.455 (0.8341 - 1.4976) 
  Ice cream (frozen desserts)i 1.01 0.215 (0.9958 - 1.0189) 0.90 0.403 (0.6929 - 1.1595) 
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aWeighted using sample weight [wtfa_sa]. Logistic regression with Colitis as outcome; Data source: Sample Adult Cancer file from 2015 NHIS Data release source 
(https://www.cdc.gov/nchs/nhis/nhis_2015_data_release.htm)   
bAdditional details in survey questions can be found in NHIS 2015 Data release website: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2015/cancerxx_layout.pdf    
cFood groups are based on the relationship previously established according the dietary guidelines. Details can be found on https://epi.grants.cancer.gov/nhanes/dietscreen/relationship.tml.   
dVegetables other than lettuce salads, potatoes, cooked beans in which participant already answered to in previous questions.  
eFood items in this group excludes artificially sweetened or sugar-free kinds    
fEach food item adjusted for demographic factors: Age, race, poverty status, sex, ethnicity, region   
gEach food item adjusted for lifestyle factors: Smoking, alcohol user status, alcohol consumption rate, BMI  
hOdds of having colitis with every unit increase in consumption of respective food item in the subgroup consuming either > Median or ≤Median   
iFood items appear in more than one food groups: Pizza, Ice cream, Cereal 
n.a: The median for these diet items are 0, or none. Equivalent to having never consumed in past month.  
*Statistically significant; Below the significance level of 0.05 
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Supplemental Table S1 Comparison in point prevalence of colitis in estimated subpopulation with different median monthly consumption rate, 
NHIS 2015a,b 
     Weighted, Unadjusted Weighted, Unadjusted Weighted, Unadjusted 
  
      Colitis= Yes Colitis= No Point prevalence of colitis 
    
Monthly 
medianb > Median <= Median > Median <= Median > Median <= Median Adjusted Wald Testg 
Food groupsc Food items   N % N % N % N % 95% CI % 95% CI F-test p-value 
Whole wheat 
grains Popcorn 1.00 955,904 32.60 1,976,132 67.40 76,826,625 34.37 146,696,044 1.23 (1.2265 - 1.2314) 1.33 (1.3274 - 1.3310) 0.28 0.599 
  Cereal (hot or cold) 5.00 1,392,172 47.70 1,526,191 52.30 106,469,140 47.35 118,408,725 1.29 (1.2886 - 1.2928) 1.27 (1.2705 - 1.2745) 0.01 0.918 
  Brown ricef 1.00 1,151,428 39.27 1,780,608 60.73 95,612,663 42.70 128,317,454 1.19 (1.1878 - 1.1921) 1.37 (1.3667 - 1.3707) 1.24 0.266 
  Whole grain bread 8.67 1,571,509 53.60 1,360,527 46.40 109,705,733 49.08 113,821,358 1.41 (1.4101 - 1.4144) 1.18 (1.1792 - 1.1831) 2.13 0.146 
Fruits and 
vegetables Fries  4.33 1,583,515 54.26 1,334,654 45.74 116,264,228 51.85 107,984,244 1.34 (1.3416 - 1.3458) 1.22 (1.2188 - 1.2229) 0.53 0.466 
  Salad (green leafy, lettuce) 13.00 1,107,710 37.78 1,824,326 62.22 88,256,583 39.32 136,190,405 1.24 (1.2373 - 1.2418) 1.32 (1.3199 - 1.3237) 0.22 0.637 
  Fruit juices (100% pure fruit juice) 4.33 1,315,828 44.83 1,619,624 55.17 117,252,424 52.25 107,142,170 1.11 (1.1075 - 1.1117) 1.49 (1.4869 - 1.4914) 4.52 0.034* 
  Vegetablesd 21.67 1,441,793 49.17 1,490,243 50.83 110,307,851 49.28 113,536,998 1.29 (1.2881 - 1.2923) 1.30 (1.2935 - 1.2976) 0.00 0.976 
  Potato (non-fried) 4.33 1,796,601 61.27 1,135,435 38.73 133,460,620 59.59 90,497,203 1.33 (1.3264 - 1.3302) 1.24 (1.2369 - 1.2414) 0.26 0.611 
  Fruits (fresh, frozen, canned) 21.67 1,308,944 44.70 1,619,409 55.30 103,834,256 46.26 120,604,824 1.24 (1.2428 - 1.2470) 1.32 (1.3229 - 1.3270) 0.22 0.637 
  Pizza (frozen, fast food, homemade) 2.00 1,148,250 39.16 1,783,786 60.84 96,845,835 43.22 127,230,576 1.17 (1.1696 - 1.1739) 1.38 (1.3806 - 1.3846) 1.58 0.210 
  Tomato sauce 3.00 1,408,009 48.08 1,520,344 51.92 104,850,255 46.90 118,715,851 1.33 (1.3229 - 1.3273) 1.26 (1.2625 - 1.2665) 0.15 0.700 
  Salsa (made with tomatoes) 2.00 1,332,345 45.44 1,599,691 54.56 99,529,375 44.47 124,268,240 1.32 (1.3187 - 1.3232) 1.27 (1.2690 - 1.2729) 0.09 0.765 
  Beans 4.00 1,390,076 47.41 1,541,960 52.59 111,421,107 49.78 112,414,114 1.23 (1.2302 - 1.2343) 1.35 (1.3510 - 1.3552) 0.53 0.466 
Dairy Milk (cow milk, any type) 13.00 1,167,197 39.87 1,760,330 60.13 99,933,350 44.48 124,749,996 1.15 (1.1524 - 1.1566) 1.39 (1.3894 - 1.3935) 2.07 0.151 
  Cheese (excludes cheese on pizza) 13.00 1,553,612 53.05 1,374,741 46.95 98,156,072 43.88 125,524,828 1.56 (1.5557 - 1.5606) 1.08 (1.0815 - 1.0851) 8.36 0.004* 
  Pizza (frozen, fast food, homemade) 2.00 1,148,250 39.16 1,783,786 60.84 96,845,835 43.22 127,230,576 1.17 (1.1696 - 1.1739) 1.38 (1.3806 - 1.3846) 1.58 0.210 
  Ice cream (frozen desserts) 2.00 1,467,104 50.04 1,464,932 49.96 100,845,000 45.13 122,631,600 1.43 (1.4317 - 1.4363) 1.18 (1.1786 - 1.1824) 2.23 0.137 
Meat Processed meat 4.33 1,582,027 54.02 1,346,326 45.98 118,598,914 53.02 105,091,888 1.32 (1.3143 - 1.3184) 1.26 (1.2628 - 1.2670) 0.10 0.750 
  Red meat 8.67 1,315,018 44.91 1,613,335 55.09 103,391,312 46.22 120,295,901 1.26 (1.2538 - 1.2581) 1.32 (1.3214 - 1.3254) 0.18 0.675 
Sweetened 
food/drinkse Cereal (hot or cold) 5.00 1,392,172 47.70 1,526,191 52.30 106,469,140 47.35 118,408,725 1.29 (1.2886 - 1.2928) 1.27 (1.2705 - 1.2745) 0.01 0.918 
  Cookies (i.e. cake, pies, brownies) 3.00 1,561,285 53.25 1,370,751 46.75 103,811,055 46.46 119,620,113 1.48 (1.4794 - 1.4840) 1.13 (1.1311 - 1.1348) 4.13 0.043* 
  Donut (i.e. Danish, pastries, muffins) 1.00 1,206,191 41.14 1,725,845 58.86 95,378,659 42.66 128,188,042 1.25 (1.2466 - 1.2511) 1.33 (1.3265 - 1.3304) 0.24 0.622 
  Candy (i.e. chocolates) 4.33 1,729,593 58.99 1,202,443 41.01 125,187,020 56.02 98,275,868 1.36 (1.3608 - 1.3648) 1.21 (1.1207 - 1.2109) 0.85 0.356 
  Sports and energy drinksf 0.00 865,600 29.52 2,066,436 70.48 63,591,743 28.30 161,101,585 1.34 (1.3401 - 1.3457) 1.27 (1.2647 - 1.2682) 0.20 0.656 
  Coffee or tea (sugar or honey added) 4.33 1,399,154 47.72 1,532,882 52.28 112,756,104 50.21 111,829,983 1.23 (1.2236 - 1.2277) 1.35 (1.3501 - 1.3543) 0.62 0.431 
  Fruit drinks (sweetened with sugar)f 0.00 860,899 29.36 2,071,137 70.64 62,814,773 27.98 161,702,108 1.35 (1.3492 - 1.3549) 1.26 (1.2629 - 1.2664) 0.28 0.596 
  Regular soda or pop 2.00 1,508,456 51.32 1,430,679 48.68 113,669,535 50.58 111,058,786 1.31 (1.3076 - 1.3118) 1.27 (1.2698 - 1.2739) 0.05 0.824 
  Ice cream (frozen desserts) 2.00 1,467,104 50.04 1,464,932 49.96 100,845,000 45.13 122,631,600 1.43 (1.4317 - 1.4363) 1.18 (1.1786 - 1.1824) 2.23 0.137 
  Regular soda or pop 2.00 1,325,501 45.10 1,613,634 54.90 102,345,627 45.54 122,382,694 1.28 (1.2764 - 1.2807) 1.30 (1.2994 - 1.3034) 0.02 0.890 
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aWeighted using sample weight [wtfa_sa]; Data source: Sample Adult Cancer file from 2015 NHIS Data release source 
(https://www.cdc.gov/nchs/nhis/nhis_2015_data_release.htm)             
bAdditional details in survey questions can be found in NHIS 2015 Data release website: 
ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2015/cancerxx_layout.pdf             
cFood groups are based on the relationship previously established according the dietary guidelines. Details can be found on 
https://epi.grants.cancer.gov/nhanes/dietscreen/relationship.html.              
dVegetables other than lettuce salads, potatoes, cooked beans in which participant already answered to in previous questions.             
eFood items in this group excludes artificially sweetened or sugar-free kinds             
fThe median for these diet items are 0, or none. Equivalent to having never consumed in past month.             
gPoint prevalence estimations between colitic subpopulation eating > Median was compared to colitic subpopulation eating ≤Median             
*Statistically significant; Below the significance level of 0.05       
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5 CONCLUSION 
IBD is a chronic disease in which the disease etiology is multifactorial. Despite the two 
most common forms, there is inter-individual variation in its manisfestion of IBD. Whether the 
disease has strong genetic influence or stimulated by the environment, gene dysregulation and 
epigenetics are a critical part of the pathogenesis243–245. In the last decade or so, the role of post-
transcriptional modification mediated by miRNAs has been introduced as a critical regulator in the 
disease mechanism and regulation10,161. We saw in our study, a single gene modification in CD98 
expression inducing a plethora of miRNA expression changes which resulted in targeting protein-
coding genes to alter the overall expression gradient of proteins in villus-crypt axis that was 
significantly different from the homeostatic expression. In clinical IBD, emerging evidence of 
potentially using differential expression of miRNA as biomarkers for diagnosis and IBD 
differentiation would provide a significant improvement in narrowing the gap of unknown aspect 
of individual variability, and perhaps improving the efficacy in therapy.   
The effect of food on IBD risk needs much elucidation, but the existing studies 
demonstrating varying, yet differential, effect of food on IBD-related symptom and the association 
of diet pattern and IBD risk provide the significance in the interaction of environmental factors 
and lifestyle with disease pathogenesis. Recently, the idea of host gene dysregulation via 
exogenous miRNAs derived from food has been introduced.  Indeed, as multiple miRNAs has 
been identified in foods derived from both animal and plants, the feasibility of taking advantage 
of cross-kingdom regulation through consumption has been explored, at least in principle, in its 
implication in disease treatment and determining dietary influence. As we saw in our study in 
prevalence of IBD and food intake pattern in US adult population, certain food intake was 
characteristic of IBD population.  More specifically, more people with IBD consumed fried 
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potatoes (fries) and ate cookies and cheese more frequently than people without IBD.  In addition, 
100% pure fruit juice was less frequently consumed by people with IBD.  We also saw 
consumption of milk and popcorn negatively associated with prevalence of the disease.  Based on 
this, one can speculate, in addition to macro- and micro-nutrients that are present in these foods, 
whether miRNAs that are abundantly found in unaltered form can be detected in these processed 
and cooked foods.  
Plant-derived miRNAs require perfect complementary with mRNA to be functional, 
whereas the mammalian derived-miRNAs can have varying homology in pairing for inducing 
post-transcriptional modification.  In addition, miRNAs from plants have a methylated terminal 
which enhances the resistence from periodate activity246 and Link et al., in their proof-of-principle 
experiment has found miRNAs from meat to survive to thermal processing, such as roasting136 and 
found detectable expression of food-derived miRNAs in human plasma and fecal samples.  Indeed, 
plant miRNAs that were abundantly detected in corn feed were also detected in various tissues and 
blood of pigs247. Furthermore, miRNAs dereived from fresh corn juice were detectable in ex vivo 
experimental set up of everted intestinal epithelial sac247, suggesting the feasibility of miRNAs 
dereived from plant (juice) crossing the GI barrier.  
Growing evidence suggest microbiota as an added etiological factor to further understand 
the complex interaction between environment and IBD development.  Changes to the composition 
and density of “good” and “bad” microbiota population in the gut have been linked to intestinal 
inflammation237. In addition, adjustments to the diet to promote healthy microbiota-host interaction 
as a new direction toward treating IBD has been introduced to the table238. A pausible mechanisms 
linking diet, microbiota, and IBD definitely warrants further exploration. Current evidence suggest 
diverse and healthy expression of gut microflora to be imperative for proper nutrient absorption 
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and utilization as a way to prevent chronic232,233.  Furthermore, various investigations of obesity-
related diseases suggest adverse expression of microbiota to be linked to poor diet234–237. It is 
thought that the maintenance of homeostatic expression of gut microbiota is critically dependent 
on the metabolism of various nutrients made available by different foods consumed by the host234.  
More recently, a study highlighted a key mechanism in which a diet shapes microbiota activity in 
the gut. Teng et al., has demonstrated the uptake of miRNAs in a small exosome-like nanovesicles 
derived from ginger by gut bacteria248. The feeding of plant-derived nanovesicle increased the 
“good” bacteria population relatve to “bad” bacteria as seen in fecal sample, and this change was 
significantly different from the PBS treated mice248.  The study saw a preferential uptake of 
exosome-like nanovesicles from different plants by different population of gut bacteria and the 
uptake of RNA content encased in these nanovesicles increased the IL22 gene expression to render 
mucosal protection in the gut248. 
Collectively, the studies introducing the novel concept and mechanisms have made it 
feasible to picture a more concerete effect food has on gut health. Changes in host gene expression 
mediated by dysregulation in endogenous expression of miRNAs associated with disease 
pathology is susceptible to exogenous influence by miRNAs found in food.   
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